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Abstract
Non-secretors of ABO blood group antigens are over-represented among patients with
meningococcal disease. The lower levels of both serum secretory antibodies reported,
for some studies, for non-secretors have been suggested to compromise their defences
against bacterial diseases. Conflicting results have been reported for differences in
immunoglobulin levels between secretors and non-secretors; however, most of these
studies measured total amounts of antibodies in serum and saliva by single radial
immunodiffusion (SRED) assays and there have been no studies of their functional
activities.
The objectives of the study were (1) to assess total and specific antibodies in sera and
saliva of secretors and non-secretors with reference to carriage of meningococci and
smoking; (2) to assess the ability of saliva from secretors and non-secretors to inhibit
bacterial binding to epithelial cells; (3) to assess bactericidal activity of sera from
secretors and non-secretors.
As a preliminary step, a sensitive precise and accurate enzyme linked immunosorbent
assay (ELISA) was developed to assess the total and specific levels of IgA, IgM, IgG
in serum and saliva. In a parallel trial, antibody levels obtained with the ELISA and
SRID assay revealed that the ELISA was significantly more sensitive.
Total serum and salivary IgG, IgA and IgM and levels of these isotypes specific for
Neisseria lactamica and five isolates ofmeningococci were determined by ELISA from
material obtained from 357 pupils and staff of a secondary school in which an outbreak
ofmeningitis occurred. There were no differences in total or specific levels of serum
IgG, IgA or IgM or salivary IgG or IgA of secretors compared with non-secretors.
Non-secretors had significantly lower levels of total salivary IgM (p = 0.022)and lower
levels of IgM specific forA. lactamica and five meningococcal isolates. No correlation
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between levels of serum and salivary IgM suggested that this IgM was produced locally
and had not leaked from the serum. Although carriers had higher levels of antibodies
than non-carriers, the effect of secretor status on antibody levels was still significant.
Smoking had no effect on levels of total antibodies as those for neisseria.
A flow cytometric assay was developed to assess the effect of salivary antibodies on the
attachment ofmeningococci to epithelial cells. Two types of saliva were tested, fresh
saliva from individual donors and a pool from the school children. Both pooled and
fresh saliva demonstrated significantly high levels of inhibitory activity. The inhibitory
activities for pooled and fresh saliva obtained from secretors were statistically greater
than that observed for non-secretors. The pool from which anti-meningococcal
antibodies were absorbed retained a high level of inhibitory activity, suggesting factors
in saliva other than antibodies inhibited the attachment of bacteria to epithelial cells.
There was no statistical difference between the inhibitory activities of affinity purified
IgA or IgM antibodies.
Most of the sera from secretors and non-secretors had high bactericidal titres against N.
meningitidis NG:4:- isolate andN. lactamica. Bactericidal activity against capsulate
strains was associated with high IgG levels to N. lactamica. Both carriers and
secretors had significantly higher levels of IgG to N. lactamica in sera with bactericidal
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Meningococcal disease, "epidemic cerebrospinal fever", is a world wide health
problem, causing unpredictable epidemics with high mortality. The main clinical signs
and symptoms were first described in 1805 by Vieusseaux (see Branham, 1940).
Weichselaum (1887) (see Branham, 1940) who first recognized the causative bacterium
in the cerebrospinal fluid (CSF) and called it Diplococcus intracellulars meningitidis
due to its presence within leukocytes. Subsequent studies have established the
meningococcus as the cause of epidemic cerebrospinal fever and places the organism in
the genus Neisseria (Wollstein, 1907) (see Branham, 1940). The species Neisseria
meningitidis is classified into different serogroups, serotypes and subtypes based on
capsular and outer membrane protein antigens. Monoclonal antibodies to the
lipooligosaccharide are also being used for strain differentiation.
Disease caused by N. meningitidis is limited to humans; there is no other natural host.
When restricted to the oropharygeal mucosa, these infections are referred to as the
"asymptomatic carrier state". Bacteraemic spread from the submucosal tissue is a rare
event and is associated with much more serious conditions which can rapidly lead to
death. The clinical spectrum of meningococcal disease ranges from mild, local
infection to fatal septicaemia (Apicella, 1990).
1.2 Epidemiology of meningococcal disease
1.2.1 Geographical distribution
Meningococcal meningitis can be either endemic or epidemic. Epidemic meningitis is
found in many countries. The largest epidemic occurred in Europe and in the United
States during World War II. Major epidemics have continued in other parts of the
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world. The serogroup A epidemic in Sao Paulo during 1974 had the highest incidence
recorded, 370 cases per 100,000 (Peltola, 1983). Africa contains one of the worst
affected areas known as the "meningitis belt" (Greenwood et al., 1979). These
epidemics occur every 8-12 years and last for 2-4 years. Most cases of meningitis
within the African meningitis belt occur in the hot dry seasons of the year (Greenwood
et al., 1979).
In England, the United States and Norway, peak incidences have been recorded during
the winter season (Fraser et al., 1972; Bpvre and Gedde-Dahl, 1980; Band et al.,
1983). The bacteriologic, environmental and host-specific factors that result in the
epidemics have been studied but remain largely unknown.
1.2.2 Age
The most striking epidemiologic feature of bacterial meningitis is the age distribution of
cases. Meningococcal disease can occur at any age in previously healthy individuals;
however, the disease is seen most frequent in young children between 6 months and
4.5 years. These are infants and young children in whom protective maternal antibody
has waned and who are not yet able to produce an effective long-term response to
polysaccharide antigens (Greenwood, 1984). The incidence rises again in teenagers
(Cartwright et al., 1986). A low level of disease is seen in adults between 15 and 44
years before it increases again slightly in older adults and in the elderly. The age
distribution can vary depending on the bacterial strain and the population affected.
In the United Kingdom at least one child in every 1000 develops acute bacterial
meningitis by the age of 10 (Greenwood, 1984). In some areas of Africa, acute
bacterial meningitis in childhood can be as high as 1 in 100 (Greenwood, 1984).
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1.2.3 Carrier state and transmission
Direct comparison between studies must be made with caution since many techniques
and identification schemes have been used in meningococcal carriage studies. N.
meningitidis is carried asymptomatically in the nasopharynx by 5 - 20% of the adult
population in non-epidemic periods (Greenfield et al., 1971). Although
meningococcal disease peaks during winter months, no significant difference in
carriage was demonstrated among Greek recruits examined in summer months
compared with winter months (Kremastinou et al., in press a). Higher rates of
meningococcal carriage have been demonstrated in household contacts, hospital
personnel and children attending day-care centres (De Wals et al., 1981; Broome,
1986). There seems to be controversy about the carrier prevalence related to sex. In
the Stonehouse survey and in a study in the Faroe Islands, there was a higher
prevalence of carriage ofN. meningitidis among males (Cartwright et al., 1987; Olsen
et al., 1991); others have found no difference in N. meningitidis carriage between the
sexes (Gold et al., 1978a; Blackwell et al., 1990; Blakeborough et al., 1982;
Kremastinou et al., in press b). A higher carriage rate found for the 15 - 19 age range
(Cartwright et al., 1987; Blackwell et al., 1992a).
Wide variations in duration and acquisition of carriage have been demonstrated
(Greenfield et al., 1971; Blakeborough et al., 1982). Efficient transmission of
meningococci is associated with close contacts, crowding, and poverty (Cartwright et
al., 1987; De Wals et al., 1983) and might be influenced by co-existent viral infection
(Wall, 1988). Such environmental and sociologic factors might lead to the higher
carrier rates seen in house-hold contacts of cases (Kaiser et al., 1974), carriers (Marks
et al., 1979) or closed populations such as military recruits and boarding school pupils.
In studies of Greek military recruits, the carriage rate was 25% during the summer
when 4.9% had symptoms of upper respiratory infection and only 27% in the winter
when 46.4% had symptoms of viral infection (Kremastinou et al., in press a).
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1.3 Classification of N. meningitidis
N. meningitidis are encapsulated Gram negative diplococci with a flattened shape and
an average size of 0.6 x 0.8 Jim. Much effort has been spent on their classification.
1.3.1 Serogroups
There are 13 different serogroups ofN. meningitidis based on the antigenic specificity
of the capsular polysaccharide: A, B, C, D, X, Y, Z, 29E, W135, H, I, K, and L (see
Apicella, 1991). Approximately 90% of meningococcal disease world-wide is caused
by serogroups A, B or C (reviewed by Schwartz et al., 1989). Historically, strains of
serogroups A have been the cause of major epidemics and pandemics. Most African
epidemics have been caused by meningococci belonging to serogroup A. The reasons
for the association between serogroup A and epidemics are unclear. Strains of
serogroup C have less frequently been responsible for major epidemics (Peltola, 1983,
Olyhoek et al„ 1985). Serogroup B meningococci have generally been associated
only with sporadic cases and localized outbreaks of disease; but, beginning in the
1970's, epidemics caused by serogroup B strains have occurred in several European
countries, Norway, the United Kingdom and Iceland (Peltola, 1983; Poolman et al.,
1985). There have been outbreaks due to this serogroup in Chile and Cuba (Cruz et
al., 1990). Serogroup Y and W135 account for almost all the rest (Ashton et al.,
1983). Strains of other serogroups as well as non-groupable strains are usually non¬
pathogenic carrier isolates (Craven et al., 1980).
Only capsulate meningococci are pathogenic, and non-capsular mutants of virulent
strains lose their virulence for mice (Bpvre et al., 1983). Systemic isolates have more
capsule than pharyngeal strains. Non-capsular strains which account for 20-50% of
the nasopharyngeal isolates from healthy carriers usually do not cause systemic
meningococcal disease (Craven et al., 1980). This might be explained by the inverse
relationship between the amount of capsular material and both the adherence to
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epithelial cells and the antiphagocytic properties of the polysaccharide capsule (Craven
et al., 1980). Protective immunity to serogroups A and C meningococci is induced by
the purified polysaccharide A and C vaccines (Griffiss, 1982; Griffiss et al., 1987a).
In contrast, serogroup B strains seem not to induce bactericidal anti-polysaccharide
antibodies in man (Wyle et al., 1972; Zollinger and Mandrell, 1983).
1.3.2 Outer membrane proteins (OMPs)
Serogrouping by the capsular polysaccharide is of limited value in epidemiological
research because one serogroup often predominates at any one period or in a
geographical region (Peltola, 1983). Meningococci have been subdivided into a series
of serotypes and subtypes based upon immunologically distinct OMPs.
Five classes ofOMPs can be demonstrated by chromatography (Frasch and Gotschlich,
1974; Mocca and Frasch, 1982), but the functions of the majority of these are not
clearly understood. The class 1 and class 2/3 proteins are not subject to antigenic shift
but show variations between strains and are used to determine subtype and serotype
specificity, respectively. The class 5 proteins elicit bactericidal antibodies during
infection (Poolman et al., 1983); they might play role in the adhesion process (see
Verheul et al., 1993) but undergo antigenic shift and by this means they can escape
recognition by the immune host response (Tinsley and Heckels, 1986). In contrast,
the class 4 protein appear to be highly conserved between meningococcal strains and
shows considerable homology with the equivalent protein (PIII) present in gonococci
(Klugman et al., 1989). Evidence exists that antibody to this protein blocks the
bactericidal activity of antibodies directed against other OMPs (Munkley etal., 1991).
Table 1.1 shows the OMPs (porins) designated for A. gonorrhoeae and its counterpart
for A. meningitidis (adapted from Hitchcock, 1989).
5
Table 1.1: OMPs ofN. gonorrhoeae andN. meningitidis





Class 2 and 3
Class 4
Class 5
Adapted from Hitchcock, 1989
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The OMP serotyping is based upon antigenic differences of the most stable proteins of
classes 2 and 3; and at least 20 to 30 serotypes have been described (Apicella, 1991).
In addition, subtyping to distinguish between strains based on class 1 OMPs, and, to a
lesser extent, upon differences among class 5 OMPs have been developed. Serotyping
based on OMP antigens offers a more detailed approach to the epidemiology of
meningococcal disease and has been a valuable tool in these studies (Frasch, 1977).
Significant numbers of isolates are, however, non-typable. The endemic form of the
disease appears to be caused by a heterogeneous collection of serotypes whilst a single
serotype is usually involved in epidemics (Apicella, 1990). There are difficulties with
serogroup A meningococci because certain serotype proteins are apparently invariant
(Frasch et al., 1985). Whole-cell ELISA is used for sero- and subtyping of N.
meningitidis (Abdillahi and Poolman, 1987). This technique could discriminate clearly
between strains carrying the antigens by use of monoclonal antibodies.
The OMP serotype 2 had been associated with disease-causing isolates of the serogroup
B meningococcus during epidemics in the United States and Western Europe during the
1970s. This has been replaced by epidemics of organisms expressing other OMP
serotypes (4 and 15). In Europe, at first in Norway, but later in other European
countries (Poolman et al., 1986), the phenotype associated with epidemics and
prolonged outbreaks is B: 15:P1.7,16. In England and Wales, this phenotype has been
responsible for meningococcal disease since 1980. Epidemiologically this has been
characterized by the persistence of infection in certain communities over a period of
several years (Cartwright et al., 1986).
Kasper and colleagues (1973b) found that bactericidal activity in convalescent phase
sera from adults correlates better with titres of antibodies to serotype antigens than with
titres to the serogroup B polysaccharide. The serotype and serosubtype proteins are
being explored as vaccine candidates for meningococcal disease.
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1.3.3 Lipooligosaccharide
Lipooligosaccharide (LOSs) are surface glycolipids which are a major component of the
outer membranes ofN. meningitidis. LOS can be utilized for classification into LOS
serotypes (Frasch et al., 1985). At present, there are 13 different lipooligosaccharide
immunotypes (L1-L13) (Achtman etal., 1992) and monoclonal antibodies against these
epitopes have been produced. The serogroup B and C LOS antigens (L1-L8) are
shared, whereas the LOS antigens of the serogroup A (L9-L12) appear to be unique to
that serogroup (Achtman et al., 1992). L2 - L3 were found to be most prevalent
among serogroup B and C meningococci (Achtman et al., 1992). The scheme seems
to be prone to errors, especially for serogroup A it is not possible to discriminate
between LI 1 and L12 (Poolman, personal communication). The distribution of LOS
immunotypes among serogroup B meningococci might become of special interest,
because the LOS is a potential vaccine candidate (Poolman, 1990).
1.3.4 Enzymatic typing
The clonal typing method has now been used in epidemiological studies of serogroup A
(Olyhoek et al., 1987) and of other serogroups (Caugant et al., 1987). The method is
based on either the isoenzyme analysis by electrophoretic mobilities of soluble
cytoplasmic enzymes (Olyhoek, 1985, Selander et al., 1987) or on a combination of
isoenzyme analyses and OMP analysis (Achtman and Pluschke, 1986). Clonal analysis
has not been found to correlate with serotyping results for serogroup B and C strains
(Caugant et al., 1987); but, serotyping results with serogroup A strains showed a clear
correlation with clonal analysis (Crowe et al., 1989).
These methods were capable of distinguishing between strains of the same serogroup
and have provided additional insight into the epidemiology ofmeningococcal disease.
This method provides a high resolution system for the characterization of all isolates of
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N. meningitidis and provides estimates of the extent of variation in the chromosome as
a whole and of the genetic relatedness of the strains (Selander et al., 1987).
1.3.5 Molecular methods
New molecular techniques such as the restriction fragment length polymorphism
(RFLP) typing method have been developed for N. meningitidis. The RFLP method
is based upon detection of minor differences in base sequence which often can not be
discerned in the phenotype (Tompkins et al., 1986). Fox and colleagues (1991) found
that the RFLP technique was highly discriminatory and reproducible; and RFLP data
were consistent with those from the alternative typing methods such as the isoenzyme
electrophoretic typing method suggesting that RFLP might be useful as an additional
tool for epidemiological typing ofmeningococci.
1.4 Pathogenesis of meningococcal disease
A microorganism must successfully take many sequential steps to cause disease. This
section will focus on the ultrastructural events and possible molecular mechanisms of
the steps leading to disease due to N. meningitidis. The sequence of events leading to
disease is generally held to be:
1) colonization of the oro- or nasopharynx (carrier state).
2) a meningococcal bacteraemic phase in which the bacteria enter the blood stream and
give rise to meningococcaemia;
3) involvement of the inflammatory response in damage to skin, eyes, joints, adrenal
glands or meninges with various clinical symptoms.
9
1.4.1 Attachment and transgression of the mucosal epithelium
Only a few individuals colonized with meningococci in their upper respiratory tract
develop meningococcal disease. This might, in part, be due to differences between the
meningococcal strains in their pili, capsular polysaccharides, OMP, IgA protease and
LPS composition which appear to be involved in the bacterial attachment to the mucosa
or invasiveness of the meningococci (De Voe, 1982; Poolman et al., 1983).
Early investigations of meningococcal pathogenesis implicated the nasopharynx as the
natural habitat of the meningococcus. This site acts as a focus from which the
organism can be transmitted to other individuals and as the initial site of mucosal
colonization preceding systemic disease. Although the nasopharynx is important in the
maintenance of the organism in the environment, the factors that determine attachment
of meningococci predominantly to this site rather than to other mucosal surfaces are
poorly understood.
After deposition onto the mucus, the bacteria must adhere rapidly to the underlying cell
surface if they are not to be removed by the muco-ciliary escalator. Colonization
probably depends largely on ligands or adhesins on the organisms interacting with
receptors on host cells. Attachment of microorganisms might vary with different cell
types and with cells of the same type under different conditions (Svanborg-Eden et al.,
1980).
Pili or fimbriae, long hair-like structures, are important bacterial adhesins. Adherence
of Escherichia coli by means of fimbrial antigens to epithelial cell receptors in the
human urinary tract is an important event in the pathogenesis of acute pyelonephritis
(Lomberg et al., 1983). Uropathogenic E. coli strains attach to glycolipids of the
globo-series on urogenital epithelial cells, antigens of the P blood group system.
Information about bacterial ligands responsible for attachment to host cell receptors has
been successfully applied in the development of vaccines that prevent disease by
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inducing attachment blocking antibodies. Jones and Rutter (1972) observed protection
of newborn piglets against E. coli diarrhoea after immunization of the pregnant sows
with purified K88 fimbriae.
Pili are found on 80% of primary meningococcal isolates from nasopharyngeal of
carriers as well as from cerebrospinal fluid of meningitis patients (De Voe and
Gilchrist, 1975). Attachment of pilate meningococci differed markedly among
epithelial cells from different sites. There was significantly more attachment of
meningococci to nasopharyngeal and buccal epithelial cell compared with cells from the
urethra, transitional bladder or anterior nasal epithelial cells (Stephens and McGee,
1981). Pili have been identified on N. meningitidis and are associated with enhanced
attachment to the host cells and increased virulence (Silverblatt and Cohen, 1979). On
the other hand non-piliate strains more easily escape from phagocytosis by PMNLs
(Buchanan et al., 1978), and systemic meningococcal isolates are less piliate than
pharyngeal strains (Craven et al., 1980). Pili were demonstrated on the bacteria
isolated from CSF from a patient with meningococcal meningitis indicating a possible
role for pili in the later stages of disease (Stephens et al., 1982). The protective role of
anti-pili antibodies remains uncertain (De Voe, 1982).
Capsular polysaccharide, outer membrane proteins and lipooligosaccharide might also
influence the attachment ofN. meningitidis to human cells (Craven and Frasch, 1978).
The presence of the capsule has been suggested to decrease the adherence of
meningococci to mucosa and human erythrocytes (Craven et al., 1980; Stephens et al.,
1993). The role of these bacterial components on binding of the organism needs to be
assessed with reference to the effects of the host's mucosal defences: secretory
immunoglobulins; mucus; ciliary action and phagocytes (McNabb andTomasi, 1981).
Mechanisms that affect some local defences (e.g. damage to ciliary activity or IgA
protease) might have evolved in meningococci. Damage to ciliary function is a
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characteristic of pathogenic bacteria that infect mucosal surfaces. Bordetella pertussis
causes damage to ciliated cells after direct attachment, and N. gonorrhoeae damages
ciliated cells from a distance by release of soluble substance (e.g. LPS) (Stephens et
al., 1987). N. meningitidis also exerts a cytoxic effect on ciliated human
nasopharyngeal mucosal cells by means of soluble substances (Stephens and Farley,
1991). In addition, concurrent upper respiratory tract viral or mycoplasma infections
have been postulated to enhance invasion by meningococci at the nasopharynx
(Schwartz et al., 1989), possibly by disrupting the mucociliary barrier or epithelium.
Stephens and colleagues (1983b) found that meningococci appeared to adhere solely to
the microvilli of non-ciliated cells of the epithelium in human nasopharyngeal mucosa.
The microvilli then become restructured and surround the microorganisms.
Simultaneously with this attachment phase (up to 12 hours post-infection), a rapid
decrease in the ciliary activity together with sloughing of the ciliated epithelial cells was
observed. The meningococci attached to the non-ciliate cells were then engulfed within
phagocytic vesicles. Despite the apparent absence of the endocytic vacuoles in the
basal aspects of the cells, meningococci appear in the subepithelial tissues 18-24 hours
post-infection. Unlike gonococci invading human fallopian tube mucosa (McGee et
al., 1988), meningococci were not observed penetrating the apical junctions and
intercellular spaces.
1.4.2 Bacteraemia
Once the mucosal barrier is crossed, bacteria might gain access to the blood stream and
must overcome additional host defence mechanisms. Surface encapsulation is the most
important bacterial factor which effectively inhibits neutrophil phagocytosis. It also
has a role in resistance to bactericidal activity mediated by the alternative complement
mediated pathway. This enhances blood stream survival and facilitates intravascular
replication to high bacterial densities.
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The terminal complement components (C5-C9) are especially important in host
defences against meningococcal infections and congenital or acquired deficiencies in
any of these components predispose individuals to recurrent or chronic infections with
N. meningitidis (Ross and Densen, 1984; Rosen et al., 1988). The bacteraemia
associated with meningitis is usually assumed to be primary; that is, it follows
nasopharyngeal colonization and leads to central nervous system (CNS) invasion.
1.4.3 Inflammation and damage in CNS
LOS of meningococci is probably the most potent bacterial endotoxin known. The
effect of endotoxins released from the bacteria on the host system can be due to direct
action on the tissue (reviewed by Jacobs and Tabor, 1990). Systemic isolates of
meningococci release higher amounts of LOS than carrier strains (Andersen et al.,
1987). LOS ofmeningococci induce a complex system of reactions which might lead
to septic shock, disseminated intravascular coagulation and multiple organ failure (De
Voe 1982). As a consequence, LOSs appears to play a major role in modulating the
course of the disease and determining the outcome of the disease (Mceland, 1980).
LOS activates the complement system (Greenwood et al., 1976) and stimulates the
release from leukocytes of a number of physiologically active cytokines (Rietschel et
al., 1982), including tumor necrosis factor (TNF) (Waage et al., 1986). Waage and
colleagues (1989a) measured the level of TNF in patients with meningococcal
meningitis. The level was high in 10 of 11 patients who died compared with 8 of 68
survivors from the disease. Interleukin 1 (IL-1) and interleukin (IL-6) are present in
the systemic circulation during the development of septic shock (Waage etal., 1989b).
These cytokines are also produced in the CSF. Interleukin (IL-8) appears to participate
in the complex cytokine network during the initial phase of systemic meningococcal
infections (Halstensen etal., 1993).
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Damage to the host results from the inflammatory changes causing injury to the
vascular endoththelium, which leads to increased blood-brain barrier permeability
(BBBP) and activation of the coagulation cascade. Depending on the potency and
duration of the inflammatory stimuli, the BBBP is altered to different degrees, and
serum proteins and other macromolecules penetrate into CSF. The consequences
include severe brain oedema, increased intracranial pressure and reduced cerebral blood
flow. The interaction of all these events will eventually lead to neuronal injury and to
the irreversible focal or diffuse brain damage that can occur as consequence of bacterial
meningitis.
1.5 Immune responses to meningococci
Once a microorganism has penetrated subepithelial tissues and invaded the circulatory
system, a number of immune mechanisms defend the host against proliferation of the
bacteria and establishment of the disease state. The process of eliminating invading
encapsulated bacteria from the circulatory system is based on three factors:
phagocytosis; production of humoral antibodies; and the activation of complement.
1.5.1 Phagocytosis in the non-immune host
Normal human serum has bactericidal and opsonising activities against N. meningitidis.
Most of the attention has been given to the serum bactericidal activity against
meningococcal disease (Craven et al., 1982). Less work has focused upon the killing
of the bacteria by phagocytes (Ross et al., 1987); therefore, little is, known about the
relative importance of phagocyte-mediated killing of meningococci compared to
humoral mediated bactericidal activity.
There is increasing evidence for different mechanisms of protection against various
serogroups. Complement-dependent phagocytosis is relatively more important in
defence against serogroup B meningococci than against serogroups A, C, Y and W135
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(Ross et al., 1987). This has recently been supported by the report that monoclonal
antibodies against the serogroup B polysaccharide are opsonic but not bactericidal in the
presence of human complement and are highly protective in three animal models (Raff
et al., 1988). The serogroup B meningococcal sialic acid capsules appear to inhibit
activation of the late components of the alternative complement pathway. This
compromises the bactericidal defence against serogroup B meningococcal disease in the
nonimmune host, especially in individuals with deficiency in early complement
component (Ross et al., 1987; Jarvis and Vedros, 1987).
1.5.2 Production of antibodies and their function
1.5.2.1 IgM and IgG antibodies
Low bactericidal activity is a major factor in the development of systemic infections
with N. meningitidis (Goldschneider et al., 1969a; Griffiss and Bertram, 1977;
Skevakis et al., 1984). Families and individuals with IgM deficiency are at increased
risk of disseminated meningococcal disease (Hobbs et al., 1967; Jones et al., 1973).
There are wide variations in the efficiency with which different antibody classes can
function in complement killing. Griffiss and Bertram (1977) reported that natural
antibodies to meningococci are predominantly IgM. They emphasized the superiority
of IgM antibodies over IgG as an activator of the classical pathway in the bactericidal
reaction; there are large differences in the relative activities of the two antibody classes.
Together they probably account for the rapid classical pathway-mediated bacterial
killing in the unchelated assay system (Skevakis et al., 1984).
1.5.2.2 IgA antibodies
Early studies with purified IgA suggested that this antibody could activate bacteriolysis
in the presence of complement and lysozyme (Adinolfi et al., 1966). Subsequent
studies have failed to confirm this finding (Eddie et al., 1971; Heddle et al., 1975);
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and, it has been suggested that the IgA fraction examined by Adinolfi and colleagues
might have been contaminated with small amounts of immunoglobulins of other classes
(Eddie et al., 1971; Rowley, 1973). The finding that circulating, strain specific IgA
antibody to N. meningitidis isolated from convalescent phase sera is capable of
blocking the complement mediated bacteriolytic activity of IgG and IgM separated from
the same sera (Griffiss et al., 1975) raised the possibility that the blocking by IgA
might be responsible for the absence of the lytic activity in the sera of some susceptible
individuals. This blocking effect is antigen-specific, i.e., both the blocking IgA and
the lytic antibody compete for the same antigenic site (Griffiss et al., 1975). Later
reports have, however, provided evidence that IgA can activate the alternative
complement pathway in bactericidal reactions against E. coli (Sirotak et al., 1976).
Chemically aggregated human myeloma IgAl and IgA2 as well as Fc fragments can
function as classical pathway activators (Burritt et al., 1977). In addition, Hiemstra
and colleagues (1988) demonstrated that IgAl and IgA2, in both monomeric and
aggregated forms, activate complement via the alternative pathway.
This controversy over the ability of IgA to activate complement has not been settled.
Griffiss (1982) presented an interesting model of the epidemic behaviour of meningitis
due to N. meningitidis. The experimental data for this model is based on the
observation that the acute sera of military recruits with meningococcal meningitis
contains IgA antibodies which block the bactericidal effect of IgM and IgG antibodies
against the pathogen (Griffiss and Bertram, 1977). It was suggested that IgA
'blocking' antibody arises from coincidental enteric exposure to non-pathogenic enteric
organisms which express structurally similar surface antigenic determinants. This
results in the stimulation of cross-reactive blocking antibodies which render the host
susceptible if exposed to the meningococcus. This hypothesis might explain the
epidemic spread of the meningococcus through populations.
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In contrast to this earlier work, Jarvis and Griffiss (1989) reported that IgAl can initiate
complement mediated lysis of serogroup C meningococci through the classical pathway
when bound to specific outer membrane proteins. The initiation of lysis is an Fc-
dependent process; however IgAl, can also function as a blocking antibody when
bound to the meningococcal polysaccharide capsule. Recently Jarvis and Griffiss
(1991) found that human IgAl and its Fab and F(ab')2 fragments can inhibit IgG-
initiated lysis of serogroup C meningococci via either the classical or alternative
pathway before and after the organism is exposed to IgG. The blockage is not
dependent on the Fc portion binding to capsular polysaccharide epitopes. They
suggested that the biologic effect of IgAl is dependent primarily upon the antigen to
which IgAl binds rather than on the structure of the IgA itself.
1.5.2.3 Development of natural antibodies to meningococci
Exposure of many Gram-negative bacteria to suitable concentrations of human or
animal serum results in loss of viability and sometimes dissolution of the bacterial cells.
An inverse relationship exists between the development of bactericidal immunity and
risk ofmeningococcal disease (Goldschneider et al., 1969b).
In serological studies on healthy human populations, the presence of antibodies having
a specificity for the capsular polysaccharides of serogroups A, B, and C meningococci
is frequently detected, and this cannot be satisfactorily explained by asymptomatic
carriage (Robbins, 1979). These antibodies probably result from exposure to
structurally similar antigens among the nonpathogenic bacteria found on the mucosal
surface.
Neonates have a low incidence of meningococcal disease, probably due to anti-
meningococcal IgG obtained from the mother by placental transfer. The development
of bactericidal antibodies reactive with serogroupable meningococci confers the
increased resistance observed in later childhood. These antibodies are thought to
17
develop as a consequence of antigenic stimulation by carriage of N. meningitidis
(especially non-serogroupable strains), colonization with the genetically closely related
but rarely pathogenic N. lactamica (Reller et al., 1973; Gold et al., 1978a) or
colonization with commensal enteric bacteria which express structures antigenically
similar to the capsular and somatic antigens of meningococci (Robbins et al., 1974).
Gold and colleagues (1978a) found that 40% of children who carried N. lactamica
developed increased titres of bactericidal antibody reactive with meningococci of
serogroups A, B and C.
Antibodies against the capsular polysaccharide of serogroups A and C meningococci
are also acquired in early childhood, although at markedly different rates. Most infants
have detectable anti-A antibody by the age of 1 year but do not have detectable anti-C
antibody until 2-3 years of age (Gold and Lepow, 1976). These anti-polysaccharide
antibodies are acquired in the absence of detectable carriage of serogroup A or C
meningococci (Gold et al., 1978b).
1.5.2.4 Antibody responses to infection
After infection, a strong immune response to the capsular antigen occurs: IgM, IgG and
IgA to these polysaccharides can be measured. These are of the same order of
magnitude as those seen in postvaccine sera (Kayhty et al., 1981).
The antigens inducing the antibody following disease include the cell membrane
proteins and lipooligosaccharide as well as serogroup specific capsular
polysaccharides. Frasch (1977) has shown that children under 2 years of age can
make antibody to the protein serotype expressing the 2 antigen after recovery from
disease due to serogroup B or C serotype 2 meningococci of antigens. Adult levels
of antibody to serotype 2 are not reached until age 10. Zollinger and colleagues
(1974) demonstrated that, although the titres of antibody to the protein and
lipooligosaccharide antigens are the same after disease caused by serogroups B or C,
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very little antibody is induced by the serogroup B polysaccharide in comparison to the
C polysaccharide. Most of the antibody resulting from infection with serogroup B
meningococci was directed against the cell membrane protein with little antibody found
against the lipooligosaccharide or capsular polysaccharide (Zollinger et al., 1974).
Natural infections with serogroup B meningococci do not appear to result in a strong
antibody responses to the serogroup B polysaccharide (Brandt et al., 1972; Zollinger et
al., 1974). In addition, Kasper and colleagues (1973a) found that antibodies to
serogroup B polysaccharide were apparently not bactericidal for all serogroup B
strains.
1.5.3 Bactericidal assay
The specificity of human antibodies which are bactericidal for meningococcal serogroup
B has been examined by a number of investigators, often with conflicting results
(Goldschneider et al., 1969b; Kasper et al., 1973a; Reller et al., 1973; Frasch, 1979;
Craven et al., 1982). Some of the discrepancies might be attributable to differences in
complement sources and to differences in the assays used. The source of complement
and the bacterial test strain are critical (Griffiss et al., 1987b). The majority of
investigators of bactericidal phenomena have utilized serum from humans (Oiling,
1977); others have used domestic (Mittal and Ingram, 1975) or laboratory animals
(Collins, 1967) as a source of complement. Zollinger and Mandrell (1983) have
demonstrated that human antibodies to meningococcal serogroup B polysaccharide are
strongly bactericidal with rabbit complement but not with human complement; and,
antibodies that were bactericidal with human complement were primarily directed
against non-capsular antigens.
No single technique has been recognized as a readily acceptable and widely applicable
standard assay for estimation of serum bactericidal activity. Many variations exist in
both bactericidal assay techniques and analysis of results. Investigation of serum
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bactericidal activity involves exposure of a suspension of viable organisms to a suitable
concentration of antibody and complement, incubation at the optimum temperature for
complement activity and determination (after suitable periods of time) of the absolute
concentration of viable organisms by some form of counting. The differences among
the data obtained by different investigators might be a reflection of the source of
complement, antibody isotype, antibody avidity, the presence of blocking antibody and
the resistance or sensitivity of the organism to complement mediated lysis.
1.5.4 The role of complement
It is now clear that activation of complement by Gram-negative bacteria can occur via
the classical or the alternative pathway. Killing of Gram-negative bacteria via the
classical pathway normally requires all nine complement components. There are
bacteria that appear to be resistant to serum bactericidal systems; these resistant strains
are frequently isolated from bacteraemic patients, while the majority of related serum-
sensitive strains are isolated from mucosal surfaces of normal individuals or patients
without invasive disease. Both serum sensitive and serum resistant strains of N.
gonorrhoeae activate complement and bind the complement components to their
surfaces; however, the elements on the bacterial surface to which complement is bound
differ for the serum sensitive and serum resistant forms (Joiner et al., 1985).
Antibodies directed against outer membrane components bind, activate complement and
kill encapsulated strains ofmeningococci (Goldschneider et al., 1969b; Frasch, 1979).
Killing of the meningococcus and the gonococcus appears to require the late
components of complement and the lytic attack mechanism (Ross and Densen, 1984).
Serum bactericidal reactions might be of protective importance in vivo because
individuals with defects of the membrane-attack complex sequence of complement (C5-
C9) frequently develop systemic infections with neisseriae, despite the presence of
normal antibody levels and intact C3 opsonic functions (Ross and Densen, 1984). The
occurrence of repeated meningococcal infections in individuals with deficiencies in the
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late complement components provides further evidence of the importance of the lytic
system in meningococcal immunity.
Inherited complement deficiency states have been found in association with 10%-30%
of the sporadic adult cases of meningococcal disease (Ross and Densen, 1984). An
intact classical complement pathway might be important in resisting infection with N.
meningitidis especially in families with properdin deficiency (Sjoholm and Nilsson,
1985). Individuals with inherited deficiency of properdin have a functional classical
pathway of complement, and vaccination might be protective (Soderstrom et al., 1989).
Complement-dependent phagocytosis requires complement activation only through C3.
1.6 Mucosal immunity
The molecular basis for local immunity was established when Tomasi and colleagues
(1965) confirmed that external secretions contained a unique immunoglobulin called
secretory IgA (slgA). Subsequent studies showed that slgA was locally produced
(Tomasi and Bienenstock, 1968; Ogra and Karzon, 1969); its titre in secretions
correlated better than serum levels with protection against infectious disease (Perkins et
al., 1969). Local application of antigen was the most efficient method of stimulating
production of this isotype (Waldman and Bergmann, 1984). Immunity at mucosal
surfaces of children and adults is brought about mainly by slgA and slgM which
represent quantitatively the most important immune responses at these sites
(Brandtzaeg, 1989). In general, natural infections acquired via the respiratory or
intestinal mucosa appear to be the most effective means of inducing specific antibody
responses at these portals of entry as well as at other distant mucosal sites.
1.6.1 Production of antibodies
For effective transport of IgA into external secretions, the most important prerequisite is
its polymeric configuration. Although initially slgA was thought to be assembled from
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monomelic IgA (mlgA) by complexing with secretory component (SC) after its
secretion from cells (South, et al., 1966), subsequent studies showed that polymers are
formed within IgA-producing cells before their selective transport into external
secretions (Lawton and Mage, 1969; Bienenstock and Strauss, 1970). Brandtzaeg
(1974) proposed a model of IgA transport in which SC functioned as a surface receptor
for polymeric J-chain-containing IgA or IgM on various epithelial cells, and evidence
for this concept was obtained in different studies (Brandtzaeg, 1978; Nagura et al.,
1979). SC is the epithelial cell receptor for polymeric immunoglobulins responsible for
their selective transport (Brandtzaeg, 1985; Vaerman, 1987). After formation of SC
in the rough endoplasmic reticulum of epithelial cells and glycosylation in the Golgi
complex, it is transported to the laterobasal membrane where it acts as a receptor for
polymeric IgA (plgA) or IgM. SC-immunoglobulin complexes are translocated by
endocytosis to the lumen. This translocation starts with a non-covalent interaction
between the polymeric immunoglobulin and the membrane bound SC. The complex is
endocytosed in vesicles and transported to the other pole of the cell. The translocation
ends after fusion of the vesicle with the cell membrane and splitting of the
extracytoplasmic SC. SC is produced by epithelial cells irrespective of the presence of
plgA or IgM, and it is found in many secretions in free as well as in IgA- or IgM-
bound forms. The J chain is responsible for the selectivity of the transport because it
induces a particular conformation in polymeric immunoglobulins required for strong
SC binding (Vaerman, 1987). These observations of a specialized molecule in
secretions provided an explanation for specific immunological resistance to mucosal
infection existing in the absence of demonstrable serum antibody.
1.6.2 Secretory IgA
In humans there are two subclasses of IgA, IgAl and IgA2 which are the products of
separate immunoglobulin heavy chain genes. In secretions, the two subclasses are
present in approximately equal concentration (Delacroix et al., 1982), but they are not
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equally distributed between serum and the mucosal immune system. IgAl is markedly
enriched in serum and constitutes 85% of serum IgA (Delacroix et al., 1982, 1983).
IgA2 exists as two allotypic variants IgA2m[l] and IgA2m[2], Although 95% of the
IgA in secretions is polymeric, only 12% of the IgA in serum is in this form, 88%
being monomelic (Delacroix et al., 1983).
Although IgA is synthesized locally and secreted throughout the mucosal surfaces of
the body, quantitatively the most important site of the mucosal IgA production is the
gastrointestinal tract because of its vast surface area (Crabbe and Heremans, 1966).
Stephans and colleagues (1983a) found that nasopharyngeal organ cultures contain a
large population of highly reactive, terminally differentiated B lymphocytes that might
be an important source of upper respiratory tract IgA. Comparison of the molecular
properties of IgA, such as subclass distribution and molecular forms in serum and
external secretions and of IgA-producing cells in the bone marrow and mucosal tissues
suggests a relative independence of the serum and mucosal IgA systems (Mestecky and
Russell, 1986).
There is a characteristic difference in the subclass distribution of IgA to certain antigens
between the two systems. Considerable information now exists on human IgA
responses to infection with a variety of microorganisms or to immunization with
purified antigens (Mestecky et al., 1989). Studies on serum IgAl and IgA2 to protein
antigens (Russell et al., 1986) and LPS (Moldoveanu et al., 1987) indicated that in the
serum of healthy individuals, most are of the IgAl subclass. In contrast, salivary
(Brown and Mestecky, 1985) and colostral (Ladjeva et al., 1989) IgAl and IgA2 to
various antigens display characteristic patterns of distribution, though with considerable
individual variability. In the majority of subjects, slgA to protein antigens are of the
IgAl subclass, while those reactive with polysaccharide, lipopolysaccharide and
lipoteichoic acid are predominantly of the IgA2 subclass.
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The host defence mechanisms are not fully developed in infants. At birth, slgA is
essentially absent from the oral cavity (Cripps et al., 1987). Shortly after birth IgA
appears in whole saliva and its concentration increases as the infant develops
(Alaluusua, 1983; Mellander et al., 1984; Smith et al., 1987).
It has been documented that plgA is more effective in viral neutralization than
corresponding mlgA (Taylor and Dimmock, 1985). In addition, various receptors
found on many different cell types such as phagocytes, T cells and hepatocytes bind
plgA more effectively than mlgA (Mestecky and McGhee, 1987), and this might be
reflected in greater functional activity of plgA.
1.6.3 The role of IgA in local immune protection
It is generally accepted that slgA antibodies act as a first line of defence of mucosal
surfaces principally by simple binding to antigens (Hanson and Brandtzaeg, 1988). In
vivo coating of oral bacteria with slgA can be directly demonstrated by
immunofluorescent staining (Brandtzaeg et al., 1968). Human slgA is effective in
cross-linking antigens (Newcomb and Sutoris, 1974) and shows better agglutinating
properties than monomelic antibodies (Newcomb and De Vald, 1969). Its primary
function might be to aggregate particulate antigens. In addition, it can protect the host
by binding to microorganisms or their products. Such a simple function might explain
neutralization of bacterial toxins (Kaur et al., 1972) and inhibition of virus. The
coating and clumping of bacteria might inhibit their adherence to epithelial cells (Fubara
and Freter, 1972; Hanson et al., 1987). The polymeric nature of slgA provides not
only increased avidity for antigens but also enhanced ability to cross-link particles
(Ishizaka et al., 1965).
Salivary IgA to mucosal bacteria such as E. coli, Streptococcus mitis, or S. salivaris
begin to appear as early as the first week of life (Smith et al., 1990). In general, the
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appearance of antibodies in saliva correlates with the colonization of the oral cavity by
the respective microorganisms.
When microorganisms such as virus particles succeed in reaching the epithelium, they
attach to the membrane through receptors complementary to structures on the epithelial
cell surfaces. Binding of the antibody to the surface of an organism could prevent
attachment by direct blocking, steric hindrance or induction of conformational change
(Dimmock, 1984; Lachmann, 1985). Purified slgA antibodies have been shown to
prevent the attachment of bacteria to mucosal surfaces (Fubara and Freter, 1973;
Svanborg-Eden and Svennerholm, 1978). slgA can specifically inhibit cellular
attachment and penetration of influenza virus in contrast to monomeric IgA and IgG
neutralizing antibodies (Taylor and Dimmock, 1985).
1.6.3.1 IgA protease
slgA is remarkably resistant to protease action by enteric and oral bacteria; however,
meningococci produce a protease that specifically cleaves molecules of the subclass
IgAl into Fc and Fab fragments (Kilian and Reinholdt, 1986). The production of
IgAl protease by meningococci has been postulated to be an important virulence factor
(Plaut, 1983). Bacteria that colonize the IgA-rich environment of the upper respiratory
tract such as N. meningitidis and H influenzae produce IgA proteases and might cause
a relative local slgA deficiency. IgA2, unlike IgAl, is resistant to these enzymes
(Killian and Reinholdt, 1986).
1.6.3.2 IgA antibodies in milk
Some of the best evidence that slgA antibodies are protective can be found in studies of
human milk. Epidemiological studies in communities where bacterial and viral
intestinal infections are common indicate that infants who receive mother's milk
containing antibodies to intestinal pathogens have less disease due to those organisms
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than infants receiving mother's milk without the antibodies. For instance, anti-adhesin
and anti-toxin antibodies against cholera seem to reduce diarrhoeal disease (Glass et al.,
1983). This suggests that these slgA antibodies which are at high concentrations in
many samples of human milk can passively protect the infant. For some pathogens
such as rotavirus, feeding antibody-containing milk diminishes the severity of the
disease (Duffy et al., 1986) and might reduce the infection rate. Goldman and
colleagues (1986) suggested that specific slgA molecules, along with the other immune
factors present in the milk, confer disease protection through non-inflammatory
antimicrobial mechanisms.
1.6.3.3 IgA and phagocytosis
The effects of IgA and slgA on functions of polymorphonuclear cells (PMN),
monocytes, macrophages, and lymphocytes, all of which express Fc-alpha receptor,
have been reported. Oral cavity PMN express more Fc-alpha receptors than blood
PMN; and oral but not blood PMN phagocytose red cells coated only with slgA.
Human blood monocytes are able to kill slgA coated gonococci by antibody-dependent
cell mediated cytotoxicity (ADCC) (Vaerman, 1987).
1.6.4 Secretory IgM
Relatively small amounts of 19S IgM are found in normal secretions, but the
concentration is much increased in infants and in individuals with selective IgA
deficiency (Brandtzaeg, 1971; Savilahti, 1973). It was originally thought that 19S
IgM antibodies in serum and secretions were identical (Brandtzaeg et al., 1978); but it
has been shown that IgM in secretions is associated with SC although only 60 to 70%
of the molecules retain the SC after purification (Brandtzaeg, 1975). slgM is not as
resistant to proteolytic degradation as slgA (Richman and Brown, 1977).
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slgM is increased in infancy and is the prominent secreted isotype for the first few
months after birth (Glesson et al., 1982) and in selective IgA deficiency (Brandtzaeg,
1971). Various antibody activities have been shown for IgM in nasal secretions (Ogra
et al., 1974) and salivary fluids (Mellander et al., 1984; 1986a and b). Evidence from
measurement of antibody activity to antigens to which infants are naturally exposed
(Mellander et al., 1984, 1986a) or to which they have been immunized (Carlsson et al.,
1985; Smith et al., 1986) indicates that IgM antibody is also present in whole saliva
early in life. IgM has been detected in saliva of some infants who were as young as
one month of age (Glesson et al., 1982; Smith et al., 1989).
Hanson and colleagues (1987) have observed that IgM activity decreased as IgA
antibody activity increased in infants and suggested that both isotypes were contributing
to protective functions in the oral cavity. It is probable, therefore, that IgM might
function like slgA as a first line of mucosal defence. Thrane and colleagues (1991)
observed more IgM than IgA producing cells during the foetal and neonatal period.
This is in accordance with a preferential early salivary IgM response (Mellander et al.,
1986a). During this period, and up to about 2 years of age, there is a striking increase
of the IgA level (Alaluusua, 1983). In the following few years very little increase
seems to take place (Alaluusua, 1983; DAmelio et al., 1986); most studies agree that
adult salivary IgA levels are reached late in childhood (Burgio et al., 1980; D'Amelio et
al., 1986). Thrane and colleagues (1991) suggested that the local production of IgA
increased up to 15 months, while no such increase was observed for IgM and IgG cells
after 7 months.
1.6.5 Secretory IgM function
There is evidence to suggest that protection against mucosal infection in individuals
with selective IgA-deficiency might be effectively provided by the compensatory local
production of virus specific IgM and IgG in the intestinal and respiratory tracts
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respectively (Ogra et al., 1974). Gregory and colleagues (1985) found that IgA-
deficient subjects had fewer carious lesions than did immunoglobulin-deficient
individuals, suggesting that the salivary IgM antibodies reduced the level of caries in
these individuals. Arnold and colleagues (1977) observed slgM in the saliva of 11 out
of 38 IgA-deficient patients which comprised functional antibodies directed to antigens
of oral bacteria. Immunohistochemical examination of salivary glands from such
patients revealed numerous IgM-containing plasma cells in locations occupied in normal
individuals by IgA plasma cells (Brandtzaeg, 1975); and significantly increased levels
of innate humoral factors, including lysozyme, were detected (Arnold et al., 1977).
1.7 Prevention of meningococcal disease: chemoprophylaxis and
vaccines
Most cases ofmeningococcal disease result from the transmission of a virulent strain of
N. meningitidis from the nasopharynx of a healthy carrier to a susceptible host. Many
factors facilitate susceptibility to the disease including complement (Ross and Densen,
1984) and immunoglobulin deficiencies (Hobbs et al., 1967); however, the only clearly
defined risk factor for the development of disease is being a close contact of an index
case (Meningococcal Disease Surveillance Group, 1976a; Cooke et al., 1989).
Chemoprophylaxis of contacts of cases can offer protection for a limited period of time.
Only active immunization, preferably of young children who are at greatest risk, can
induce long lasting immunity. Effective vaccines offer the best chance of significantly
reducing the incidence of bacterial meninigitis as has been demonstrated with vaccines
against type b H. influenzae. Prevention of infection is the only realistic method of
reducing the long term morbidity and mortality of meningococcal disease.
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1.7.1 Antibiotic prophylaxis
Eradication ofN. meningitidis from the pharynx of carriers is considered important in
the management of outbreaks ofmeningococcal disease. Prophylaxis with antibiotics
is currently recommended for contacts of persons with invasive disease caused by N.
meningitidis: members of the same house-hold (Olcen etal., 1981); children in day-care
centres (De Wals et al., 1981); closed populations such as military recruits (Sivonen et
al., 1978). Household contacts of patients with meningococcal meningitis often
become colonized by the microorganism (McCormrick and Bennett, 1975); and, in
many cases newly acquired bacteria can lead to disease (Sanders and Deal, 1970).
Sulphonamides were effective not only in eradicating the carrier state but also in
preventing meningococcal disease in military populations; however, the use of
sulphonamides for chemoprophylaxis is now limited by resistance to these drugs in
many areas of the world. In 1973, 57% of serogroup A, 20% of serogroup B, 75% of
serogroup C and 4% of serogroup Y meningococcal isolates were resistant to
sulphonamide (McCormick et al., 1974). The recent outbreak in Stonehouse and
Airdrie were due to sulphonamide-resistant strains (Cartwright et al., 1987; Blackwell
et al., 1990).
Other antibiotics have been examined as alternatives to sulphonamides but with limited
success. Penicillin, ampicillin and erythromycin were ineffective for eradication of
nasopharyngeal carriage of meningococci (Band et al., 1983); however, success has
been obtained with rifampicin, minocycline and ciprofloxacin. Rifampicin is as
effective as minocycline (Weidmer et al., 1971; Shapiro and Wald, 1980). It
eliminates meningococci from the nasopharynx and protects against recolonization
(Sivonen et al., 1978). Several studies have documented the emergence of resistant
strains ofmeningococci following treatment with rifampicin (Weidmer et al., 1971). In
different studies, up to a 12% of the isolates in the nasopharynx were resistant to this
29
antibiotic (Weidmer et al., 1971). A recent study in Gloucestershire found
chemoprophylaxis with rifampicin to be 96% effective in eradicating nasopharyngeal
carriage, but a high secondary attack rate was noted (Stuart et al., 1989). The
secondary cases can be defined as disease in a household contact that begins more than
24 hours and less than 30 days after the index case in the household is hospitalized
(McCormick and Bennett, 1975).
Ciprofloxacin, a carboxyquinolone antibiotic, has been demonstrated to be effective in
adults in eradicating nasal carriage even after a single oral dose (Gaunt and Lambert,
1988). A single intramuscular dose of ceftriaxone proved to be superior to rifamipcin
in eradicating carriage of serogroup A meningococci in Saudi Arabia (Schwartz et al.,
1988). Further studies on the protective efficacy of this agent are required before its
routine use can be recommended.
1.7.2 Vaccines
1.7.2.1 Development of polysaccharide vaccines for serogroup A and
serogroup C
In the late 1960s when the usefulness of sulfadiazine as a prophylactic agent began to
decline and other antibiotics proved to be inadequate substitutes, purified carbohydrate
antigens derived from the capsules of N. meningitidis were developed as vaccines
against serogroups A and C. Their safety and efficacy in older children and adults
have been demonstrated in a number of controlled field trials and epidemic situations
(Erwa et al., 1973; Greenwood and Wali, 1980; Peltola, 1978). Although there are 13
different meningococcal capsular serogroups (Apicella, 1990), serogroups A, B and C
are responsible for approximately 90% of the cases of meningococcal meningitis
(Gotschlich et al., 1977). A tetravalent vaccine composed of serogroup A, C, W135
and Y has proved to be safe and in humans (Cadoz et al., 1985) and is currently in use.
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Unfortunately, only the serogroup A polysaccharide was shown to be an effective
immunogen in infants. Protection by vaccination against disease due to serogroup C
organisms has not been demonstrated in infants below 2 years of age (Frasch, 1983).
Since the peak incidence of meningococcal disease occurs among children less than two
years of age, alternative vaccines are necessary to induce protective immunity to
serogroup C vaccine into the age group at greatest risk.
The immunity gained after recovery from infection by encapsulated bacteria, in terms of
the polysaccharide antigens, differs from that generated by immunization with purified
capsular polysaccharide vaccines (Jennings, 1983). Generally, the immune response
to purified polysaccharides is thymus-independent with production of IgM antibodies;
and, no enhancement of the response is observed after subsequent immunization.
There are exceptions in which a booster response can be induced in young children
with meningococcal serogroup A polysaccharide (Gotschlich et al., 1978), and high
levels of IgG antibodies can be induced in mice with the serogroup C polysaccharide
(Moreno and Esdaile, 1983). Capsular polysaccharide cannot induce consistent,
boostable high titre antibody responses; and, they cannot prime by themselves for IgG
memory response (Anderson et al., 1985).
By comparison with adults, infants respond very poorly to polysaccharide vaccines
(Gotschlich et al., 1977; Peltola et al., 1977); the antibodies produced are almost
exclusively of the IgM isotype, and the immune response is not enhanced by
subsequent vaccination. In infants, due to the nature of their immune responses, these
polysaccharide vaccines are only ofmarginal benefit (Robbins, 1978).
The nature of these different responses in humans has been investigated by studies in
children on the cellular basis of the immune response to polysaccharide. In healthy
human infants, the antibody response to several polysaccharide antigens are delayed in
ontogeny (Smith et al., 1973; Borgono et al., 1978). Precursers of B cells expressing
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specificity for different polysaccharide antigens such as a-l,3-dextran (Howard and
Hale, 1976) and levan (Bona et al., 1979) have been shown to appear late in ontogeny,
whereas precursers to some proteins have been detected on the day of birth.
Polysaccharides have traditionally been characterized as T-independent antigens,
capable of activating B cells without T cell help, producing mainly IgM antibody.
Young children make little or no antibody to such T-cell independent antigens
(Anderson and Betts, 1989). To overcome this problem, polysaccharides have been
conjugated to proteins. Schneerson and colleagues (1980) adopted this approach and
produced conjugates of the capsular polysaccharide of H. influenzae type b with several
proteins. This preparation proved to be significantly more immunogenic than the
polysaccharide alone when injected into immature animals and humans (Schneerson et
al, 1986).
The serogroup A meningococcal vaccine is immunogenic in adults and children,
although antibody responses in children less than two years of age are significantly
lower than in older children (Goldschneider et al., 1973). The duration of the
immunity is also age related; only older children demonstrate evidence of vaccine
derived immunity three years after primary immunization (Kayhty et al., 1980). In
contrast to polyribosyl phosphate (PRP) of type b H. influenzae and other
polysaccharide vaccines, immune responses can be elicited to the serogroup A
meningococcal vaccine in children as young as 6 months of age and a booster response
can be demonstrated in children who have been immunized (Goldschneider et al., 1973;
Gold et al., 1975; Kayhty et al., 1980). Serogroup A meningococcal polysaccharide-
protein conjugate vaccines are under development; these might provide higher level and
longer lasting immunity.
The serogroup C meningococcal polysaccharide vaccine elicits a weaker antibody
response than the serogroup A vaccine. As with other polysaccharide vaccines, it is
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poorly immunogenic in infants and children less than two years of age (Goldschneider
et al., 1973). The duration of the antibody response is also age related, with a faster
decline in antibody levels compared with the serogroup A vaccine (Gold et al., 1979).
No booster response is observed (Goldschneider et al., 1973; Gold et al., 1975), and
there is some suggestion of immunologic tolerance. Infants immunized at a young age
can have lower antibody responses after the booster dose than they did after their
primary immunization (Gold et al., 1975).
1.7.2.2 Problems associated with development of vaccines for
serogroup B capsular antigen
There has been a spectacular lack of success in producing an effective vaccine against
disease caused by serogroup B meningococci. In early trials, the high molecular
weight serogroup B capsular polysaccharide proved to be very poorly immunogenic
even in adults (Wyle et al., 1972). This has been attributed to immune tolerance
induced by the close structural similarity between the polysaccharide and antigenically
cross-reacting oligosaccharides found in human and animal foetal brain (Finne et al.,
1983). The serogroup B polysaccharide primarily induces low-avidity IgM antibodies
with little or no bactericidal activity in conjunction with human complement (Zollinger
and Mandrell, 1983).
1.7.2.3 Group B polysaccharide-OMP complexes
Much research has been carried out on the major OMPs of meningococci as potential
vaccines. Since the response to OMP vaccines is serotype dependent, an effective
vaccine would have to contain a number of the most common serotypes. The outer
membrane proteins of serogroup B meningococci induce anti-meningococcal antibodies
after disease or vaccination (Griffiss et al., 1987a). A vaccine effective against
multiple serogroups, especially serogroup B and C, might need to contain outer
membrane proteins from relatively few serotypes. Much of the work on OMP
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vaccines has been based on serotype antigens found among strains causing outbreaks in
Northern Europe and America. Recent studies suggest that the majority of strains
isolated from patients with meningococcal disease in Greece are non-typable. Vaccines
based on serotype or subtype antigens need to be tailored for specific areas based on
epidemiological monitoring (Tzanakaki et al., 1993).
Serogroup B polysaccharide non-covalent complexed with meningococcal OMPs has
been prepared in several laboratories (Zollinger et al., 1979; Frasch and Peppier, 1982;
Moreno et al., 1985). These vaccine are now being tested in Cuba (Sierra et al.,
1991), Chile (Zollinger et al., 1991) and Norway (Rosenqvist et al., 1991). Such a
vaccine is a mixture of different components, they contain class 1, class 2/3, class 5
OMPs and LOS. The majority of bactericidal response generated by these vaccines is
induced by the class 1, class 2/3 proteins and LOS (Apicella, 1991).
1.7.2.4 Enhancement of immune response to the B capsular
polysaccharide
Another approach is to enhance the immune response to the group B polysaccharide
either by physical manipulation (Zollinger et al., 1979; Frasch and Peppier, 1982;
Moreno et al., 1985) or by chemical modification creating synthetic epitopes capable of
modulating the immune response in such a way as to produce enhanced levels of cross-
reactive antibodies specific for B polysaccharide (Jennings etal., 1986). Sarvamangala
and colleagues (1991) have developed a vaccine consisting of the synthetic B
polysaccharide conjugated with tetanus toxoid. So far the vaccine has been tested only
in mice.
1.7.7.5 Recommended uses of vaccine
The use of capsular polysaccharide as an immunoprophylactic agent against human
disease caused by encapsulated bacteria is now firmly established, mainly for military
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personnel. Licensed vaccines are now available in Britain against serogroups A and C
(Meningivac A & C or ACVax); immunization is recommended for local outbreaks and
contacts of patient with disease due to serogroups other than B (Department of Health,
1990).
Routine vaccination of the civilian population in developed countries in not currently
recommended because the risk of infection is low and most of the endemic disease
occurs in young children. Vaccination is advised to control outbreaks due to
meningococcal serogroups covered by the available vaccines. Routine vaccination is
recommended for travellers to countries recognized as hyperendemic with periodic
epidemic meningococcal disease, such as the meningitis belt of Africa or areas where
recent epidemics have occured such as Saudi Arabia and Nepal. Vaccination of
individuals with a deficiency in one of the terminal complement components or with
properdin deficiency might be effective in preventing disease.
The use of serogroup C vaccine was found to reduce carriage rate by 30-50%
(Gotschlich et al„ 1969b). In another study, a vaccination trial in Africa found
serogroup A polysaccharide vaccine had no effect on the carriage rate (Blakebrough et
al., 1983).
Despite the many advantages of capsular polysaccharides as human vaccines, one
serious limitation of their general use is the poor immune response to these purified
polysaccharides in infants (Robbins, 1978; Jennings, 1983). Determination of the
host parasite interactions that enhance susceptibility of individuals to the disease might
identify the population that should be immunized. Prevention of many of the deaths
and disability caused by meningococcal disease will depend on the efficacy of the
vaccines in infants.
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1.8 Blood groups, secretor status, and susceptibility to
infectious agents
1.8.1 Blood groups and diseases
There is a large body of epidemiological evidence for associations between ABO blood
groups and secretor status with susceptibility not only to infectious disease but also to
other conditions (Mourant, 1989). Examples of the reported association for infectious
disease and ABO blood groups are given in Table 1.2 and that for secretor status in
Table 1.3. Many of the associations between ABO blood groups and diseases were
severely criticised by Wiener (1970) who stated that if an hypothesis could not be
formulated to explain the findings, they were most likely due to chance. Associations
between ABO blood groups and infectious diseases were excluded from these
criticisms as many micro-organisms have antigenic components cross-reactive with
ABH antigens.
The ABO blood group system was first described by Landsteiner in 1900. Epstein and
Ottenberg suggested that the ABO blood groups were inherited characteristics
(reviewed by Race and Sanger, 1975) and later it was demonstrated by von Dungern
and Hirszfeld in 1910 that the blood group of an individual was inherited as a
Mendelian trait in a dominant pattern (reviewed by Mourant et al., 1978). The ABO
groups are inherited through multiple alleles at one locus. Many additional blood
groups were discovered after the ABO system, e.g., Kell, Duffy, M, N, S, I, P and
Lewis.
It has long been known that the ABH blood group determinants are not confined to red
cells but can be found in many secretions and on numerous cells of the human body.
Similar structures are widely distributed in many animals, some plants and many
bacteria. Springer (1970) demonstrated that Gram-negative bacteria express
substances which are similar to the A, B and H antigens of human.
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Table 1.2: Association between ABO blood groups and susceptibility to infections




Influenza A 0 Potter, 1969
M. tuberculosis






Haverkom, and Goslings, 1969















Socha et al., 1969
Robbinson etal., 1971













Foster and Labrum, 1976








Gupta and Chaudhuri 1980
Derensiski etal., 1979
Table reproduced from Blackwell (1989) with modifications.
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Table 1.3: Association between secretor status and susecptibilty to infections







Influenza A and B
Parainfluenza virus
S. pyogenes (Group A)
S. pneumoniae
N. meningitidis














Raza et al., 1991
Haverkorn and Goslings, 1969






































Blackwell et al., 1991
Blackwell et al., 1991
Blackwell et al., 1991
Table reproduced from Blackwell (1989) with modifications.
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1.8.2 Distribution of secretor status
The majority of individuals have the water-soluble glycoprotein form of their ABO
blood group antigens in their body fluids (saliva, urine and ovarian cyst fluid). Non-
secretor individuals do not express their ABO blood group antigens in body fluids.
Because the secretor gene (Se) is inherited in a Mendelian dominant pattern, the
predicted proportion of these two phenotypes within a population is secretors 75-80%
and non-secretors 20-25%. This ratio can vary widely in different ethnic groups and
some geographically isolated populations (Mourant et al., 1978).
Epidemiological evidence from different studies in the United Kingdom, Iceland and
Nigeria suggest that there is an association between non-secretion and susceptibility to
invasive disease caused by meningococci, pneumococci and type b H. influenzae
(Blackwell et al., 1986a; 1986b). In areas where there have been prolonged outbreaks
of meningococcal disease and where the secretor status of the population has been
determined (Northern Nigeria, Iceland), there are unusually high proportions of non-
secretors (Blackwell et al., 1990). In the United Kingdom a similar pattern was found
in Stonehouse (Glouscestershire) (Blackwell et al., 1989b) and Plymouth (Blackwell
and Weir, 1990) where there have been prolonged outbreaks due to the B:15:P1.7,16
strains and among a school population in which an outbreak of meningitis due to a
B:4:P1.15 strain occurred (Blackwell et al., 1990).
1.8.3 The H, Lewis and secretor genes
The secretor (Se) gene also affects expression of the Lewis (Le) blood group antigen.
Non-secretors can only express Lewis3 (Lea) while secretors express Lewisb (Leb)
predominantly and variable amounts of Lea. The Lea in non-secretor saliva was first
identified by Japanese workers in 1939 (for review see Race and Sanger, 1975). In
1946 Mourant described Lea which he had detected on red cells by the use of human
agglutinating sera. Anti-Leb was described by Andersen (for review see Race and
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Sanger, 1975). Unlike the ABO antigens which are part of the structure of red cells,
Lea or Leb antigens are adsorbed from the plasma (see Race and Sanger, 1975).
The Se, H and Le genes have been mapped to the same linkage group of chromosome
19 (see Watkins, 1980). There is active gene H and a silent gene h. The H-deficient
phenotype (h/h) is refered to as Bombay phenotype. Most of these H-deficient
individuals also lack the H determinants in saliva. The (Se) gene also has an active
allele Se and a silent allele se. An individual homozygous for the (SeSe) or
heterozygous (Sese) is a "secretor"; whereas, an individual homozygous for the silent
(sese) is a "non-secretor".
1.8.4 Structures of the ABO and Lewis blood groups
The ABO blood group determinants are carried on macromolecules, mainly
glycoproteins in secretions and glycolipids and glycosphingolipids on the cell surfaces.
Blood group molecules consist of a peptide or lipid backbone to which relatively short
carbohydrate chains are attached. It is generally assumed that the synthesis of
carbohydrate structures occurs in the endoplasmic reticulum and Golgi complex by the
stepwise addition of single sugars, each addition being catalysed by a relatively specific
glycosyl transferase (Dawson, 1978). Most transferases are specific for both the sugar
they transfer and the acceptor molecule. Some transferases such as that coded for by
the Le gene, can transfer the same monosaccharide to several different acceptors leading
to the formation of Lea and Leb (Figure 1.2).
1.8.4.1 Precursor chains
The backbone consists of carbohydrate chains, the terminal groupings of which are
responsible for the specificity. The actual specificity of the molecule is determined by
the sugar occurring at the non-reducing end of the chain. Four types of precursor
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chains that carry the ABH determinants have been described (Rege et al., 1963,
Donald, 1981, Bremer etal., 1984) Table 1.4.
Type 1 precursor is synthesized in epithelia (Rege et al., 1963). It constitutes the main
carrier of ABH and Lewis epitopes in body fluids and secretions. Because they are
adsorbed from the plasma, they are present on the surface of the erythrocytes. Type 2
precursor is the main type found on erythrocytes and coexists with Type 1 precursor on
epithelia (Rege et al., 1963). Both Type 1 and Type 2 chains can occur as branches on
a single carbohydrate chain. Type 3 and Type 4 precursor chains have been only
recently discovered (Takasaki et al., 1978; Donald, 1981). Their biosynthetic
regulation and distribution is not yet fully understood (Clausen et al., 1986).
1.8.4.2 ABH antigens
The terminal sugar responsible for A specificity is N-acetyl-galactosamine attached to
C-3 of the terminal galactose of the H structure, while in the same position D-galactose
determines the B specificity and L-fucose is the sugar associated with H the antigens of
blood group O. The Type 1 precursor chain is fucosylated by the product of the Se
gene, an al-2 fucosyltransferase to form H Type 1 determinants (Watkins et al.,
1988). H Type 1 acts as a substrate for A or B glycosyltransferases to give rise to
their respective antigens. The H gene codes for production of a fucosyltransferase
enzyme which adds L-fucose to the C2 position of the terminal sugar residue of Type 2
chains. The steps in synthesis of the structures of H (Lloyd et al., 1966), A and B
(Painter et al., 1965; Lloyd et al., 1966) determinants based on Type 1 and Type 2
chains are shown in Figure 1.1.
1.8.5 Interaction of the products of the A,B,H, Se and Le genes
Once the H gene encoded transferase has added L-fucose to Type 2 chains, the A or B
gene-specified products can act to add sugars to the chains that carry H determinants.
Cells ofO individuals express the unmodified structure of the H antigen. When both
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Type 1 Type 2
Precursor ^1 ^ P1-4
□"CHD-O- Protein chain D_q_q_0_ iipid chain
Se gene-encoded a 1-2 fucosyltransferase H gene-encoded al-2 fucosyltransferase
H (O) antigen p 1-3 P1-4
oMgOOO al.2g-OCK3
N-acetyl galactosaminyl transferase
A antigen p 1-3 P 1-4
Og"(KK> OHg-0-OO
Galactosyl transferase






Figure 1.1: Production of A, B and H (O) antigens from precursor Type 1 and 2
chains. The enzymes facilitating conversion of antigens are shown. Note that
H Type land H Type 2 are substances for N-acetyl galactosaminyl transferase
and/or galactosyltransferase.
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H and A transferases are present, the precursor chains are converted first to H and then
to A. A similar conversion to B occurs with H and B transferases (Figure 1.2).
The presence of the Se gene means that individuals with hh/SeSe or hh/Sese will
express Type 1 chain based blood group antigens in their secretions but will have no
ABH antigens on their red cells. Such individuals are refered to as para-Bombay
phenotype.
A and B substances cannot appear in saliva without the prior conversion of the Type 1
precursor substance into H. This conversion does not take place in the absence of the
Se gene. The failure to secrete A and B substances depends on the absence of the
requisite H Type 1 structure and not on the absence of the products of the A and B
genes.
The production of the Le determinants is not dependent upon the Se gene product;
therefore, Lea substance is produced whether or not the Se gene is present.
Although there are two antigens, Lea and Leb, there is only one Le gene, which
encodes an al-3/4 fucosyltransferase. The enzyme adds L-fucose to the C-4 position
of the subterminal N-acetylglucosamine of the H Type 1 or precursor Type 1 chain
(Oriol et al., 1986). The presence of Lewis antigens in secretions and on cell surfaces
depends on the expression of the Le gene and not on the Se gene. Individuals who
do not express any Lewis determinants on their red blood cells or in secretions are
known as Lewis-negative (Lea_b").
Since the Lewis antigens are not fully developed at birth, haemolytic disease of new
born due to anti-Lea is almost unknown. Lea determinants are present on the cells of
80-90% of infants at around two months of age (Issit, 1986). Infants express
detectable amounts of Lea, because Lewis enzyme is more active than Se gene product.
As the Se enzyme becomes more active, the levels of Lea drop with the appearance of






Figure 1.2: Production of H, A, B and Lewis antigens in secretions. Note that
the a 1-2 fucosyltransferase (Se gene-encoded) and the al-4 fucosyltransferase
(Le gene-encoded) compete for the precursor Type 1 chain. The al-4 fucosyl¬
transferase also competes with the A and B glycosyltransferasees (see text).
Symbols as in figure 1.1.
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1.8.6 Mechanisms underlying susceptibility of non-secretors to
bacterial infections
1.8.6.1 Factors affecting colonization
Table 1.5 lists examples of blood group antigens that act as receptors for
microorganisms (Blackwell, 1989). The increased proportion of non-secretors among
carriers of some potentially pathogenic bacteria and yeasts might be attributed to the
Lewis3 antigen acting as one of the host cell receptors for some organisms (Blackwell,
1989; May etal., 1989; Rahat, 1990, Tosh and Douglas, 1991; Aly, 1992; Saadi etal.,
1993). Saadi and colleagues (1993) found that buccal epithelial cells (BEC) obtained
from non-secretors bound toxigenic strains of staphylococci in greater numbers
compared with BEC from secretors. Pretreatment of epithelial cells with either
monoclonal anti-Lewis3 or anti-precursor type 1 antibodies significantly reduced
bacterial binding. The attachment of bacteria was positively correlated with the amount
of Lewis3 antigen detected on cells of secretors and non-secretors. A membrane
protein of 67 K. dalton has recently been isolated by affinity purification with synsorb
Lea (Saadi et al., submitted for publication). It has been suggested that the expression
of Lewis3 antigen among young infants might enhance their colonization by
staphylococci. The role of Lewis3 antigen in body fluids on bacterial inhibition needs
to be further investigated.
1.8.6.2 Immune responses, blood groups and secretor status
1.8.6.2.1 Cholera and ABO association
Group O individuals are at greater risk of cholera than individuals of any other ABO
blood group; blood group AB individuals are at lowest risk (Barua, and Paguio, 1977;
Chaudhuri, 1977; Levine et al., 1979; Glass et al., 1985). The work of Clemens and
colleagues (1989) supported these findings, but indicated that these relationships apply
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Kallenius et al., 1980
Vaisanen et al., 1982
Jann et al., 1988
Korhonen et al., 1984




Lea Saadi etal., 1993
May et al., 1986
Raza et al., unpublished
observation
Plasmodium knowlesi Duffy Miller et al., 1975
Table reproduced from Blackwell (1989) with modifications
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only to El Tor cholera. The secretion of blood group substances has not consistently
correlated with the risk of cholera (Chaudhuri and DasAdhikary, 1978; Glass et al.,
1985). As part of a large field trial, Clemens and colleagues (1989) investigated the
relationship between efficacy of the vaccine for cholera and ABO blood groups. The
protection induced by the vaccine to severe cholera was lowest for group O vaccinees
compared with other blood groups. It was suggested that this might reflect a less
effective immune response to the vaccine in group O participants. No hypothesis as to
the mechanisms involved was proposed.
1.8.6.2.2 Immune responses and secretor status
The differences in humoral immune responses associated with secretor status have been
investigated by a number of workers for their possible contributions to prevention of
infection and to explain the increased susceptibility of non-secretors to infection. The
lower immunoglobulin levels found in non-secretors compared to secretors were used
to explain the increased susceptibility of non-secretors to rheumatic fever and rheumatic
heart disease (Glynn et al., 1956, Clarke et al., 1960). Streptococcal tonsillitis was
observed more frequently in non-secretors than in secretors (Chipail et al., 1966).
Haverkorn and Gosling (1969) summarized the studies on secretor status and group A
streptococcal disease and carriage. Group A S. pyogenes was isolated more frequently
from non-secretors than secretors, indicating that secretor status is associated with
carriage of these bacteria. The initiation of disease following colonization could be
influenced by the ability of an individual to generate an immune response to the
bacteria. Lower levels of immunoglobulins found in non-secretors compared with
secretors might result in increased susceptibility to streptococcal infection.
Grundbacher and Shreffler (1970) found that the level of the anti-B isoantibodies in
sera of secretors was significantly higher than those ofnon-secretors; subsequently,
other studies found that non-secretors had lower levels of total salivary IgA
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(Waissbluth and Langman, 1971) and serum IgA (Grundbacher, 1972). Secretors had
higher levels of serum IgG compared with non-secretors, but the differences were not
statistically significant. The authors suggested this might be due to the small number
tested (Waissbluth and Langman, 1971).
Blackwell and colleagues (1987) studied the association between secretor status and
immunoglobulin levels among women who had been followed for 20 years because of
problems with recurrent urinary tract infections. Non-secretor women in this group
had significantly higher levels of total serum IgA than the secretors. The levels of total
serum IgA among non-secretors who had improved over the 20 years period were
higher than those found for secretors who had improved. No differences were found
between these immunoglobulin levels for secretors and non-secretors who had not
improved or in whom there was no change in the number of infections during the
second decade compared with the first decade.
Antibody levels and the carriage of N. meningitidis was studied by Blackwell and
colleagues (1989a). There was no difference in the levels of IgA in the saliva of
secretors compared with non-secretors from whom no neisseriae were isolated.
Compared with non-carriers, carriers had significantly higher levels of salivary IgA.
Both secretor and non-secretor carriers of N. lactamica had salivary IgA levels
comparable to those of non-carriers. Similar results were obtained when patients with
spondyloarthropathies; no difference in total serum or salivary IgA between secretors
and non-secretors was found (Shinebaum et al., 1987).
These conflicting results reported for the differences in immunoglobulin levels between
secretors and non-secretors might be due to effects of environmental factors or
differences in techniques for assessment of antibody levels. Most of these studies
measured total antibodies not specific antibodies for the bacteria under investigation.
Barton and colleagues (1990) found that smokers have higher levels of IgM and lower
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IgA in saliva. Most studies have been limited to serum or saliva (Grundbacher and
Shreffler, 1970; Grundbacher 1972; Blackwell et al., 1986; 1989a). For those studies
in which both serum and saliva were used, most did not measure all three isotypes
(IgA, IgM and IgG) (Blackwell et al., 1986a; 1989a).
The choice of saliva is important and it is limited to either whole saliva or parotid saliva
for practical reasons. Many studies that examined saliva did not describe which type
of saliva was used. Unstimulated whole saliva is easy to collect, has a good flow rate,
and contains only small amounts of serum derived from crevicular fluid (Brandtzaeg et
al., 1970; Lindstrom and Folke, 1973; Izutsu et al., 1985). Mechanically stimulated
whole saliva contains increased contamination with crevicular fluid. The problem with
stimulated saliva obtained by chewing paraffin gum is that the gum absorbs
immunoglobulins from saliva (see Barton, 1992). Parotid saliva contains lower
concentrations of ABH antigens and is difficult to collect.
The choice of technique to measure the antibodies in serum and saliva is important;
however, most studies measured total antibodies in serum and saliva by the SRID
technique. A small error in such a measurement can result in a large error in the
determination of the immunoglobulin concentration. A more sensitive technique would
be particularly useful for the measurement of immunoglobulin isotypes which are
present in lower concentrations.
The total amount of slgA has often been difficult to estimate due to the presence of
monomelic IgA and free SC together with slgA in exocrine secretions. It is difficult to
find a proper standard to use as a reference for the commonly employed
immunodiffusion assay (Brandtzaeg et al., 1970; Wadsworth and Hanson, 1976). A
standard of 7S IgA preparation results in very inaccurate measurement of slgA (Tomasi
and Bienenstock, 1968). The use of a correction factor (1.4) is helpful (Brandtzaeg et
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al., 1970) since IgA is present in the secretions predominantly in a 1 IS form which
diffuses more slowly than the 7S form.
1.9 Aims of the study
This study examines antibodies to meningococci with reference to mucosal colonization
with these bacteria and smoking, a factor associated with carriage of meningococci
(Blackwell et al., 1990; 1992a) and implicated in immunoglobulin levels in parotid
saliva (Barton et al., 1990). This was the first study designed to examine any
functional differences in secretory and serum antibodies of secretors and non-secretors.
The objectives of the study were:
(1) to develop a sensitive, precise and accurate ELISA method for assessing total
immunoglobulins (IgA, IgG and IgM) and those isotypes specific for N. lactamica and
N. meningitidis in serum and saliva;
(2) to determine if there are differences in the immunoglobulin levels of secretors and
non-secretors that could contribute to the apparent increased susceptibility of non-
secretors to meningococcal disease;
(3) to investigate whether there are differences in secretory IgA or IgM levels of
secretors and non-secretors that might affect attachment of meningococci to epithelial
cells;
(4) to determine if there are differences in bactericidal activity against pathogenic and
non-pathogenic strains ofNeisseria in the sera of secretors and non-secretors.
General materials and methods
2.1 Subjects
2.1.1 Staff and pupils of Airdrie Academy
Sera and unstimulated whole saliva specimens (357) were obtained from members of
the staff and pupils (most within the 12-18 years age group) of a school in which there
was an outbreak of meningococcal disease due to a serogroup B, serotype 4, subtype
PI.15 sulphonamide resistant strain (B:4:P1.15) of N. meningitidis. Carriage of
meningococci, secretor status, ABO and Lewis blood group antigens in this population
were reported previously (Blackwell et al„ 1990). Informed consent to participate in
the survey was obtained from parents or guardians of the children.
Sera and saliva examined included samples from:
1) students and staff who were carriers ofN. meningitidis ;
2) students and staff who were not carriers matched as closely as possible for age, sex,
and class or duties within the school if a staff member.
2.1.2 Subjects for binding assay
Unstimulated whole saliva and buccal epithelial cells (BEC) were collected from healthy
students and members of staff from the Department of Medical Microbiology,
University of Edinburgh. The subjects were matched for age, sex and blood type
when a comparison was made.
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2.2 Saliva and serum samples
2.2.1 Collection of saliva
Unstimulated whole saliva specimens from pupils and staff were transported to
Edinburgh within six hours of collection and stored at -20 °C.
Unstimulated whole saliva was also collected from colleagues within the Department of
Medical Microbiology and centrifuged at 1000 g for 20 min. The supernatant was
collected and stored at -20 °C until used. The secretor state of individuals was
determined by haemagglutination inhibition assays with saliva (Mollison, 1983) and
ELISA for H (Rahat, 1990) or Lewis antigens (Raza et al., 1991).
2.2.2 Blood specimens
Blood samples were collected and placed in EDTA anti-coagulant tubes. The plasma
was separated and stored at -20 °C within 24 h of collection. Each was assayed for
ABO blood groups by agglutination with monoclonal anti-A and anti-B antibodies
Scottish National Blood Transfusion Service (S.N.B.T.S.) and for Lewis blood
groups by tube agglutination with monoclonal anti-Lea and anti-Leb antibodies
(S.N.B.T.S.) (Blackwell et al., 1990).
2.3 Collection of epithelial cells
BEC from healthy individuals were collected between 0900 and 1100 h by rubbing the
inside of the cheeks with cotton swabs. To remove the cells, swabs were agitated in
20 ml PBS. Cells were washed three times in D.PBS+B (300 g for 10 min) in a Sorvall
RC2B centrifuge and their concentration adjusted to 2.5 x 105 cells/ml after
determination of the number of cells microscopically with a Neubauer Improved
haemocytometer. Cells from each subject were agitated vigorously to disrupt clumps
prior to use in the adhesion assay.
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2.4 Isolates of Neisseria
One strain of N. lactamica and five different isolates ofN. meningitidis expressing
different combination of serogroup, serotype and subtype antigens were obtained from
the freeze-dried strains in the collection of the Infection and Immunity Laboratory,
Medical Microbiology Department, University ofEdinburgh. The outbreak strain and
a B:15:P1.16 sulphonamide resistant isolate were obtained from Dr. R.J. Fallon,
Meningococcus Reference Laboratory (Scotland), Ruchill Hospital, Glasgow, (Table
2.1). The isolates were characterised as N. meningitidis or N. lactamica by Gram
stain, positive oxidase reaction and the utilization of sugars.
2.4.1 Modified New York City medium (MNYC)
Modified New York City (MNYC) was prepared as described by Young (1978).
Difco gonococcal base was supplemented with 10% horse blood lysed with 0.5%
Saponin, 2.5% yeast dialysate, 0.1% glucose, lincomycin (1.0 (ig/ml), colistin (6
(ig/ml), amphotericin B (1.0 (ig/ml) and trimethoprim lactate (6.5 |ig/ml). The plates
were stored at 4 °C.
2.4.2 Incubation conditions
Standard incubation conditions, unless otherwise stated, were overnight at 37 °C an
aerobic, CO2 enriched (10%) humidified atmosphere.
2.4.3 Maintenance of cultures
All the isolates were maintained in the lyophilised state. When required, ampoules of
the relevant strains were opened and reconstituted with sterile distilled water, 2-3 drops
of the suspension were plated onto MNYC and the drops streaked out to obtain well
isolated colonies. The plates were incubated overnight at 37 °C. Single colonies were
subcultured for preparation of bacterial suspensions.
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Table 2.1: Bacterial isolates
Strain source serogroup serotype subtype
N. meningitidis
All patient B 15 PI.16
A43 patient B 4 PI.15
A41 carrier B 4 -
A26 carrier C 4 -
A48 carrier NG* 4 -
N. lactamica
LOl carrier NG - -
* = Non groupable
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2.4.4 Enumeration of bacteria
An 18 h culture of bacteria was harvested from MNYC and suspended in saline. For
each bacterial strain used, seven doubling dilutions and nine tenfold dilutions were
made. The optical density (OD) was measured with a SP 30 spectrophotometer at 541
nm. Bacteria were also counted directly with a counting chamber (Thoma). A 20 (il
drop of the ten fold dilution was plated onto MNYC, and incubated overnight at 37 °C.
The average number of colony forming units (c.f.u) per 20 pi drop, for each dilution
was multiplied by 50 and then by the dilution factor to calculate the number of c.f.u.
The total count and viable count were correlated with the OD.
2.4.5 Standardization of bacterial concentration
Young (18 h) cultures were used for the ELISA. The bacteria were harvested with
cotton wool swabs, the cell mass was suspended in saline and washed three times by
centrifugation at 1000 g for 20 min. The bacteria were killed by resuspending them in
formalin (2%) overnight. The killed bacteria were suspended in coating buffer and the
bacterial concentration was calibrated at a spectrophotometer reading of 541 nm and
adjusted to 4.8 x 109 c.f.u / ml.
2.5 Solutions for ELISA
2.5.1 Saline for harvesting of bacteria
NaCl (0.85%) in distilled water was dispensed into 100 ml bottles and autoclaved at
121°C for 15 min.
2.5.2 Phosphate-buffered saline (PBS)
PBS contained 8 mM NaHPC>4, 1 mM KH2PO4, 3 mM KC1 and 0.15 M NaCl. The
pH adjusted to 7.2.
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2.5.3 Phosphate citrate buffer (PCB)
PCB contained 0.1 NaHC03 and 0.1 M C(0H)(C00H)(CH2.C00H)2.H20. The pH
was adjusted to 5.0.
2.5.4 Coating buffer
Coating buffer contained 15 mM Na2C03, 35 mM NaH2C03, and 3mM NaN3 (pH
9.6).
2.5.5 Washing buffer
Washing buffer was prepared by adding bovine serum albumin (BSA) (Sigma) 0.1%
(w/v), and Tween-20 0.05% (v/v) to 0.01 M PBS (pH 7.2). The buffer was used for
all washing procedures during the assay.
2.5.6 Blocking buffer
Blocking buffer contained 1% (w/v) BSA in 0.01 M PBS (pH 7.2).
2.5.7 Substrate solution
The substrate solution used to detect horseradish peroxidase contained 40 mg O-
phenylenediamine in 100 ml of 0.1 M phosphate citrate buffer (pH 5.0) activated
immediately before use by adding 40 |il H2O2 (30% v/v).
2.5.8 Monoclonal anti-human IgA
Monoclonal antibody to human IgA (a-chain specific) was a mouse immunoglobulin
class IgGl, clone GA-112 (Sigma, Pool, Dorset, product number 1 0636). It was
diluted in coating buffer for attachment to ELISA plates.-
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2.5.9 Monoclonal anti-human IgM
Monoclonal antibody to human IgM (p-chain specific) was a mouse immunoglobulin
class IgG2b, clone MB-11 (Sigma, product number 1 0636). It was diluted in coating
buffer for attachment to ELISA plates.-
2.5.10 Standard-human-serum
Standard human serum is a stabilized mixture of sera from healthy adults used as a
reference preparation for quantitative determination of immunoglobulins (Behring
Dignostics, U.K., Code ORDT, number 07).
2.5.11 Sheep anti-human IgM (p-chain specific)
The anti-human IgM serum is a pool of selected sheep sera which has been highly
purified for anti-p chain by solid-phase immunadsorption by the Scottish Antibody
Production Unit (SAPU) (product code S 042-205).
2.5.12 Horseradish peroxidase (HRP) conjugated antibodies
2.5.12.1 Rabbit HRP-anti-human IgA
Polyclonal antisera to human IgA (a-chain specific) prepared in rabbits, was
conjugated with horseradish peroxidase (Dako, Code number 216).
2.5.12.2 Sheep HRP-anti-human IgG
The IgG fraction of sheep anti-human IgG was conjugated with horseradish peroxidase
was conjugated to HRP (SAPU, product number S 079-201).
2.5.12.3 Donkey HRP-anti-sheep/goat IgG
The IgG fraction of donkey anti-sheep/goat IgG was conjugated to horseradish
peroxidase (SAPU, product code S048-201).
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2.6 Single radial immunodiffusion plates
2.6.1 Nor-Partigen IgA
Immunodiffusion plates for determination of human IgA (Behring, product number
OSLM 03) contained monospecific antiserum to human IgA (a chain specific) in
agarose gel (assay range 0.42 - 6.34 g/1).
2.6.2 Nor-Partigen IgM
Immunodiffusion plates for determination of human IgM (Behring, product number
OSLP 03) contained monospecific antiserum to human IgM (p. chain specific) in
agarose gel (assay range 0.32 - 4.83 g/1).
2.6.3 Nor-Partigen IgG
Immunodiffusion plates for determination of human IgG (Behring, product number
OSLN 03) contained monospecific antiserum to human IgG (y chain specific) in
agarose gel (assay range 0.23 - 3.4 g/1).
2.7 SDS-PAGE
Proteins were separated by SDS-PAGE using the SDS-discontinous system of
Laemmli (1970) on a mini-protein II cell (Bio-Rad Laboratories Ltd., Watford,
Hertfordshire, U.K). Equal volumes of protein sample and sample buffer were mixed
and heated to 100 °C for 3 min. Approximately 20 pi of sample were applied to each
lane and electrophoresis carried out at a constant voltage of 100 V through the stacking
gel (10% acrylamide) and a constant voltage of 150V through the resolving gel (10%
acrylamide). Proteins were visualised by staining with Coomassie blue [0.5% (w/v)
Coomassie brilliant blue in 25% (v/v) propan-2-ol + 10% (v/v) glacial acetic acid]
followed by destaining with 10% (v/v) glacial acetic acid. Molecular weight markers
(Sigma) in the range of 26,600 to 180,000 were run in parallel. The meningococcal
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outermembrane proteins were identified by their molecular weight as defined in Tsai et
al., 1981.
2.8 Flow cytometric technique
2.8.1 Monoclonal anti-human IgG
Monoclonal anti-human IgG (Fc specific) is of the mouse IgG2a subclass as
determined by double diffusion assay, clone HP-6017 (Sigma, Pool, Dorset, product
number 1 6760).
2.8.2 Pool
Two pools of saliva, one from secretors (n=120) and one from non-secretors (n=120),
were prepared from material collected in the survey of school children. Each contained
a total of 120 ml.
2.8.3 Coupling protein to Sephasose 4B
Monoclonal anti-human IgA, monoclonal anti-human IgG and monoclonal anti-human
IgM were used for the purification of IgA, IgM and IgG from saliva. The three
monoclonal antibodies were coupled to cyanogen bromide activated Sepharose 4B
beads (Pharmacia, Uppsala, Sweden) (0.5 g of dry beads can bind up to 3.5 mg of
protein). Impurities were washed away from the beads by mixing them with 10 ml of
mM HC1 (pH 3.0) for 15 min at room temperature. The beads were pelleted by
centrifugation at 50 g for 5 min. Each of the three antibodies were diluted in coupling
buffer (0.1 M sodium bicarbonate + 0.5 M sodium chloride, pH 9.0).
The gel-protein mixtures were rotated overnight at 4 °C. Unbound material was
removed by centrifugation at 50 g for 5 min. The beads were washed three times with
15 ml NET buffer (0.15 M sodium chloride + 0.04 M Tris + 0.2 mM phenylmethyl
sulfonyl fluoride, pH 7.0). Free active groups on the gel were blocked by mixing with
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1 M ethanolamine (pH 8.0) for 2 h. Non-covently bound material was removed by
three cycles of washing with 15 ml 0.1 M acetate buffer (0.1 M sodium acetate + 1 M
sodium chloride, pH 4.0) and then with 15 ml 0.1 M bicarbonate (0.1 M sodium
hydrogen carbonate + 1 M sodium chloride pH 8.0).
2.8.4 Antibody purification on Sepharose beads
The pool (5 ml) was mixed with 1.5 ml of anti-human IgA, anti-human IgG or anti-
human IgM Sepharose 4B beads (see section 2.8.2). After overnight incubation at
4 °C the supernatant was removed and the Sepharose beads washed three times with 15
ml NET buffer. The antibodies were eluted by incubation with 3 ml of 1 M acetic acid
for 30 min at 20 °C with continuous rotation. The elute was dialysed against three
changes of PBS. The presence and purity of IgA, IgG and IgM antibodies was tested
using ELISA system as described in sections 4.2.1.1 and 3.3.9.1 respectively.
The unbound material of the three pools was kept at -20 °C for further studies.
2.8.5 Analysis of cells by flow cytometery
Analysis was done on an EPICS "C" flow cytometer (Coulter Electronic, Luton, UK)
equipped with a 5 watt laser using a power output of 300 mw at 488 nm. The cells
were selected from a display of forward angle light scatter versus 90° light scatter by
means of a bit map. More than 3,000 cells were analysed from each sample. The
percentage of cells showing fluorescence greater than the background level was
recorded on a one parameter histogram measuring fluorescence on a logarithmic scale.
The mean fluorescence channel values for the positive cells were acquired from a one
parameter histogram measuring fluorescence on a linear scale. The results were
analysed by the immunoanalysis program (Coulter).
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2.9 Solutions for bactericidal assay
2.9.1 Dulbecco's phosphate buffered saline
Dulbecco's phosphate buffered saline (D.PBS) (pH 7.1) was prepared from
Dulbecco's A tablets (Oxoid Ltd., England) to give a solution containing sodium
chloride (5 g/1). potassium chloride (0.2 g/1), sodium phosphate monobasic (1.15 g/1)
and potassium phosphate dibasic (0.2 g/1). Phenol red indicator was added to give a
final concentration of 0.0002%.
Every 100 ml D.PBS was supplemented with 0.5 ml Dulbecco's B containing calcium
chloride (20 g/1) and magnesium chloride (20 g/1) (D.PBS + B).
2.9.2 GC Broth
GC Broth (Difco) (pH 7.2) was prepared to give a solution containing protease peptone
no. 3 (15 g/1), corn starch (1 g/1), potassium phosphate dibasic (4 gA), potassium
phosphate monobasic (1 g/1), and sodium chloride (5 g/1).
2.9.3 Sheep red blood cells
Whole blood taken aseptically from healthy sheep was supplied as a 50% (v/v) mixture
in Alsever's solution (SAPU, product number S 033-220).
2.9.4 Donkey anti-sheep/goat IgG
Anti-sheep/goat IgG is a pool of selected antisera obtained from donkeys immunized
with sheep/goat IgG (SAPU, product number S 024-220).
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Development of ELISA for detection of total and specific
antibodies to Neisseria
3.1 Introduction
Since the introduction of enzymes as markers for the labelling of antigens and
antibodies (Nakane and Pierce, 1966), immunoenzymatic techniques have been
developed and diversified for the qualitative and quantitative detection of
macromolecules. These methods are routinely used for the localisation of antigens (or
antibodies) on tissues, for the detection of antigens (or antibodies) immobilised on
various solid phases, for titration of antibodies and the precise measurement of antigens
and antibodies.
Antibodies to whole bacteria have been detected by fluorescent antibody tests (Lehner et
al., 1976) or by agglutination (Challacombe and Lehner, 1976). These assays are not
very sensitive and are not strictly quantitative. Detection of specific antibodies by the
ELISA method was first described by Engvall and Perlmann (1972). The use of solid
phase immunoassays offers an attractive approach since they combine sensitivity and
specificity and can detect specific isotypes. In addition, the use of ELISA microtitre
plate readers enables a large number of reactions to be read in a short time.
The growing interest in development of meningococcal vaccines has prompted the
establishment of ELISA methods for assay of responses to the vaccines (Rosenqvist et
al., 1988; 1991). The purpose of this study was the development of ELISA methods
capable of reliably quantifying total and specific serum and salivary antibodies. To
optimise the techniques, the following parameters were analyzed: time and temperature
of incubation; buffers used for washing; type and concentration of the reagents;
concentration of saliva and serum in the assay. Information from these analyses was
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used to choose conditions under which the background absorbance was reduced by
preventing non-specific interactions, but at the same time, maximum immunological
and enzymatic reactions were obtained.
3.2 Materials and methods
3.2.1 ELISA system
3.2.1.1 General conditions of the assay
3.2.1.1.1 Detection of the IgA and IgM
For the measurement of total IgM and IgA, a capture ELISA system was used. The
wells of polystyrene microtitre plates were coated overnight at 4 "C with either mouse
monoclonal anti-human IgM or mouse monoclonal anti-human IgA diluted in coating
buffer. The coated plates were washed and blocked with blocking buffer. Serum or
saliva specimen were added and incubated at room temperature. Plates for detecting
IgM were washed and sheep anti-human IgM was added. After washing, HRP
labelled donkey anti-sheep/goat IgG was added to the plates. For IgA plates, HRP
labelled rabbit anti-human IgA was added to the plates.
Finally, the plates were washed and substrate was added. The colour change was
stopped after 20-30 min. by adding 12.5% H2SO4 (Figures 3.1 and 3.2).
3.2.1.1.2 Detection of total IgG
To determine total IgG, serum or saliva specimens diluted in coating buffer were added
directly to ELISA plates and incubated overnight. After blocking with blocking buffer
HRP labelled sheep anti-human IgG was added to the plate. The plates were then
treated as for IgA and IgM (Figure 3.3).
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Optical density (OD) was determined by an ELISA plate reader (Dynatech). Readings
for the test samples were corrected by subtracting the OD of the corresponding blank
which contained no serum or saliva; the OD of the blank was usually between 0.056
and 0.067. Results obtained with a series of twofold dilutions of standard human
serum containing known concentrations of immunoglobulin (mg/ml) were used to
construct a graph from which the OD readings of the specimens could be used to
calculate the immunoglobulin levels.
For detection of specific antibodies, plates were coated with N. meningitidis or N.
lactamica isolates. Serum or saliva was added to the wells. The assay was carried
out as described above to detect antibodies of each isotype (Figure 3.4).
The above variables were each defined by experiments outlined below.
3.2.1.2 Coating with whole bacteria
Bacterial suspensions prepared as described in (section 2.4.5) were prepared in
bicarbonate buffer or PBS. The bacteria (100 p.1) were added to wells of microtitre
plates and the plates incubated overnight at 4 °C.
3.2.1.3 Determination of the dilutions of serum, saliva and reagents
For detection of total IgA and IgM, different concentrations of capture antibody (anti-
human IgA and anti-human IgM) were used to coat the plates with either bicarbonate
buffer or PBS. Serum or saliva specimens and standard serum (50 p,l) were serially
diluted in blocking buffer and added to the capture antibody. HRP-conjugate
antibodies were also tested in the same manner. Assays with different dilutions were
performed to establish: (a) optimal conditions for coating the plate; (b) concentrations of
all the reagents; (c) the OD obtained with the dilutions of serum and saliva fitted within
the curve obtained with standard serum.
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Figure 3.1: Capture ELISA for detection of total IgA in serum
and saliva
O/N = Overnight RT = Room temperature
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Figure 3,2: Capture ELISA for detection of total IgM in serum
and saliva
O/N = Overnight RT *= Room temperature
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Figure 3.3: Direct ELISA for detection of total IgG in serum
and saliva
O/N = Overnight RT = Room temperature
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Figure 3.4: ELISA for detection of anti-meningococcal antibodies
in serum and saliva
Q/N = Overnight RT = Room temperature
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For determination of total IgG, various dilutions of serum, saliva or standard serum
diluted in coating buffer (100 (0.1) were added directly to the plates.
3.2.1.4 Time Course
Serum, saliva and HRP conjugated antibodies (HRP anti-human IgA, HRP anti-human
IgG, sheep anti-human IgM and HRP anti-sheep/goat IgG) were tested at different
times (0 - 4 h) to determine the optimum incubation period for detection of serum and
salivary antibodies.
3.2.1.5 Specificity of the binding assay for detection of total
antibodies
To illustrate that the ELISA is specific, the following method was devised. Mouse
monoclonal anti-human IgA or anti-human IgM were added to separate plates (100 |J.l)
then a constant dilution of serum was added (50 |xl). To separate wells in each plate
one of the three labelled antibodies (50 p.1) was added: HRP conjugated anti-human
IgA; HRP anti-human IgG; or sheep anti-human IgM followed by HRP conjugated
anti-sheep/goat IgG. After washing, the substrate (50 |xl) was added and the reaction
stopped by adding (50 jxl) 12.5 % H2SO4.
3.2.1.6 Specificity of the assay for detection specific antibodies
A serum sample was adsorbed for 1 h at 37 °C then overnight at 4 °C with different
strains of Neisseria;: B:4:P1.15; NG: 4: -; N.gonorrhoeae ; and A. lactamica.. In
addition, serum was incubated with purified outer membrane proteins (OMPs) from the
outbreak strain (section 2.7). OMPs were added to the serum and incubated for 1 h at
37 °C followed by overnight incubation at 4 °C. Binding of unabsorbed and adsorbed
sera to the outbreak strain was examined by ELISA.
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3.2.1.6.1 Preparation of OMPs
Outbreak strain B:4:P1.15 was grown on MNYC under standard conditions. Bacteria
were harvested into 60 ml of PBS (pH 7.2) to give a heavy suspension and centrifuged
at 2000 g for 20 min. The bacteria were resuspended in 30 ml of PBS and sonicated
on ice three times, 6 ml at a time at an amplitude of 6 microns for 60 sec (MSE,
Leicestershire, UK). Unbroken cells were removed by centrifugation at 3000 g for 20
min at 4 °C; and, the total cell envelope fraction from the supernatant was pelleted by
centrifugation at 60,000 g at 4 °C for 60 min. The pellet was resuspended in 30 ml of
2 % (w/v) sodium N-lauroylsarcosine ('Sarkosyl', Sigma) for 20 min at room
temperature. This detergent selectively solubilizes the inner membrane from the crude
envelope preparations and provides a method for obtaining the outer membrane
(Hancock and Poxton, 1988). The remaining outer membrane fraction was pelleted by
centrifugation at 60,000 g at 4 °C for 60 min and resuspended in distilled waster.
3.2.2 Single radial immunodifusion (SRID) system
Immunoglobulins were quantitated by the SRID technique of Mancini et al., (1965)
with commercially available antibody agar plates (IgA, IgG and IgM) (section 2.6). To
check the accuracy of the system, a control serum was added to one well of each plate.
Wells two to twelve were used for the specimens to be examined. Serum (5 pi) was
added to each well with a Behring dispenser. Serum diluted in isotonic saline was
used for IgA, IgG and IgM. The plates were incubated for 48 h in a moist box at 4 °C.
Diameters of precipitin rings were measured in four different directions in millimeters
and the average was taken. All samples with diffusion rings larger than 9.3 mm were
retested with more dilute serum. SRID readings were converted into g/1 value by the
calibration table provided by the manufacture.
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3.2.3 Comparison between ELISA and SRID
For comparison between ELISA and SRID methods, 16 serum samples were used to
compare the values obtained by the ELISA with those obtained by commercially
available SRID.
3.3 Results
Four serum and saliva samples were chosen randomly from the collection to determine
the optimum dilution of serum, saliva and working reagents.
3.3.1 Determination of optimal concentration of antibodies bound
to the solid phase
To obtain the highest level of sensitivity of the ELISA, it was necessary to determine
the optimum concentration of capture antibody to provide an acceptable level of capture
antibody to bind the IgA or IgM from the samples and to prevent non-specific uptake of
immunoglobulins from the serum or saliva. Serum or saliva specimens undiluted were
incubated in wells pre-incubated with 100 jal of different dilutions of capture antibody
in coating buffer. Optimum readings were observed at dilutions from 1/400 to 1/1000
for both mouse monoclonal anti-human IgA and mouse monoclonal anti-human IgM
(Figure 3.5). At higher concentrations, the absorbance reached a plateau. Both
monoclonal antibody preparations gave similar curves. A dilution of 1/500 for both
monoclonal antibodies were used in subsequent experiments.
For IgG assays, the standard and test sera diluted in coating buffer were applied
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Figure 3.5: Titration of monoclonal anti-human IgA (closed) and
monoclonal anti-human IgM (open) for capture ELISA with standard
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Dilutions of the standard serum
Figure 3.6: Titration of IgG in the standard serum coated directly onto
ELISA plates. Each point represents the mean ± SEM of 8 replicates.
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3.2.2 Adsorption of bacteria onto the solid phase
Binding of the bacteria (outbreak strain B:4:P1.15) to the microtitre plates was detected
with antibody from a single donor. Formaldehyde treated bacterial preparations 4.8 x
108/ml could not be bound to the solid phase if suspended in PBS. High levels of
attachment were achieved when carbonate-bicarbonate buffer was used to suspend the
same concentration of bacteria for detection of IgA, IgM and IgG (Figures 3.7 - 3.9).
The results of titrations indicated that at concentrations between 2.4 x 108 and 4.8 x 108
high OD values were obtained within a reasonable reaction time (20 min) with the
substrate. Similar results were found for all strains examined.
3.3.3 Determination of the optimal dilutions of serum and saliva
Serial dilutions of serum or saliva were prepared from one donor and assayed for total
levels of IgA, IgG and IgM. A dilutions of 1/2000 of serum and 1/10 of saliva were
found suitable for total IgA and IgM (Figures 3.10 and 3.11). For detection of IgG in
serum a dilution between 1/30000 and 1/50000 (Figure 3.12) and 1/2 of saliva in
coating buffer was used.
For measurement of specific antibodies to different isolates, undiluted serum or saliva
was used for IgA, IgG and IgM after coating the plate with bacteria (Figure 3.13).
All the above dilutions were selected to obtain the highest level of sensitivity and fitted
within the range of of the slope standard.
3.3.4 Determination of the optimal concentration of HRP-Iabelled
antibodies
Four randomly chosen serum or saliva specimens were used in these assays.
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Concentration of bacteria
Figure 3.7: Binding of bacteria to ELISA plates with bicarbonate
buffer (■, □ ) or PBS (A, A) for detection of serum (closed)
and salivary (open) IgA
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Concentration of bacteria
Figure 3.8: Binding of bacteria to ELISA plates with bicarbonate
buffer (■, □ ) or PBS ( A, A) for detection of serum (closed)
and salivary (open) IgM
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4.8 x 10 4.8 x 10 4.8 x 10 4.8 x 10 4.8 x 10
Concentration of bacteria
Figure 3.9: Binding of bacteria to ELISA plates with bicarbonate
buffer (■, □) and PBS (A, A) for detection of serum (closed)















Figure 3.10: Titration of serum for detection of total IgA (open) and IgM
(closed). Each point represents the mean ± SEM optical density
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1/40 1/20 1/10 neat
Saliva dilutions
Figure 3.11: Titration of saliva for detection of total IgA (open) and IgM
(closed). Each point represents the mean ± SEM optical density
obtained from 4 replicates.
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Serum dilutions
Figure 3.12: Titration of serum for detection of total IgG. Each point













Figure 3.13: Titration of serum IgA (O ), IgG (• ) and IgM ( ■ ) to
meningococci. Each point represents the mean ± SEM optical
density obtained from 4 experiments
(ND = non-diluted)
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3.3.4.1 Detection of IgA and IgG
The dilutions of HRP-labelled antibodies used to detect IgA or IgG bound to the solid
phase are shown in (Figures 3.14 and 3.15). They were tested at dilutions from 1/100
to 1/1600 for HRP anti-human IgA and 1/10 to 1/120 for HRP anti-human IgG in
doubling dilution steps. With increasing amounts of HRP anti-human IgA or HRP
anti-human IgG, the enzymatic activity increased. A dilutions of 1/500 of HRP-anti-
human IgA and 1/20 of HRP-anti-human IgG were used in subsequent assays.
3.3.4.2 Detection of IgM
For detection of IgM, sheep anti-human IgM was added first followed by HRP anti-
sheep/goat IgG. Anti-human IgM was serially diluted from 1/40 to 1/200, and HRP
sheep/goat IgG was diluted from 1/10 to 1/100 (Figures 3.16 and 3.17). Dilutions of
the labelled antibody resulted in dose response curves in assays for detection of total or
specific antibodies in serum or saliva. On the basis of these results, further tests were
routinely performed with dilutions of 1/80 and 1/20 for anti-human IgM and HRP
sheep/goat IgG respectively.
3.3.4.3 HRP-conjugated reagents
Each lot of HRP-conjugated reagent was checked for non-specific binding to the
coating and the blocking reagent (section 2.5.6). Any conjugates yielding a non¬
specific reaction with either the coating antigen or bovine serum albumin were rejected.
3.3.5 The effect of incubation time
Incubation times for the various stages of the assay were selected to combine high
sensitivity with timing convenient for the working day. Figure 3.18 demonstrates the
time course for binding of IgA from serum or saliva to the capture antibody; a levelling
off was observed was reached between 2 and 4 h at room temperature. Similar results
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were obtained in other assays for detection of total IgM or IgG and for detection of
these isotypes specific for the bacteria in serum and salivary antibodies (data not
shown). The influence of incubation time of labelled antibody (HRP anti-human IgA,
HRP anti-human IgG) with the solid phase was determined between 0 - 4 h (Figure
3.19). Anti-human IgM and HRP anti-sheep goat IgG were tested within the same
range (Figure 3.20). On the basis of these results, the tests were routinely performed
for 2 h for all the incubation periods except for donkey HRP anti-sheep/goat IgG which
was 1 h for both serum and saliva, total and specific. For the incubation with substrate
a maximum of 20 min. at room temperature was selected. Within this period, the
reaction was stopped when strong colour had developed in the positive control and the
negative control was still colourless.
3.3.6 Serum standard
Using a standard serum, calibration curves for IgA, IgM and IgG were generated. A
linear relationship was obtained for the three classes of antibodies within the dilutions
of the standard that were used (Figures 3.21 - 3.23).
3.3.7 Linearity
Linearity was tested on the same plate with serial dilutions of three samples selected
randomly and a pool of twenty sera chosen randomly. Figures 3.24 - 3.26
demonstrate the linearity of the four samples tested over a range of dilutions. For each
isotype, the linear part of the graph for test sera was within the linear portion of then-
corresponding standard curve. The results of the linearity are also presented as
coefficient of variance which ranged from 1.5 - 5.1% for the three immunoglobulin
isotypes (Table 3.1).
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HRP anti-human IgA dilutions
Figure 3.14: Titration of HRP anti-human IgA. Each point represents the
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HRP anti human IgG dilutions
Figure 3.15: Titration of HRP anti-human IgG. Each point represents the
mean ± SEM of 4 replicates.
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1/200 1/180 1/160 1/140 1/120 1/100 1/80 1/60 1/40
Anti-human IgM dilutions
Figure 3.16: Titration of sheep anti-human IgM with HRP anti-sheep/goat
IgG (1/20). Each point represents the mean ± SEM of 4 replicates.
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1/100 1/80 1/60 1/40 1/20 1/1 0
Anti-sheep/goat IgG dilutions
Figure 3.17: Titration of HRP anti-sheep/goat IgG with sheep anti-human
IgM. Each point represents the mean ± SEM of 4 replicates.
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0.0 V 1 1 1 1
0 2 3 4
Time h
Figure 3.18: The time course for binding of total IgA from serum (• )
or saliva (Q ) to capture antibody. Values are means ± SEM of
duplicate wells from a representative experiment.
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u.u-^ 1 1 1 1
0 2 3 4
Time h
Figure 3.19: Binding of ofHRP anti-human IgA (O) and HRP anti-human
IgG () to serum IgA and IgG respectively as a function of time. Values
are means ± SEM of duplicate wells from a representative experiment.
90
0.0 1 1 1 1
0 2 3 4
Time h
Figure 3.20: Binding of anti-human IgM ( o ) and HRP anti-sheep/goat
IgG ( s ) to serum IgM as a function of time. Values are means ±
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Figure 3.21: Optical density ofELISA for detection of IgA in the
serum standard. Each point represents a mean ± SEM of 5 replicates.
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Concentration of IgM standard (mg/ml)
Figure 3.22: Optical density of ELISA for detection of IgM in the
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Figure 3.23: Optical density of ELISA for detection of IgG in the
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Concentrations (mg/ml)
Figure 3.24: The linearity of total serum IgA antibodies of four samples
compared to the standard (•). Each point represents the mean
± SEM of 4 experiments.
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Figure 3.25: The linearity of total serum IgM antibodies of four samples
compared to the standard (•). Each point represents the mean













.003 .006 .012 .023 .046 .092 .184 .368
Concentrations (mg/ml)
Figure 3.26: The linearity of total serum IgG antibodies of four samples
compared to the standard (•). Each point represents the mean
± SEM of 4 experiments.
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Table 3.1: Coefficient of variance (CV) values for four readings at different
dilutions for the measurement of the three isotypes. The 4 randomly
chosen samples were compared with the standard curve.
Samples Concentration in mg/ml * C.V. (%)
IgM
pool 15.1 ±0.311 2.0
1 20.8 ± 0.327 1.6
2 8.80 ± 0.326 3.7
3 4.75 ±0.180 3.8
IgA
pool 9.50 ± 0.212 2.2
1 7.75 ± 0.296 3.8
2 17.5 ± 0.319 1.8
3 12.2 ± 0.432 3.5
IgG
pool 7.40 ± 0.212 2.9
1 10.3 ± 0.303 2.9
2 4.90 ± 0.204 4.2
3 5.10 ±0.259 5.1
* Mean of five replicate ± 1S.D.
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3.3.8 Reproducibility
Intra-assay variation was measured by testing eight samples including the pool run in
six replicates on the same occasion at a dilution of 1/2000 on the same plate with a
dilution curve for the standard serum. The mean (range) CV for intra-assay was
2.216% (1.496 - 3.01%), 1.797% (0.863 - 2.644%) and 3.475% (2.255 - 5.844%)
for IgA, IgM and IgG respectively.
Interassay variation of the same eight samples was examined on six occasions and
titrated against the standard serum. The mean (range) CV for interassay was 2.987%
(1.558 - 3.866%), 3.039% (1.04 - 6.135%) and 5.029% (3.062 - 7.324%) for IgA,
IgM and IgG respectively.
3.3.9 Specificity of the assays
The specificity of the assays for total and specific antibodies were determined as
outlined in section 3.2.1.5.
3.3.9.1 Binding of HRP conjugates antibodies
The specificity of the capture assay was tested by adding the three conjugates at the
appropriate step to different wells in the IgA or IgM capture antibody assay. Table
3.2 demonstrates that high OD were obtained only with the corresponding HRP
labelled antibody.
3.3.9.2 Specificity of anti-meningococcal antibodies
The specificity of the assay for detection of antibodies to meningococci has been
determined for the outbreak strain B:4:P1.15 in three different ways.
Binding of antibody to B:4:P1.15 after absorbing the serum with the outbreak strain
greatly reduced the binding for IgA and IgG but less so IgM. Absorption with NG:4:-
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reduced the binding by over 50% for IgA and IgG whereas binding was reduced by
36.3% for IgM antibodies. Absorbtion with N. lactamica reduced the binding by over
50% for IgA and about 30% for IgG and IgM (Figure 3.27). Absorption of human
sera with a mixture of bacteria used in the study virtually abolished the binding of IgG
(Figure 3.28).
3.3.9.3. OMP profile obtained on SDS-PAGE
SDS-PAGE analysis of the crude "Sarkosyl" extract produced a profile typical of
Gram-negative OMPs; there were two major OMPs and a further minor proteins
(Figure 3.29). The two major outer membrane proteins identified in this preparation
are identical to those shown by (Tsai, et al., 1981; Frasch et al., 1985; 1986).
Adsorption of serum with OMPs reduced the binding of antibodies to bacteria by
approximately 55% for IgG and IgM, definite reduction was found with IgA of about
77% (Figure 3.30).
3.3.10 Comparison between ELISA and SRID
The comparison between ELISA and SRID methods for 16 samples of widely differing
immunoglobulin concentration is shown in Figures 3.31 - 3.33. Total IgA, IgG and
IgM were measured in jj.g/1 by ELISA and SRID assays. There was significant
correlation between both assays: IgA r= 0.97; IgG r=0.94; IgM r=0.98. The ELISA
value for serum was significantly greater than the SRID values. Significance of
differences between two detection systems were calculated using Student's t-test (two
tailed): IgA p < .0001; IgM; p < .0008; IgG < 0.0449.
3.4 Discussion
The aim of this study was to develop an ELISA system using whole bacteria suitable
for the routine detection of an antibody response against N. meningitidis. In this study
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Table 3.2: The specificity of the capture antibody assay determined by










HRP anti-sheep/ goat IgG
anti-IgA 0.058 0.634 0.062 0.066





unabsorbed B:4:P1.15 NG:4:- N. lactamica
Strain
Figure 3.27: The antibody bound to B:4:P1.15 before absorption
(unabsorbed) and after absorption of a serum sample with two strains of









Absorbed with cocktail of bacteria
Figure 3.28: Binding of IgG to B:4P1.15 before absorption and after
absorption with a mixture of differentNeisseria isolates. (The blank
value = O.D 0.056)
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Figure 3.29: Separation of outer membrane preparation ofN. meningitidis
(B:4:P1.15) by SDS-PAGE in a 10% gel stained with Coomassie
brilliant blue. The two major outer membrane proteins identified in this
















Figure 3.30: Binding of antibody to B:4:P1.15 from an unabsorbed sample
and after absorption with OMPs ofN. meningitidis (B:4:P1.15).
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IgA (SRID) [gAj
Figure 3.31: Correlation between ELISA and SRID readings for detection









Figure 3.32: Correlation between ELISA and SRID readings for detection
of total IgM antibody
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Figure 3.33: Correlation between ELISA and SRID readings for detection
of total IgG antibody
108
an attempt to standardise ELISAs for the quantitation of human IgA, IgG and IgM anti-
meningococcal antibodies without the use of a specific standard serum was developed
based on the principle of Zollinger and Boslego (1981). The principle of standard-
free ELISA is a combination of two simultaneously performed assays; an indirect
ELISA for specific (anti-meningococcal) antibodies; and a sandwich ELISA for total
immunoglobulin of the antibody class. For this purpose, sandwich ELISAs for
quantitation of total IgA and IgM were developed. Optimal concentrations of capture
antibody and peroxidase-labelled antibody were determined and the assay modified so
that it could be performed simultaneously with the assays for anti-meningococcal
antibodies on one micro-test plate.
The sandwich ELISAs for total IgA or IgM immunoglobulins were used to produce
reference curves from serial dilutions of a standard serum with known immunoglobulin
concentrations. For detection of IgG, the plates were coated directly. The same
conjugate was used simultaneously to detect bound immunoglobulin molecules for both
total and specific antibodies. Equal enzymatic activity in both assays is assumed to
represent identical amounts of the assayed immunoglobulin type. Specific antibody
concentrations for different isolates of Neisseria were determined from the standard
curves for total IgA, IgG or IgM. The standardisation principle can be used to
quantitate specific antibodies in individual serum and saliva samples. The
standardisation conditions were achieved by the use of identical conjugate, assay
conditions and parallel dose-response curves. The advantage of this method is its
independence of any specific standard material. Whenever a direct standard cannot be
obtained, this method is recommended for the quantitation of specific antibodies from
different classes in individual sera and for estabh ting a standard serum. Zollinger
and Boslego (1981) have proposed a procedure for the quantification of specific
antibodies by a combination of two radioimmunoassays (RIA).
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The sandwich method with a standard containing a known concentration of
immunoglobulin of a given class to quantitate the assay was attractive for three reasons.
Firstly, since the method essentially standardizes the conjugated-antibody preparation,
it is independent of the particular antigen used; therefore it can be applied to a wide
range of antigen-antibody systems and to a variety of a solid-phase assays. Secondly,
in studies involving the measurement of antibodies in secretions, both total and antigen-
specific antibody can be measured in the same assay with the same standard. Finally,
since standards for human IgA, IgM and IgG are commercially available, the
verification and comparison of data by different laboratories can easily be
accomplished.
The use of ELISA for quantitation of total and specific antibodies of a particular
immunoglobulin class requires a suitable procedure for optimization of the assay for
each antibody class of interest. The ELISA was composed of a blocking step and four
incubation steps. All steps and working concentrations were adjusted to obtain the
maximum reading while keeping the negative control low. Each interaction step was
followed by washing to remove excess reagents and sample constituents. Two
reagents are especially important: the solid-phase antibody and the peroxidase-labelled
antibody. In the first step, binding of monoclonal antibody to microtitre plate, there is
an optimal protein concentration in the coating solution which leads to the formation of
a monolayer of antibody molecules on the surface of the wells (Cantarero et al., 1980).
The optimum concentration ofmonoclonal antibodies and whole bacteria for coating the
plates were determined by testing different dilutions of these preparations. In this type
ofELISA, the concentration of immunoglobulin class in the sample is directly related to
the peroxidase-labelled antibody bound to the solid phase after the completion of the
ELISA.
There are several commercially available assays for quantitation of normal and low
levels of antibodies in human serum. Quantitation of human serum and salivary
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immunoglobulins has been performed for many years using radial immunodiffusion
techniques (Mancini et al., 1965). This method is based upon the formation of
precipitates as serum components are allowed to diffuse in an agar matrix containing
monospecific antiserum to human IgA, IgG or IgM. The concentration of
immunoglobulin is proportional to the diameter of the ring of precipitation. A small
error in such a measurement can result in a large error in the determination of the
immunoglobulin concentration. A more sensitive technique would be particularly
useful for the measurement of immunoglobulin isotypes which are present in much
lower concentration. In addition, radial immunodiffusion analysis requires incubation
ranging from 18 h to 3 days.
If the concentration of IgM is high, radial immunodiffusion is the method of choice;
however, this method is not of sufficient sensitivity to assay IgM samples in which the
IgM concentration is low and a more sensitive method is needed. Among the most
sensitive methods, RIA (Jensenius et al., 1983) and ELISA (Dinesen and Saxtrup,
1979; Ishiguro et al., 1982; Smart and Koh, 1983) have been employed for IgM
quantitation. Dinesen and Saxtrup, 1979 used two-site solid phase (coated cuvettes)
enzyme immunoassay. Ishiguro and colleagues (1982) also used two-site solid phase
in which the antiserum was immobilized on silicone rubber pieces. Smart and Koh
(1983) used a competitive inhibition enzyme immunoassay. A sandwich design (two-
site solid phase) has been used in the present method.
Compared with ELISAs, RIAs, while quite sensitive, have several disadvantages for
routine serology. The first disadvantage is the need for relatively expensive counting
and monitoring devices as well as adequately trained personnel. Secondly, reagents
are expensive and have a short life span.
The ELISA is of comparable sensitivity and specificity compared with counterimmu-
noelectrophoresis (CIE) precipitin methods. Compared with the CIE method an
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ELISA with whole bacteria as antigen, is easier when handling a large number of
samples and quantitative results can be obtained.
The aim of this part of the study was to develop a sensitive, precise and accurate
method for assessing total immunoglobulin levels and those specific for meningococci
in serum and secretions. The data generated and the slopes of the dose response
curves were linear for a wide range of immunoglobulin concentrations or serum
dilutions. This eliminated a major criticism of using only a single dilution of unknown
samples (Challacombe, personal communication); because the dilution slope of the
sample is the same as that of the control, the affinity of the sample and control are
similar. The CV of linearity was between 1.5-5.1% and did not vary between the test
sera and the standard.
A number of ELISA tests using whole bacteria as antigen have been developed for
epidemiological and diagnostic purposes (Floegtad et al., 1990). By using whole
organisms, one uses a preparation similar to that to which the immune system of the
host is exposed. Antibodies to a variety of cell surface antigens might, therefore, be
detected. The results of the present study show that adhesion, and more importantly,
retention of bacteria to a polystyrene surface can be achieved directly with coating
buffer at pH 9.6. This eliminates the need to use either IgG antibodies coated to the
plastic surface followed by the immunoadsorption of the corresponding micro¬
organism or a polyaldehyde derivative (methyl glyoxal) to link the bacteria directly to
the solid phase. PBS was ineffective as a coupling agent.
In a parallel trial, antibody levels obtained with the ELISA and a SRID assays of the
same aliquot of serum revealed that the ELISA provided significantly higher values.
The superiority of the ELISA over the SRID technique lies in its sensitivity.
Evidence of specificity of the ELISA for each isotype was obtained with experiments
involving the addition of the three HRP labelled antibodies to separate wells of the same
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plate. Those conjugates mismatched with the capture antibodies in the system gave
low readings. For instance, on the IgA capture plate, high reading were obtained with
corresponding conjugated antibodies (HRP anti-human IgA); however, with other
conjugates, the results were the similar to the background reading. This excluded the
possibility that other components in serum or saliva could interact with the antigen-
binding site of the molecules, either in a cross reactive manner or by non-specific
binding. The specificity of the assay was also determined by absorption of the serum
with different isolates of Neisseria and a mixture of all the strains used in this study.
In addition, the specificity was determined by absorption of the serum with OMPs.
The assay has proved sensitive and reproducible and has been satisfactory for all
isolates so far examined. The technique for coating the bacteria is easy to perform and
to standardize. The method can be applied to a wide range ofNeisseria isolates and
should allow antibodies to particulate antigens to be assayed by solid phase methods.
The ELISA systems described above were used in subsequent studies to investigate the
differences in the total and specific immunoglobulin levels, in serum and saliva,
between secretors and non-secretors.
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Secretor status and humoral immune responses to N.
lactamica and N.meningitidis
4.1 Introduction
Protective immunity to disease due to N. meningitidis is associated with the presence
of an intact complement system and opsonization or bactericidal antibodies specific for
the invading strain (Goldschneider et al., 1969a; b; Lee et al., 1978). These antibodies
can be formed through nasopharyngeal carriage of meningococci (Reller et al., 1973).
The majority of individuals who develop invasive disease lack protective antibody to
the pathogen (Goldschneider et al., 1969a; b). The age range in which meningococcal
infection is most prevalent (6 months to 4.5 years) reflects the natural development of
antibodies to these pathogens.
The ability of the host to resist infection or colonization by microorganisms is partly
dependent on the presence of a fully functional mucosal immune system. Although
IgA is the most abundant immunoglobulin in exocrine secretions such as tears, saliva
and milk, IgG and IgM are also found in these fluids (Brandtzaeg et al., 1970; Smith et
al., 1989). IgM can also function as a true secretory immunoglobulin (Brandtzaeg,
1981), reaching the mucosal surface by the identical secretory-component mediated
transcellular pathway that transports IgA. The full protective potential of slgA is not
present in the infant at birth (Berg, 1968). Adult levels of slgA are not reached until
after one year of age (Burgio et al., 1980; Mellander et al., 1984). It has been
suggested that in infants the presence of IgM compensates partially for the low levels of
IgA (Mellander et al., 1984). IgM to poliovirus and E. coli has been found in infants
(Mellander et al., 1984; 1986a).
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Non-secretors of ABO blood group antigens are over-represented among patients with
disease due to N. meningitidis (Blackwell et al., 1986a) and in one study among
carriers of this bacterium (Blackwell et al., 1990). The lower immunoglobulin levels
found in non-secretors compared with secretors have been used to explain the increased
susceptibility of non-secretors to rheumatic fever and rheumatic heart disease (Glynn et
al., 1956; Clarke et al., 1960). In later studies, non-secretors were reported to have
lower levels of both serum (Grundbacher, 1972) and salivary (Waissbluth and
Langman, 1971) IgA. It was suggested that specific immune responses at mucosal
surfaces of non-secretors might be compromised compared with that of secretors.
The objectives of this part of the study were to use an ELISA system to examine the
following questions:
1) Is there a differences in the amount of total serum and salivary IgA, IgG and
IgM of secretors compared with non-secretors?
2) Is there a difference in the levels of isotypes specific for N. lactamica and N.
meningitidis in serum or saliva of secretors and non-secretors?
3) Is there a correlation between levels of specific anti-meningococcal antibodies in
secretions and in serum?
4) Does recent carriage ofmeningococci affect the levels of antibody to these
bacteria found in secretors and non-secretors?
4.2 Materials and Methods
4.2.1 Determination of immunoglobulin antibodies in serum and
saliva by an ELISA technique
Sera and saliva specimens (357) were obtained from staff and pupils (most within the
12-18 years age group) of a school in which there was an outbreak of meningococcal
disease.
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4.2.1.1 Determination of total immunoglobulin isotype levels.
The total amounts of IgM and IgA were assayed by a capture ELISA method. IgG from
serum and saliva was coated directly onto ELISA plates. For the measurement of total
IgM and IgA, the wells of polystyrene microtitre plates were coated overnight at 4 °C
with either 100 pi ofmouse monoclonal anti-human IgM (1/500) or mouse monoclonal
anti-serum IgA (1/500) diluted in coating buffer. The coated plates were washed three
times with washing buffer and blocked with blocking buffer for 30 min. After
washing, 50 pi of serum (1/2000) or saliva (1/10) diluted in blocking buffer were
added and incubated for 2 h at room temperature. Plates for detecting IgM were
washed and 50 pi of sheep p-chain specific anti-human IgM (1/80) were added. After
washing, 50 pi of HRP donkey anti-sheep/goat IgG (1/20) were added to the plates
for 1 h. For IgA plates, 50 pi ofHRP rabbit a-chain specific anti-human IgA (1/500)
were added to the plates and incubated for 2 h.
Finally, the plates were washed and 50 pi phosphate citrate buffer containing the
substrate O-phenylenediamine (0.4 mg/ml, pH 5.0) activated by 40 pi H2O2 (30% v/v)
were added. The colour change was stopped after 20-30 min by adding 50 pi of
H2S02 (12.5%).
To determine total IgG, 100 pi of serum (1/30000-1/50000) or saliva (1/2) diluted in
coating buffer were added to the microtitre plates and the plates incubated overnight.
After washing, 50 pi of HRP sheep anti-human IgG (1/20) diluted in blocking buffer
were added for 2 h. The plates were then treated as for IgA and IgM.
Optical density at 490 nm was determined by an ELISA plate reader (Dynatech) and
corrected by subtracting the O.D. of the corresponding blank. A series of twofold
dilutions of standard human serum containing known concentrations of
immunoglobulins (mg/ml) were tested with the specimens from the study. Samples
were tested in duplicate and the readings averaged. ELISA readings were converted to
mg/ml by extrapolating from the curve that was constructed from the readings obtained
with standard human serum: IgG = 1140 mg/dl; IgA = 250 mg/dl; IgM =114 mg/dl.
4.2.1.2 Whole cell ELISA for detection of antibodies to Neisseria
Sera and saliva were examined for anti-meningococcal antibodies by whole cell ELISA
(section 3.3.2). N. meningitidis and N. lactamica were cultured overnight on MNYC
agar at 37 °C. Large batches of microtitre plates were coated with bacteria to minimise
variations due to different antigen preparations and coating procedures. Plates were
coated overnight at 4 °C with 100 |il of one of the six bacterial isolates (4.8 x 108
bacteria /ml). The plates were washed and blocked with blocking buffer. The buffer
was removed and the plates washed with washing buffer. Undiluted serum or saliva
(50 |il) was added to the wells and incubated at room temperature for 2 h. The assay
was continued in the same way as the ELISA for total antibodies. The assays for total
and specific antibodies were determined at the same time under the same conditions.
4.2.2 Statistical Methods
The statistical analysis of the data was performed with the package SPSS/PC+. The
results were summarised by geometric means since the logarithmic values were more
normally distributed than the raw data. The significance levels for differences between
groups were examined with the Mann-Whitney U test and a P value of 0.05 was
regarded as significant. The association between levels of antibodies in serum and in
saliva was assessed by Spearman rank correlation.
4.3 Results
A total of 39 variables was recorded for each subject, including: secretor status,
carriage of meningococci, smoking habit, total serum and salivary IgA, IgM and IgG
and specific IgA and IgM to six different isolates ofNeisseria.
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4.3.1 Total IgA, IgG and IgM antibodies of secretors and non-
secretors
The results of the serum and salivary immunoglobulin determinations are shown in
Tables 4.1 - 4.5. There was no marked difference in total immunoglobulin levels in
sera from secretors compared with non-secretors. Non-secretors had higher levels of
the serum IgM antibody compared with secretors, but the difference was not
statistically significant. There were differences in the levels of IgA or IgG in the saliva
from secretors compared with non-secretors; but, there was significantly more total
IgM in the saliva of secretors (p = 0.0274) (Table 4.4).
There was no difference in serum or salivary immunoglobulin levels of smokers (37)
compared with non-smokers (320) (p > 0.05).
4.3.2 Specific immune responses to Neisseria species
The results of the specific immune responses to the Neisseria species tested are shown
in Tables 4.1 - 4.5. There was no marked difference in antibody levels to the isolates
in sera of secretors compared with non-secretors, except for IgM to the non-groupable
serotype 4 isolate (Table 4.3).
There were significant differences in the mean specific salivary IgM immunoglobulin
levels of secretors and non-secretors. Non-secretors had significantly lower levels of
IgM for A. lactamica and each of the meningococcal isolates tested (Table 4.4), the
highest levels of IgM were observed for the NG:4 isolate. Statistical comparison of
IgA and IgG antibody levels was also performed, but there was no difference between
secretors and non-secretors (Table 4.2 and 4.5).
4.3.3 The correlation between serum and salivary antibodies
Analysis by the Spearman correlation test found no correlation between the levels of
IgG, IgA and IgM antibodies in serum and saliva (p > 0.05). This suggests that the
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Table 4.1: Geometric mean levels of total and specific
serum IgA of secretors and non-secretors.
IgA non-secretors secretors P
serum n = 107 n = 169
total IgA 1.34 1.29 0.30
specific
N. lactamica 14.0 13.0 0.72
B:15:P1.16 12.0 10.0 0.38
C:4 13.0 10.0 0.35
B:4 12.0 11.0 0.76
NG:4 17.0 16.0 0.98
B:4:P1.15 7.1 7.5 0.75
units are for mean total serum IgA is expressed in mg/ml and
specific IgA in |lg/ml.
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Table 4.2: Geometric mean levels of total and specific
salivary IgA of secretors and non-secretors.
IgA non-secretors secretors P
saliva n = 128 n = 205
total IgA 0.37 0.42 0.13
specific
N. lactamica 3.4 3.6 0.56
B:15:P1.16 4.0 3.8 0.85
C:4 3.7 3.4 0.63
B:4 3.4 3.5 0.67
NG:4 7.2 7.3 0.98
B:4:P1.15 9.5 7.1 0.12
units are for mean total salivary IgA is expressed in mg/ml and
specific IgA in (ig/ml.
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Table 4.3: Geometric mean levels of total and specific
serum IgM of secretors and non-secretors.
IgM non-secretors secretors P
serum n = 107 n = 171
total IgM 1.27 1.08 0.05
specific
N. lactamica 9.7 7.7 0.12
B: 15:P1.16 10.5 8.5 0.15
C:4:- 6.0 5.3 0.25
B:4:- 22.4 14.7 0.11
NG:4:- 26.4 22.2 0.03
B:4:P1.15 5.2 4.8 0.48
units are for mean total serum IgM are expressed in mg/ml
and mean specific IgM in (ig/ml.
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Table 4.4: Geometric mean levels of total and specific
salivary IgM of secretors and non-secretors.
IgM non-secretors secretors P
saliva n = 129 n = 205
total IgM 63.0 87.0 0.027
specific
N. lactamica 1.8 2.5 0.0000
B:15:P1.16 2.1 3.1 0.0000
C:4 2.9 3.6 0.040
B:4 2.2 3.5 0.0000
NG:4 4.7 5.9 0.017
B:4:P1.15 1.9 2.9 0.0008
units are for mean total and specific salivary IgM levels are
expressed in pg/ml.
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Table 4.5: Geometric mean levels of total and specific
IgG of secretors and non-secretors.
IgG non-secretors secretors P
serum n = 103 n = 170
total IgG 8.22 7.21 0.29
specific
N. lactamica 5.4 5.3 0.55
B:15:P1.16 5.4 4.2 0.64
C:4 4.5 4.5 0.90
B:4 4.1 3.4 0.61
NG:4 4.6 4.6 0.44
B:4:P1.15 4.4 4.3 0.51
saliva n = 36 n = 48
total IgG 3.9 4.2 0.46
units are for mean total serum IgG levels are expressed in mg/ml
and total salivary and specific serum IgG levels in |lg/ml.
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Table 4.6: Geometric mean of immunoglobulin levels of carriers and
non-carriers
isotype strain
Mean immunoglobulin levels (|lg/ml)
carriers (n) non-carriers (n) P
serum
IgA C:4 18.0 (67) 13.0 (209) 0.03
IgA B:4:P1.15 9.5 (66) 8.4 (207) 0.02
IgM N. lactamica 14.4 (68) 7.1 (210) 0.0000
IgM B:15:P1.16 13.8 (68) 8.2 (210) 0.0002
IgM C:4 12.4 (68) 4.1 (210) 0.0000
IgM B:4:P1.15 8.3 (66) 6.5 (207) 0.0025
IgG B:4:P1.15 7.2 (64) 6.1 (207) 0.0033
IgG C:4 5.3 (68) 4.2 (205) 0.01
total IgG* 8.28 (68) 7.36 (205) 0.03
saliva
IgA NG:4 9.7 (89) 6.6 (243) 0.01
IgM NG:4 6.5 (89) 5.1 (243) 0.03
* = unit for mean total serum IgG are expressed in (mg/ml)
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Table 4.7: Geometric mean of salivary IgM levels of secretors
and non-secretors among non-carriers
Mean immunoglobulin levels ((ag/ml)
non-secretors (n) secretors (n) P
Total IgM 43.4 (86) 90.05 (158) 0.0007
N. lactamica 1.83 (86) 2.60 (158) 0.0004
B:15:P1.16 2.18 (86) 3.09 (158) 0.0013
C:4:- 5.01 (86) 5.87 (158) 0.135
NG:4:- 4.38 (66) 5.46 (207) 0.0039
B:4:- 2.26 (86) 3.60 (210) 0.0000
B:4:P1.15 1.99 (73) 2.84 (210) 0.0314
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Table 4.8: Geometric mean of salivary IgM levels of secretors
and non-secretors among carriers
Mean immunoglobulin levels ((ig/ml)
non-secretors (n) secretors (n) P
Total IgM 1.5 (45) 1.9 (52) 0.63
N. lactamica 2.29 (43) 3.61 (49) 0.01
B:15:P1.16 3.07 (43) 4.84 (49) 0.001
C:4:- 3.79 (43) 4.55 (49) 0.22
B:4:- 3.29 (43) 4.94 (49) 0.005
NG:4:- 7.39 (34) 8.80 (32) 0.14
B:4:P1.15 2.83 (43) 4.43 (49) 0.09
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increased levels of secretory IgM found among secretors are due to locally produced
immunoglobulins.
4.3.4 Carriage of meningococci and immunoglobulin levels
Compared with non-carriers, carriers of meningococci had significantly higher levels of
antibodies to some isolates in serum and saliva (Table 4.6); however, analysis with
respect to both secretor status and carriage revealed that immunoglobulin levels still
differed according to secretor status when carriage was taken into account. Among the
non-carriers, IgM in saliva was significantly higher in secretors, both total salivary IgM
(p < 0.001), and specific salivary IgM: N. lactamica (p < 0.001); B:4:P1.15 (p <0.05;
B:4:- (p < 0.001), B:15:P1.16 (p < 0.001) and NG:4:- (p < 0.05) (Table 4.7). Among
the carriers, IgM in saliva was significantly higher in secretors for N. lactamica (p =
0.01), B:15:P1.16 (p = 0.001) and B:4:- (p = 0.001) (Table 4.8).
4.4 Discussion
The results provided evidence to answer the questions posed in the introduction: (1)
There was no marked difference in total immunoglobulin levels in sera from secretors
and non-secretors. (2) There was no difference between secretors and non-secretors in
total or specific levels of salivary IgA or IgG; however, non-secretors had statistically
significantly less total IgM in their saliva compared with secretors. These differences
were also observed for salivary IgM to N. lactamica and to five isolates of
meningococci expressing different combinations of serogroup, serotype and subtype
antigens. (3) There was no correlation between levels of serum IgM and secretory
IgM in saliva, suggesting that salivary IgM is locally produced and has not leaked from
the serum. (4) Although serum and saliva of carriers had significantly higher levels of
antibodies to some of the Neisseria isolates, the effect of secretor status on IgM
remained after adjustment for the effect of carriage.
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The association between secretors status and antibody levels has been investigated by a
number of researchers, often with conflicting results. Many of these studies failed to
look at the factors that might influence results: serum compared with secretory
antibodies; total isotype levels; specific isotypes levels; the effect of carriage; the effect
of smoking; type of saliva used whether stimulated or unstimulated. Some of the
discrepancies might be attributable to the fact that previous studies did not take into
account all the factors outlined above; many studies have used only serum in their study
(Grundbacher and Shreffler, 1970; Grundbacher, 1972; Blackwell et al., 1986b).
Most of the previous studies measured total amounts of immunoglobulin in serum and
saliva (Grundbacher, 1972; Blackwell et al., 1989a). Waissbluth and Langman (1971)
measured total IgA, IgG and IgM in serum and IgG and IgA in saliva; but they did not
measure IgM in saliva. The measurement of specific immune response and the effect
of carriage is important; Grundbacher (1972) measured total antibodies only to explain
the association between non-secretion with susceptibility to rheumatic fever and
rheumatic heart disease. This present study covered the factors identified so far that
might influence antibody levels (smoking and carriage) and measured total and specific
levels of the three classes of antibody for strains with different antigenic phenotypes.
The ELISA was more sensitive than SRID technique used in other studies (Waissbluth
and Langman 1971; Grundbacher 1972; Blackwell etal., 1987).
Lower levels of both serum (Waissbluth and Langman, 1971) and salivary IgA
(Grundbacher, 1972) were reported for non-secretors, suggesting that specific immune
responses at the mucosal surfaces of non-secretors might be compromised compared
with secretors. Blackwell and colleagues (1989a) did not confirm this earlier
observation with SRID; higher levels of IgA were associated with the presence of
meningococci in the individuals from whom the saliva was obtained.
Two recent studies provided evidence of the effects of smoking on local immunity in a
case-controlled study ofmeningococcal carriage during an outbreak of meningococcal
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disease. Smoking significantly increased the carriage rate; however, secretory
antibodies to meningococci were not measured (Stuart et al., 1989; Blackwell et al
1990; 1992a).
Diminished local antibody production might account for the increased carriage rate. The
effects of smoking on the concentrations of salivary immunoglobulin isotypes have
been investigated in many studies, with conflicting results. Barton and colleagues
(1990) found that smokers have higher levels of IgM and lower IgA in saliva. In
contrast Olson and colleagues (1984) who used the SRID technique and this study
using ELISA found no difference between smokers and non-smokers. The small
number of smokers in the present study are considered to be light smokers because of
the age range sampled (most within the 12-18 years age group). In addition, the type
of saliva is important; whole saliva was used in this study and in Olson's work (1984),
whereas Barton and colleagues (1990) used parotid saliva.
There is a large literature on the influence of ageing on systemic immune parameters but
few studies of its effects on secretory immunity. In a small study, using the SRID
technique with unstimulated saliva, total salivary IgA and IgG levels were not different
between 10 young and 10 old subjects; IgM was not detected (Ganguly, 1987).
Others have demonstrated a fall in total IgA concentration in nasal secretion with age
(Alford, 1968). IgA subclasses in parotid saliva did not change with aging in a
comprehensive study (Smith et al., 1987). Salivary antibodies become detectable in
the neonatal period, and slowly mature to adult levels. There is no conclusive evidence
of any changes in salivary antibodies in a healthy aged population (Barton, 1992).
A major biological role of high molecular weight, polyvalent IgA and IgM secretory
antibodies might be to provide a first line of defence against particulate and polyvalent
antigens such as bacteria. Individuals with IgM deficiency appear to be at risk of
disseminated meningococcal disease (Hobbs et al., 1967; Jones et al., 1973). It has
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been demonstrated that locally produced IgM in IgA-deficient patients had anti-viral
activity (Ogra et al., 1974). The lower levels of slgM in non-secretors might
contribute to susceptibility to colonization, particularly among infants under the age of
12 months in whom slgM is the major class of antibody on mucosal surfaces. The
presence of slgM in early infancy has been suggested to compensate for the absence of
slgA (Mellander et al., 1984). IgM has been detected in saliva of infants who were as
young as one month of age (Gleeson et al., 1982). If slgM provides a crucial host
defence during this period of life the lower levels of slgM found for non-secretors
might contribute to their apparent susceptibility to meningococcal disease.
The carrier state and the subsequent natural immunization to meningococci that occurs
are logical starting points in investigating the human immune response to this organism.
The method developed here and the results will be useful in examination of serum and
secretory response to antigens under consideration as candidate vaccines.
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Inhibitory effect of saliva on attachment of bacteria to
epithelial cells
5.1 Introduction
The ability of a number of bacterial pathogens to cause disease is associated with then-
ability to attach to mucosal surfaces (Smith, 1977; Silverblatt and Cohen, 1979; McGee
et al., 1988). Although non-specific factors such as surface charge, pH, ionic
bridging and hydrophobic interactions might be important (Watt and Ward, 1980),
specific adherence of microorganism to epithelial cells is an important step in the
colonization process.
Early investigators of meningococcal pathogenesis identified the nasopharynx as the
natural habitat of these bacteria. This was suggested to be the site from which the
organism was transmitted to other individuals (see Stephens and Whitney, 1985). The
meningococcal carrier state and, most likely, meningococcal disease result from the
initial colonization of nasopharyngeal mucous membranes by N. meningitidis. Once
colonization is established, internalization of the bacteria by epithelial cells is possible
(Stephens, 1989).
Colonization of mucosal surfaces by bacteria is in part determined by the capacity of the
host to block attachment to specific receptors on epithelial cells. The first line of
defence is the immunoglobulins, primarily secretory IgA, and high molecular weight
glycoconjugates present on the mucosal surface that prevent the interaction of bacterial
adhesins with complementary host cell receptors (Gibbons and van Houte, 1975;
Beachey 1981).
As this present study showed that non-secretors had lower levels of total IgM and IgM
specific for Neisseria, a flow cytometric assay was developed to assess the effect of
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salivary antibodies on the attachment of meningococci to epithelial cells. The
following questions were examined:
1) Does saliva contain factors that might inhibit the attachment of meningococci to
buccal epithelial cells (BEC)?
2) Is there any difference between saliva specimens from secretors and non-secretors in
their ability to inhibit binding ofmeningococci to epithelial cells?
3) Is saliva from which specific antibodies have been absorbed still capable of
inhibiting the attachment of meningococci?
4) Is salivary IgA the prime factor in the inhibition of bacterial binding to epithelial
cells?
5.2 Materials and Methods
5.2.1 Antibody source
5.2.1.1 Pool
Two pools of saliva, one from secretors and one from non-secretors, were prepared
from material collected in the survey of school children (section 2.8.2). Each pool was
divided into four aliquots. The first was not treated. The second was absorbed with a
mixture of bacteria (absorbed). The third was absorbed with the bacteria then filtered
as outlined below (absorbed/filtered). The fourth was used for the preparation of
purified IgA and IgM (section 2.8.4).
5.2.1.2 Absorption of the pool
A 30 ml. aliquot of the pool was absorbed with the washed sediment of bacterial
suspension containing > 1010 bacteria for 2 h at 37 °C with shaking followed by a
further 24 h at 4 °C without shaking. The bacteria were removed from the saliva by
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centrifugation at 1500 g for 20 min. This procedure was repeated three times. Each
absorption was carried out with a mixture of the Neisseria strains used in this study.
This was done to remove any reactive antibodies present.
5.2.1.3 Absorption and filtration of the pool
The further aliquot of the pool was absorbed as outlined above then filtered initially
with a 5 |im bacterial filter (Nucleopore Corporation, Pleasanton). The saliva was then
passed through a filter (0.22 pm) with a sterilising Nuflow cellulose acetate membrane
(Oxoid Ltd., England). This procedure was performed because any unlabelled
components of bacteria remaining after centrifugation might competitively inhibit the
attachment of fluorescein-labelled meningococci to epithelial cells.
5.2.2 Quantitation of antibodies
Specific N. meningitidis antibodies were measured with the whole cell ELISA (section
4.2.1.2) in the saliva preparations: unabsorbed pool, absorbed pool, absorbed/filtered
pool and fresh saliva collected from laboratory staff. Purified IgA and IgM were also
measured by the same technique, the purity of each isotype was checked with the
ELISA as described in section 4.2.1.2.
5.2.3 Labelling the bacteria
The method used is a modification of that described by Wright and Jong (1986) for
labelling bacteria with fluorescein isothiocyanate (FITC) (Sigma). A heavy suspension
of bacteria in PBS was prepared from colonies grown overnight on MNYC plates.
Bacteria were washed three times in D.PBS+B by centrifugation at 1000 g for 20 min.
FITC (400 |ig) was dissolved in 1 ml of buffer (0.05 M sodium carbonate + 0.1 M
sodium chloride, pH 9.2) and added to the bacterial pellet. The mixture was incubated
at 37 °C for 20 min and washed three times with D.PBS+B by centrifugation at 1000 g
for 20 min to remove free FITC.
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5.2.4 Adherence to epithelial cells
The procedure for the detection of Neisseria adhering to epithelial cells is modified
from that described by Rahat (1990) and Saadi and colleagues (1993). Initially, four
isolates were used; N. lactamica and three isolates of N. meningitidis, B:4:P1.15,
C:4:-, and NG:4:-. After labelling, the bacterial concentration was adjusted by
measuring the optical density (section 2.4.5) to produce the required ratios of bacteria
to epithelial cells in the final mixture; 300:1, 100:1 and 30:1. Buccal epithelial cells
(2.5 x 105) (200 |il) were mixed with 200 fil of bacteria or buffer in a 5 ml tube and
incubated at 37 °C for 30 min with continuous shaking. The cells were washed three
times with D. PBS+B by centrifugation at 300 g for 10 min and fixed with 1% (v/v)
buffered paraformaldehyde. Binding of the bacteria to epithelial cells was analysed
with an EPICS 'C' flow cytometer (section 2.8.3). The binding of different isolates of
Neisseria were compared.
5.2.5 Inhibition of binding assay
N. meningitidis serogroup B:4:P1.15 directly conjugated with FITC was used in this
assay. After labelling, the optical density of the bacterial concentration was adjusted to
give a bacteria:BEC ratio of 100:1 in the final mixture (section 5.2.4). Equal volumes
(200 |il) of bacteria and saliva were mixed and incubated at 37 °C for 30 min with
continuous shaking. The mixture was centrifuged at 300 g for 10 min and the saliva
removed. D.BPS+B (200 (0.1) was added to the tube containing pelleted bacteria
followed by 200 j_il of BEC and incubated at 37 °C for 20 min. The BEC were washed
three times in D.PBS+B at 300 g for 10 min. The cells were fixed with 1% buffered
paraformaldehyde and analysed by flow cytometry. A control was included each time
containing D.PBS+B instead of saliva.
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5.2.6 Determination of the effect of FITC on the bacterial surface
To illustrate that the FITC did not alter binding of antibodies to the bacterial surface a
whole cell ELISA technique was used.
Separate wells of a 96-well microtitre plate were coated overnight at 4 °C with 100 |il of
FITC labelled or unlabelled bacteria (4.8 x 108 bacteria/ml). The plate was washed
and blocked with blocking buffer. After washing, undiluted saliva, absorbed saliva,
purified IgA and IgM were added to the two types of bacteria. The assay was
continued in the same way as for whole cell ELISA (section 4.2.1.2).
5.2.7 Analysis of results
For each sample analysed by flow cytometry two parameters were obtained: 1) the
percentage of cells in the population that showed fluorescence above background; 2) the
mean channel number for the population of positive cells, reflecting the mean number
of bacteria bound to the cells. In some experiments the binding index (BI) for the
preparation of cells was calculated by multiplying the percentage of fluorescent cells by
the mean channel number for the population of positive cells.
5.2.8 Statistical analysis
For comparison of inhibition of binding of the bacteria by the different saliva
preparations, the mean level of fluorescence in the population of cells in each sample
was compared with the control by the following formula: % inhibition = 100 - [(mean
channel number of the sample + mean channel number of the control) x 100]. The
results were analysed statistically by the Student's t-test to calculate confidence
intervals. Results were considered significant if p < 0.05.
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5.3 Results
5.3.1 Attachment of Neisseria isolates to BEC
The attachment ofN. lactamica and three different isolates ofmeningococci (B:4:P1.15;
C:4:- and NG:4:-) to BEC of two individuals was studied. The binding index (BI) of
each isolate was determined, and the results demonstrated that the levels of attachment
ofN. lactamica and NG:4:- were similar and were higher than B:4:P1.15 and C:4:- at
the three doses of bacteria used (Figure 5.1). The attachment ofmeningococci to BEC
decreased as the ratio of bacteria:BEC decreased. At a ratio of 30:1 the BI for all four
strains was low. In subsequent studies the intermediate bacteria:BEC ratio of 100:1
was used. This ratio was considered to be appropriate because any changes could be
clearly illustrated; therefore, it should be possible to detect inhibition of attachment
under these conditions. At the ratio of 100:1, almost all the cells showed fluorescence
above the background (cells not exposed to bacteria). The level was between 99.3-
99.7% for the different bacteria used.
5.3.2 Inhibition of attachment of meningococci by saliva
The ability of saliva to inhibit the attachment ofN. meningitidis B:4:P1.15 to BEC was
studied by the flow cytometry technique adopted for this study. BEC and saliva
collected from the laboratory staff (section 2.1.2) were also used in this study. The
binding of meningococci to BEC after treatment with saliva was compared with the
binding of meningococci to BEC treated with D.PBS+B. The mean levels of
fluorescence (as determined by mean channel number) in the population of positive
cells both in control and treated samples were used as the measurement of binding. At
the ratio of bacteria:BEC used, almost all the cells showed fluoresence above the
background (cells not exposed to bacteria). The level was usually 99.9% for the
control and between 95 - 99.8% for test sample. Treatment of the bacteria with saliva




Figure 5.1: Attachment ofN. lactamica (Q ), and three strains ofN. meningitidis:
B:4:P1.15 (•), C:4:- (O) and NG:4:- ), to BEC fron one donor.
Similar results were obtained with cells from another donor.
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(Table 5.1). The highest inhibition was obtained when one volume of bacteria was
incubated with two volumes of saliva, the lowest inhibition when 1/2 volume of saliva
(diluted with D.PBS+B) was incubated with one volume of bacteria.
5.3.3 Inhibition of attachment of meningococci by saliva from
secretors and non-secretors
Tables 5.2 and 5.3 present the assessment of inhibition of bacterial attachment by the
pool, fresh saliva and the absorbed/filtered pool preparations from secretors and non-
secretors. The BEC and saliva were collected from different subjects (section 2.1.2).
Compared with the controls, there was a statistically significant inhibition of binding of
strain B:4:P1.15 to BEC by the untreated pool (p = 0.0002) and fresh saliva (p =
0.013) from secretors and untreated pool (p =0.0004) and fresh saliva (p = 0.006)
from non-secretors (Tables 5.2 and 5.3). There was no significant difference between
the inhibitory activity of the pool compared with fresh saliva for secretors (p = 0.45) or
non-secretors (p = 0.24).
The inhibitory effect was greater for saliva from secretors, in which there were
significantly higher levels of inhibition in both the pool (p = 0.049) and fresh saliva (p
= 0.0001) compared with non-secretors. The mean level of fluorescence (determined
by mean channel number) of positive cells in control samples varied considerably from
day to day.
5.3.4 The effect of absorption of saliva with Neisseria
Absorption of antibodies with meningococci was assessed with the whole cell ELISA.
The saliva was repeatedly absorbed with bacteria until no antibody in the saliva specific
formeningococci was detectable by the ELISA.
The absorbed pool obtained from secretors was tested for its ability to inhibit the
attachment ofmeningococci to epithelial cells. In spite of no antibody being detectable
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by ELISA, there was considerable inhibition of attachment of bacteria by the absorbed
pools. The percentage of inhibition of binding by this absorbed pool was between 44-
60% and the reduction was statistically significant compared with the control containing
no saliva (p = 0.0095).
The inhibitory activity was further investigated with the absorbed/filtered pool since
residual antigen might account for the inhibition; the results were compared with the
unabsorbed pool. The percentage of inhibition of bacterial binding was not as marked
as that observed with the unabsorbed pool, but it was statistically significant for
secretors (p = 0.018) and non-secretors (p = 0.005). The mean percentage of
inhibition of bacteria by the unabsorbed pool and the absorbed/filtered pool was 72%
and 18.4% for secretors and 56.5% and 18.1% for non-secretors. There was a
significant difference in the inhibition between the pool and the absorbed/filtered pool
for secretors (p =0.0001) and for non-secretors (p = 0.018) (Tables 5.2 and 5.3).
5.3.5 Inhibition of attachment of meningococci by secretory IgA
Antibody-dependent inhibition of binding was demonstrated with purified IgA and IgM
obtained from the pool collected from the school population (section 2.8.4). Table 5.4
demonstrates the percentage inhibition of bacterial binding by affinity purified IgA and
IgM. The mean percentage inhibition following treatment of bacteria with IgA was
20% and 10% for IgM. Compared with the control, the inhibition of binding was
statistically significant for both IgA (p = 0.02) and IgM (p = 0.03). Inhibition by
purified IgA and IgM antibodies was compared to determine which antibody class had
more inhibitory activity. There was no statistical difference between IgA and IgM (p =
0.06).
The role of antibodies in inhibition of binding was further analysed by testing the
inhibitory activity of a panel of saliva preparations from which either IgA, IgM or IgG
had been absorbed and comparing results with inhibition observed with whole saliva
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1:2 74 80 58 75 52
1:1 95 70 46 68 45
1:0.5 95 58 37 53 32
± The percentage of inhibition was calculated from the mean channel number
of control and test samples
t The ratio of the volumes of bacteria (concentration of bacteria = 107 perml)
to saliva
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Table 5.2: Percentage inhibition of adherence of B:4:P1.15 to BEC by











1 80 74 79 55 10
2 273 58 75 60 25
3 254 65 80 ND 28
4 196 92 70 46 28
5 123 92 80 ND 28
6 308 60 62 44 21
7 271 63 61 50 17
± The percentage of inhibition was calculated from the means of the
control and test samples.
t Each row represents experiments on different days with BEC and
fresh saliva from different individuals
ND Not determined
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Table 5.3: Percentage inhibition of adherence of B:4:P1.15 to BEC by









1 39 60 65 28
2 381 63 54 14
3 138 55 64 24
4 150 45 55 11
5 65 58 51 20
6 406 56 43 12
7 356 59 49 18
± The percentage of inhibition was calculated from the means of the
control and test sample.









































































































(Table 5.4). Compared with the control, each type of saliva demonstrated high levels
of inhibition: for saliva without IgA (p = 0.0007); for saliva without IgG (p = 0.0015);
and for saliva without IgM (p = 0.0002). There was no statistical difference in
inhibitory activity between the three saliva preparations (p > 0.05).
5.3.6 The effect of FITC on binding of meningococci
The possibility that the procedure used to label the bacteria with fluorescein altered their
surface components was investigated using the ELISA technique. The binding of
antibacterial antibodies to FITC labelled and unlabelled bacteria was identical (data not
shown).
5.4 Discussion
The results of the experiments provided data to answer the question posed in the
introduction. (1) With the flow cytometry technique it could be shown that saliva
inhibited the attachment of bacteria to epithelial cells. (2) This inhibition was
significantly higher with saliva from secretors than saliva from non-secretors. (3) After
absorption of saliva with a mixture of bacteria, the saliva retained high levels of
inhibitory activity. Absorbed saliva that had been filtered was still inhibitory, but to a
lesser extent compared with the unfiltered absorbed saliva. (4) Significant inhibition of
binding was demonstrated with purified IgA and IgM, but there was no statistical
differences between IgA and IgM. A panel of saliva preparations from which either
IgA, IgM or IgG was absorbed was also examined and each preparation of saliva
demonstrated high levels of inhibition.
The majority of studies of inhibition of adhesion of bacteria to epithelial cells in vitro
have been carried out by light microscopy (Tramont, 1977; McChesney et al., 1982;
Taylor et al., 1990). The basic method consists ofmixing epithelial cells with bacteria
and incubating the mixture for an appropriate period. Excess bacteria are removed by
centrifugation, then the cells are resuspended and a drop of this suspension dried on a
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glass slide and examined under the light microscope. This assay is severely limited by
technical consideration. It is laborious, prone to subjective errors in counting and
samples few epithelial cells. These limitations have been overcome in this study by the
use of fluoresceinated N. meningitidis and analysis of the adherence by flow
cytometry. The advantages of flow cytometry are considerable. Over a thousand
BEC can be analysed within a few minutes; it is less prone to subjective errors; and,
unattached bacteria are not recorded by the instrument.
FITC was used to label bacteria in this study. FITC molecules bind to surface proteins
non-specifically. The dye did not interfere with the binding of immunoglobulins since
both labelled and unlabelled bacteria bound similar amounts of antibodies when
assessed by whole cell ELISA.
This study used saliva obtained from a population in which there was an outbreak due
to N. meningitidis B:4:P1.15 to demonstrate that secretions contain factors capable of
inhibiting the attachment of those bacteria to epithelial cells. A pool of saliva was
prepared and divided into four lots: unabsorbed, absorbed, absorbed/filtered and the
remainder was used to prepare purified IgA and IgM. Flow cytometry was used for
the first time to study the ability of secretions to inhibit the attachment of meningococci
to cells.
The initial experiments were simply to determine if the binding assay would provide
results similar to those obtained by light microscopy, and to allow determination of
appropriate bacteria to cell ratios for subsequent experiments. The results show that
increasing the ratio of bacteria to cells increased the level of meningococcal binding.
Different patterns of attachment were obtained with different isolates of Neisseria ;
binding of the non-capsulate N. lactamica and non-groupable N. meningitidis NG:4:-
was greater than that observed for the two capsulate strains of meningococci B:4:P1.15
and C:4:-. Studies by Stephens and McGee (1981) have previously shown that the
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non-groupable isolates bound better to epithelial cells than their serogroupable
counterparts.
The results demonstrate that treatment with saliva reduced the attachment of N.
meningitidis to epithelial cells, and this inhibition was dose dependent. Both the
pooled saliva from the school children and fresh saliva collected from departmental staff
at the time of the experiments showed significant inhibition which suggests that the
inhibitory factors did not deteriorate with long term storage at -20 °C. Significantly
higher levels of inhibition were observed with saliva from secretors compared with
saliva from non-secretors.
The inhibition of binding by the saliva led to an investigation of the effect of absorption
of antibodies specific for the bacteria tested. Although after adsorption no antibodies
could be detected by whole cell ELISA, the saliva still contained significant inhibitory
activity. Absorbed saliva that had been filtered to remove any remaining bacteria or
debries was also inhibitory, but it was not as effective as unfiltered absorbed saliva.
The possibility that the filtered material might contain some cell envelope fragments can
not be eliminated; however, this suggests that the saliva contained inhibitors that are not
immunoglobulins and are present in large quantities.
Secretory IgA is the predominant immunoglobulin in the specific immune responses at
mucosal surfaces. It has been reported to inhibit bacterial adherence to mucosal
surfaces by blocking adherence determinants (Abraham and Beachey, 1985), reduction
of negative charge and hydrophobicity of bacteria (Magnusson et al., 1979) and the
agglutination of bacteria to which it is specifically directed (Liljemark et al., 1979).
Several in vitro studies on the protective role of secretory IgA have demonstrated a
decreased attachment of Vibrio cholerae to intestinal epithelium (Fubara and Freter,
1973), streptococci to oral epithelium (Williams and Gibbons, 1975), E. coli to urinary
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tract epithelial cells (Svanborg-Eden and Svennerholm, 1978), and Pseudomonas
aeruginosa to tracheal epithelial cells (Niederman et al., 1986).
Salivary IgA probably contributed to inhibition of binding ofmeningococci to BEC and
was demonstrated by identifying blocking activity in IgA purified from the saliva. The
percentage inhibition of bacterial binding by affinity purified salivary IgA was low
(mean 20%) compared with the untreated pool (mean 80%); and, the inhibitory effect
was also lower compared with saliva containing no antibodies (absorbed) or saliva
depleted of IgA, IgG or IgM. The results indicate that salivary IgA plays a minor role
in inhibition of binding of meningococci to epithelial cells.
These observations suggest that significant amounts of non-antibody blocking factors
are present in the saliva and that these factors can reduce the numbers of bacteria
attaching to buccal cells either by binding to bacteria or acting on the epithelial surface
in the in vitro system examined in these studies. In histological examinations,
Stephens and his colleagues (1983a) found that immunoglobulin was rarely associated
with meningococci on the mucosal surface. Stephens and Farley (1991) suggested that
immunoglobulins normally present in their model might not influence the pathogenic
events.
Among the non-immune defences against bacterial adherence in the oral cavity are
naturally secreted high molecular weight glycoproteins that might behave as receptor
analogues, either aggregating (Williams and Gibbons, 1975; Babu et al., 1986a) or
binding to bacteria (Babu et al., 1986b), thereby reducing the number of organisms
available to attach to specific receptors. Innate defence factors such as salivary
lysozyme have been demonstrated to have aggregating activity (Laible and Germaine,
1982). Blood group antigens can also affect binding to mucosal cells (Blackwell,
1989). Glycoproteins might bind to epithelial cell receptors and block the adherence of
organisms (Hasty and Simpson, 1987). An imbalance in any one or combination of
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these adherence modulating factors in any subject might be significant in determining
adherence patterns of susceptibility to colonization.
The oral cavity poses a complex microenviroment where numerous components in
whole saliva make it difficult to assess the significance of any single factor such as the
inhibitory effect of salivary IgA on the adherence ofN. meningitidis.
The variation in the level of bacterial attachment in different control samples and
variation from day to day can be explained in a number of ways. Application of shear
forces can reduce the number of bacteria attached to cells. Variation in force used to
disperse cells at each washing could result in detachment of variable proportions of
bacteria (Rasanen, 1981; Christersson et al., 1988). The day to day variation might be
partly due to daily calibration of the flow cytometer which requires fine adjustment in
the alignment of the laser beam and sample stream with light sensors prior to the
experiments. Any changes in the setting can affect the reading. Changes in the cell
suspension or cell flow rate in the flow cytometer can also affect the results. In all
experiments the cells in suspension were thoroughly dispersed and flow rate was also
kept approximately at the same rate. The same conditions were always applied to
minimize any changes in the readings. Fluctuations in the binding of bacteria to
aliquots from stock samples of buccal epithelial cells have been observed (Tramont,
1977).
The influence of pili on meningococcal adhesion cannot be ignored. Pili have been
shown to be important in the binding to a number of epithelial cell types. Their ability
to bind to different epithelial surfaces was shown by Stephens and McGee (1981).
Olafson and colleagues (1985) indicated that N. meningitidis displays considerable
intra- and interstrain heterogenicity with respect to both pilus subunit size and
antigenicity. This immunologic diversity poses difficulties in assaying these
components in attachment and comparing results from different laboratories. The
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isolate used in this study was not pilate. The role of pili is discussed in detail in a later
section.
The experiments carried out in this chapter used the outbreak strain B:4:P1.15 for the
attachment and inhibition by saliva. The results shown in Figure 5.1 indicate that the
system is suitable for testing other strains; and the assay might be extended for other
strains and species of bacteria.
Further studies of interactions of meningococci with mucosal host defences should
provide information about the mechanism by which pathogenic bacteria overcome host
barriers to attach to receptors and to colonize mucosal surfaces. Further characterization
of processes that block the attachment of N. meningitidis is needed to assess this initial
step in the pathogenesis of meningitis. The observation that saliva from secretors is
more effective in inhibiting attachment to buccal epithelial cells suggests this might
contribute to their apparent increased resistance to meningococcal disease compared
with non-secretors.
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Bactericidal activity of sera to N. meningitidis and N.
lactamica
6.1 Introduction
Complement-dependent bactericidal activity of human serum is considered an important
host defence against invasive disease caused by Gram-negative bacteria (Goldschneider
et al., 1969a; Rice et al., 1980). Immunity to the meningococcus, both maternally
derived and actively induced during life, correlates with the presence of bactericidal
activity in normal sera (Goldschneider et al., 1969a; Griffiss et al., 1987b). Adults
and older children who become colonized with meningococci develop bactericidal
antibody against strains of homologous and heterologous serogroups (Goldschneider et
al., 1969a; Reller et al., 1973). This suggests carriage of meningococci plays a role in
induction and maintenance of natural meningococcal antibody (Goldschneider et al.,
1969a; Reller etal., 1973).
Reller and colleagues (1973) found that colonization of the nasopharynx of adults with
non-groupable meningococci which very rarely cause disease can be a potent stimulus
for the generation of protection against the capsulate disease causing strains. Among
men colonized with serogroup B or C organisms, 87% developed bactericidal
antibodies to one or more heterologous strains of the pathogenic meningococci
(Goldschneider et al., 1969b). Gotschlich and colleagues (1969a) showed that
antibodies to the serogroup A and C polysaccharide were of the IgG, IgM and IgA
classes and that IgG antibodies to serogroup A polysaccharide were predominant. It
was later reported that the bactericidal activity of acute phase sera from patients infected
with serogroup B, C or Y, after removal of IgA, was largely confined to antibodies of
the IgM class (Griffiss and Bertram, 1977). Bactericidal antibodies to group B
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polysaccharide were mostly of the IgM class (Zollinger and Mandrell 1983; Skevakis et
al., 1984).
In this part of the study, the objective was to use a bactericidal assay to assess the
following questions with serum specimens from the school children:
1) Is there a difference in serum bactericidal activity against pathogenic and non¬
pathogenic strains ofNeisseria ?
2) Is carriage of meningococci or secretor status associated with the bactericidal
activity ?
3) Are the levels of different isotypes, either total or specific for N. lactamica and
N. meningitidis, in sera correlated with bactericidal activity?
4) Are there differences in the levels of isotypes, either total or specific forN.
lactamica and N. meningitidis, associated with serum bactericidal activity
related to secretor status or carriage?
5) Does the outbreak strain possesses antigens cross-reactive with N. lactamica or
other meningococcal isolates which might induce bactericidal activity as a result
of carriage or systemic infection ?
6.2 Materials and methods
6.2.1 Experimental design
A standard complement source was used throughout the test. This was produced from
fresh human AB serum from a single donor. Before use, the complement source was
absorbed with a 'mixture' of the meningococcal isolates to be tested by the method
described in section 6.2.2 to remove anti-Neisseria antibodies. It was standardised in
a haemolytic assay to a minimum haemolytic titre of 1/16 to ensure standard amounts of
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exogenous complement were present in the test since endogenous complement levels
vary between individuals. The absorbed complement source was added (20 |il) to the
heat-inactivated test samples. This concentration supplied sufficient complement to
mediate antibody-dependent bacteriolysis whilst minimising any bactericidal activity
due to activation of the alternative pathway.
Small numbers of bacteria (approximately 104 bacteria/ ml) were used in the bactericidal
assay to reduce the degree of bacterial clumping and to allow easy determination of the
end-point titrations. Serum samples were replaced by GC broth to determine that the
observed bacterial killing was not due to activation of the alternative complement
pathway. Complement was replaced by GC broth in order to ensure other factors
(e.g., residual antibiotics) were not responsible for bactericidal activity. Controls in
which complement and serum were replaced by GC broth were also included.
6.2.2 Absorption of serum used as complement source
Serum from a donor of blood group AB with no history of meningococcal or
gonococcal infection was absorbed twice over a period of 24 h at 4 °C with a
suspension of the Neisseria strains (Table 2.1). This was done to remove any reactive
antibodies. The bacteria were removed from the serum by centrifugation (1500 g) at
4 "C. The remaining bacteria were removed by filtration, first with a filter with a pore
diameter of 5 (im (Nucleopore Corporation, Pleasanton, USA). The absorbed serum
was then passed through a sterilising filter with pore diameter of 0.22 |im, Nuflow
cellulose acetate membrane (Oxoid Ltd., England). Care was taken to avoid frothing
since this might denature the complement proteins. The haemolytic titre of complement
was measured as outlined below.
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6.2.3 Determination of complement activity
Sheep red blood cells were sensitized with donkey anti-sheep IgG (SAPU). Fresh
sheep red blood cells were washed in saline, centrifuged for 5 min. at 300 g and the
supernate removed. The wash was repeated 2-3 times. The red blood cells were
resuspended in saline to a concentration of 4%. This was checked by centrifugation of
the suspension in the haematocrit tube for 5 min. at 300 g. The donkey serum was
diluted 1/100 with saline and equal volumes of donkey haemolytic serum and sheep red
blood cells were mixed and incubated at 37 °C for 30 min.
Saline (25 |il) was added to one row of U well microtitre plates (Sterilin). The
complement source (25 (il) was added to the first well and a series of 7 doubling
dilution made. Sensitised sheep red blood cells (25 |il) diluted 1 in 2 were added to
each well and the plate incubated at 37 °C for 30 min. The highest dilution that
showed complete lysis was recorded as the haemolytic titre. Complement was stored
in aliquots at -20 °C until needed.
6.2.4 Assay for bactericidal activity
Sera from 67 secretors and 34 non-secretors were randomly selected from the samples
obtained from the school children and heated at 56 °C to inactivate endogenous
complement. Each of the 96 wells of an 8 x 12 U well Sterilin microtitre plates was
filled with 40 pi D.PBS+B. Heat inactivated neat serum (40 |i) was added to the first
well in each column. A series of seven two-fold dilutions was then made and 12 sera
were tested per plate.
An eighteen hour culture of the bacteria to be tested was harvested from MNYC
medium and suspended in D.PBS+B and the number of bacteria estimated by the O.D
of the suspension at 541 nm. The bacteria were diluted to provide a concentration of
approximately 104 c.f.u./ml. To each well was added 40 |il of one of the 6 bacterial
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suspensions. By adding a different bacterial suspension to each plate, the specific
bactericidal titres against all six test strains were determined under the same conditions.
A 1/16 dilution of the absorbed complement source (20 (il) was added to all the test
wells.
Serum and/or complement-free controls were also included in the test. For each strain
and each serum specimen (dilution 1/5), controls in which the complement was
replaced by GC broth and another in which the serum was replaced by GC broth were
included. Controls in which both serum and complement were replaced by GC broth
were also included.
The plates were covered and incubated at 37 °C for 30 min. Three 20 |il drops from
each well were then plated onto MNYC medium and incubated at 37 °C overnight.
The reciprocal of the highest serum dilution at which there was at least an 80% decrease
in viable count compared with the controls was recorded as the bactericidal titre.
6.2.5 Absorption of cross-reactive antibodies
Sera from nine individuals were chosen randomly and absorbed with bacteria in two
ways.
a) Sera were subjected to a series of absorptions with N. lactamica and the outbreak
strain (B:4:P1.15). Overnight cultures of bacteria grown on MNYC were harvested by
centrifugation (1000 g for 20 min) and washed three times in PBS. Sera were
absorbed first with N. lactamica by mixing equal volumes of a concentrated
suspension of bacteria and sera. Samples were incubated for 60 min at 37 °C followed
by incubation overnight at 4 °C. The bacteria were then removed by centrifugation at
1200 g for 5 min with a microcentrifuge (Sorvall MC 12C). After the first absorption,
sera were reabsorbed with the outbreak strain using the same method.
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b) Each serum sample was divided into five aliquots and absorbed with the following
strains: N. lactamica, N. gonorrhoeae or different strains of N. meningitidis
(B:4:P1.15, B:15:P1.16 and NG:4:-) by mixing equal volumes of bacteria and serum.
Samples were incubated for 60 min at 37 °C followed by incubation overnight at 4 °C.
The bacteria were removed by centrifugation at 1200 g for 5 min with a
microcentrifuge.
Absorbed and unabsorbed sera were assayed by ELISA for the measurement of the
antibody classes (section 4.2.1.2).
6.2.6 Statistical analysis
Immunoglobulin levels of sera with bactericidal activity were compared with those for
sera without bactericidal activity by the Mann-Whitney U test. Comparison of the
bactericidal titre data was made after conversion of the titres to log2.
6.3 Results
6.3.1 Enumeration of Bacteria
The optical density of the bacterial suspensions was plotted against the number of
colony forming units (c.f.u.) per ml. For each strain, the portion of the curve which
approximated a straight line was used to calculate the number of bacteria in the
suspension for testing. The best fit line of this section on each one of the graphs was
found by linear regression. This is illustrated in Figures 6.1. From the graphs for the
individual strains, appropriate dilutions could be made to obtain a suspension
containing approximately 104 bacteria/ml.
6.3.2 Haemolytic titre of complement
After adsorption of antibodies specific for the test bacteria, the complement source had



















concentration of bacteria x 10/ ml
Figure 6.1: Optical density (OD) measurements and bacterial
counts determined by viable count (cfu)
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6.3.3 Bactericidal antibody activity
Bactericidal antibody titres against N. lactamica and different isolates ofN. meningitidis
were measured for 101 individuals. The summary of bactericidal titres of all the sera
tested against six strains of Neisseria are given in table 6.1. Most of the individuals
had a bactericidal titre of at least 128 against NG:4:- (88.9%) and N. lactamica
(82.4%). The majority of individuals had no bactericidal activity to capsulate strains,
B:15:P1.16 (70.4%); C:4:- (72.2%); B:4:- (68.51%).
6.3.4 The effect of secretor status and carriage on bactericidal
activity
The effect of carriage on bactericidal activity is shown in Table 6.2. The mean of
bactericidal activity on the log scale among non-carriers was lower than that for
carriers. Negative titres were assigned a value of zero on the log scale. The slight
differences detected were not statistically significant.
Table 6.3 presents the mean of bactericidal titre according to secretor status. Although
the mean bactericidal titre on log scale was consistently higher for secretors than non-
secretors, the differences were small and not statistically significant.
6.3.5 Correlation between immunoglobulin levels and bactericidal
activity
In tables 6.4 - 6.6, the means on the log scale of the levels of total isotype and isotype
specific for the panel of bacteria examined in chapter four are correlated with
bactericidal activity to the capsulate strains: B:4:P1.15; B:15:P1.16; B:4:-; C:4:-.
There was no difference in levels of total IgA or IgM or levels of these isotypes specific
forN. lactamica or any of the five meningococcal status between sera which showed
bactericidal activity compared with sera in which there was no bactericidal activity.


































































































































































Table 6.2: Comparison of the means (on log2 scale) of the
bactericidal titres of carriers and non-carriers.
bactericidal titre (log2)
strain carriers non-carriers P
n=26 n=80
N. lactamica 6.19 5.82 0.35
B:4:P1.15 1.49 1.10 0.60
B:15:P1.16 1.49 0.89 0.09
B:4:- 1.86 0.91 0.15
C:4:- 1.19 0.97 0.60
NG:4:- 6.487 6.482 0.99
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Table 6.3: Comparison of the means (on log2 scale) of the
bactericidal titres of secretors and non-secretors
bactericidal titre (log2)
strain secretors non-secretors P
n=72 n=34
N. lactamica 5.98 5.78 0.66
B:4:P1.15 1.25 1.08 0.81
B:15:P1.16 1.34 0.90 0.43
B:4:- 1.48 0.98 0.22
C:4:- 1.28 0.94 0.21
NG:4:- 6.52 6.38 0.45
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Table 6.4: Comparison ofmean (on log scale) of IgA levels between









Total* B:4:P1.15 0.41 0.39 0.28
N. lactamica 0.73 0.88 0.46
B:4:P1.15 0.59 0.74 0.52
B:15:P1.16 0.68 0.85 0.57
B:4:- 0.58 0.90 0.17
C:4:- 0.69 0.84 0.27
NG:4:- 0.82 0.95 0.55
n=17 n=58
Total B:15:P1.16 0.42 0.39 0.08
N. lactamica 0.97 0.80 0.44
B:4:P1.15 0.73 0.69 0.74
B:15:P1.16 0.89 0.77 0.35
B:4:- 0.71 0.85 0.68
C:4:- 0.87 0.78 0.67
NG:4:- 0.10 0.88 0.29
n=17 n=58
Total B:4:- 0.41 0.39 0.37
N. lactamica 0.77 0.86 0.89
B:4:P1.15 0.71 0.69 0.72
B:15:P1.16 0.76 0.81 0.97
B:4:- 0.81 0.82 0.79
C:4:- 0.91 0.76 0.68
NG:4:- 0.10 0.89 0.38
n=17 n=58
Total C:4:- 0.40 0.39 0.78
N. lactamica 0.73 0.88 0.98
B:4:P1.15 0.69 0.70 0.95
B:15:P1.16 0.68 0.85 0.81
B:4:- 0.58 0.90 0.42
C:4:- 0.81 0.80 0.94
NG:4:- 0.83 0.95 0.49
* units for mean total serum IgA are expressed in mg/ml
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Table 6.5: Comparison ofmean (on log scale) of IgM levels between









Total * B:4:P1.15 0.41 0.39 0.43
N. lactamica 0.59 0.79 0.15
B:4:P1.15 0.69 0.57 0.35
B:15:P1.16 066 0.91 0.07
B:4:- 1.23 1.15 0.25
C:4:- 0.49 0.62 0.31
NG:4:- 1.01 1.29 0.12
n=18 n=59
Total B:15:P1.16 0.41 0.39 0.13
N. lactamica 0.77 0.67 0.65
B:4:P1.15 0.56 0.69 0.39
B:15:P1.16 0.90 0.66 0.10
B:4:- 0.88 1.26 0.25
C:4:- 0.44 0.63 0.24
NG:4:- 1.27 1.03 0.17
n=17 n=59
Total B:4:- 0.41 0.39 0.56
N. lactamica 0.75 0.72 0.76
B:4:P1.15 0.58 0.69 0.41
B:15:P1.16 0.75 0.88 0.35
B:4:- 1.22 1.07 0.74
C:4:- 0.62 0.57 0.98
NG:4:- 1.22 1.21 0.55
n=17 n=58
Total C:4:- 0.40 0.39 0.29
N. lactamica 0.79 0.67 0.18
B:4:P1.15 0.51 0.70 0.18
B:15:P1.16 0.70 0.89 0.16
B:4:- 1.50 1.10 0.79
C:4:- 0.61 0.66 0.46
NG:4:- 1.26 1.03 0.21
* units for mean total serum IgM are expressed in mg/ml
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Table 6.6: Comparison ofmean (on log scale) of IgG levels between









Total * B:4:P1.15 0.49 0.47 0.03
N. lactamica 1.21 0.56 0.009
B:4:P1.15 0.74 0.62 0.04
B:15:P1.16 0.77 0.57 0.01
B:4:- 0.65 0.44 0.05
C:4:- 0.75 0.59 0.05
NG:4:- 0.81 0.68 0.45
oorHIIa n=59
Total B:15:P1.16 0.49 0.48 0.09
N. lactamica 1.76 0.73 0.05
B:4:P1.15 0.65 0.66 0.57
B:15:P1.16 0.66 0.62 0.83
B:4:- 0.54 0.58 0.76
C:4:- 0.71 0.61 0.13
NG:4:- 0.69 0.72 0.31
n=18 n=59
Total B:4:- 0.49 0.47 0.03
N. lactamica 1.24 0.56 0.003
B:4:P1.15 0.75 0.62 0.14
B:15:P1.16 0.70 0.60 0.34
B:4:- 0.55 0.58 0.75
C:4:- 0.72 0.61 0.20
NG:4:- 0.81 0.68 0.33
OOrHIIs n=59
Total C:4:- 0.48 0.47 0.22
N. lactamica 1.19 0.59 0.01
B:4:P1.15 0.72 0.63 0.14
B:15:P1.16 0.71 0.59 0.32
B:4:- 0.60 0.56 0.47
C:4:- 0.75 0.59 0.16
NG:4:- 0.82 0.69 0.83
* units for mean total serum IgG are expressed in mg/ml
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compared with sera in which there was no bactericidal activity. IgG levels for N.
lactamica were significantly higher in sera bactericidal for all four strains tested
compared with sera in which there was no bactericidal activity. IgG levels for
B:15:P1.16, B:4:- and C:4:- were significantly higher in sera bactericidal for the
outbreak strain compared with sera in which there was no bactericidal activity, but not
for any of the other three strains tested. Compared with sera in which there was no
bactericidal activity, there were no differences in levels of IgG for NG:4:- in sera
bactericidal for any of the four strains.
6.3.6 Correlation between IgG levels and bactericidal activity
among carriers and non-carriers
Tables 6.7 and 6.8 present similar data for assessment of differences in total and
specific IgG levels and bactericidal activity with reference to carriage. Among carriers,
compared with sera in which there was no bactericidal activity, there was no differences
in the amount of total IgG; however, there were significantly higher levels of IgG
specific for N. lactamica in sera with bactericidal activity for each of the four capsulate
strains. There were higher levels of IgG specific for B:4:P1.15 in sera bactericidal for
B:15:P1.16 but not for the outbreak strain itself or B:4:- and C:4:- compared with sera
in which there was no bactericidal activity. Higher levels of IgG specific for
B:15:P1.16 or B:4:- were not found in sera bactericidal for any of the four strains tested
compared with sera in which there was no bactericidal activity. Significantly higher
levels of IgG to C:4:- were found only among sera bactericidal for B:15:P1.16
compared with sera in which there was no bactericidal activity. No difference in the
levels of IgG to NG:4:- were associated with bactericidal activity to any of the strains
(Table 6.7).
Among non-carriers, compared with sera in which there was no bactericidal activity,
the only significant increases in levels of IgG associated with bactericidal activity were
those for A. lactamica and killing of B:4:P1.15 or B:4:- (Table 6.8).
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Table 6.7: Mean of IgG levels (on log scale) in sera with bactericidal









Total * B:4:P1.15 0.49 0.47 0.06
N. lactamica 2.43 0.53 0.02
B:4:P1.15 0.77 0.63 0.19
B:15:P1.16 0.88 0.52 0.09
B:4:- 0.72 0.68 0.20
C:4:- 0.80 0.65 0.25
NG:4:- 0.88 0.67 0.55
n=4 oII
Total B:15:P1.16 0.49 0.48 0.36
N. lactamica 1.40 0.71 0.05
B:4:P1.15 0.89 0.63 0.03
B:15:P1.16 0.89 0.55 0.16
B:4:- 0.83 0.55 0.09
C:4:- 0.94 0.61 0.005
NG:4:- 0.92 0.68 0.57
n=5 n=9
Total B:4:- 0.49 0.48 0.39
N. lactamica 2.37 0.56 0.004
B:4:P1.15 0.71 0.68 1.00
B:15:P1.16 0.72 0.61 0.74
B:4:- 0.65 0.63 0.74
C:4:- 0.71 0.70 0.84
NG:4:- 0.87 0.67 0.74
n=4 ©vHIIa
Total C:4:- 0.49 0.48 0.48
N. lactamica 2.87 0.53 0.003
B:4:P1.15 0.73 0.65 0.19
B:15:P1.16 0.76 0.60 1.00
B:4:- 0.58 0.66 0.67
C:4:- 0.72 0.69 1.00
NG:4:- 0.92 0.68 0.57
* units for mean total serum IgG are expressed in mg/ml
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Table 6.8: Mean of IgG levels (on log scale) in sera with bactericidal









Total * B:4:P1.15 0.49 0.47 0.13
N. lactamica 0.82 0.57 0.02
B:4:P1.15 0.72 0.62 0.13
B:15:P1.16 0.73 0.85 0.09
B:4:- 0.62 0.54 0.29
C:4:- 0.73 0.57 0.15
NG:4:- 0.79 0.68 0.63
rHIIc n=47
Total B:15:P1.16 0.49 0.47 0.14
N. lactamica 0.78 0.59 0.09
B:4:P1.15 0.61 0.65 1.00
B:15:P1.16 0.58 0.63 0.52
B:4:- 0.46 0.59 0.22
C:4:- 0.64 0.61 0.72
NG:4:- 0.62 0.74 0.12
n=15 n=48
Total B:4:- 0.49 0.47 0.06
N. lactamica 0.86 0.56 0.003
B:4:P1.15 0.77 0.61 0.13
B:15:P1.16 0.69 0.59 0.32
B:4:- 0.51 0.57 0.57
C:4:- 0.72 0.59 0.16
NG:4:- 0.66 0.73 0.16
n=14 II
Total C:4:- 0.48 0.47 0.29
N. lactamica 0.72 0.61 0.18
B:4:P1.15 0.70 0.60 0.19
B:15:P1.16 0.69 0.59 0.36
B:4:- 0.61 0.54 0.29
C:4:- 0.76 0.58 0.13
NG:4:- 0.78 0.69 0.86
* units for mean total serum IgG are expressed in mg/ml
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6.3.7 Correlation between IgG levels and bactericidal activity
among secretors and non-nonsecretors
Secretors had significantly higher levels of IgG antibodies to N. lactamica in the sera
which contained bactericidal activity compared with sera in which there was no
bactericidal activity. The only other significant association was higher levels of IgG
specific for C:4 in sera bactericidal for that strain (Table 6.9). There were no
significant differences in IgG levels to N. lactamica among non-secretors sera with
bactericidal activity compared with sera in which there was no bactericidal activity.
Sera of non-secretors that showed bactericidal activity to the outbreak strain had higher
levels of IgG specific for B:15:P1.16 (P=0.01) and B:4:- (P=0.03) compared with sera
in which there was no bactericidal activity (Table 6.10).
6.3.8 Comparison between secretor and non-secretor sera with
bactericidal activity
Although secretors had higher IgG levels to N. lactamica in the sera which had
bactericidal activity compared with non-secretors, the differences were not statistically
significant (Table 6.11).
6.3.9 Cross-reactivity among strains of Neisseria
The presence of antibodies to B:4:P1.15 in serum of randomly selected specimens was
demonstrated by the ELISA (Tables 6.12 and 6.13).
Serum IgA, IgG and IgM antibodies to the strain were measured by ELISA before and
after absorptions with N. lactamica, N. gonorrhoeae or different isolates of N.
meningitidis . The reduction in measurable serum IgA, IgG and IgM in the absorbed
serum indicated that there are substantial amounts of antibodies in sera cross-reactive
with the outbreak strain (Table 6.12).
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Table 6.9: Mean of IgG levels (on log scale) in sera with bactericidal









Total* B:4:P1.15 0.48 0.47 0.12
N. lactamica 1.45 0.61 0.01
B:4:P1.15 0.73 0.66 0.26
B:15:P1.16 0.76 0.59 0.16
B:4:- 0.59 0.54 0.59
C:4:- 0.76 0.61 0.21
NG:4:- 0.83 0.66 0.38
IIc s n
Total B:15:P1.16 0.48 0.47 0.25
N. lactamica 1.69 0.62 0.005
B:4:P1.15 0.59 0.70 0.53
B:15:P1.16 0.66 0.62 0.89
B:4:- 0.49 0.57 0.44
C:4:- 0.73 0.63 0.25
NG:4:- 0.74 0.70 0.88
nrHIIS3 n=43
Total B:4:- 0.48 0.47 0.22
N. lactamica 1.72 0.59 0.0001
B:4:P1.15 0.80 0.64 0.27
B:15:P1.16 0.70 0.61 0.81
B:4:- 0.50 0.57 0.65
C:4:- 0.77 0.62 0.22
NG:4:- 0.80 0.68 0.81
n = 10 n=45
Total C:4:- 0.48 0.47 0.41
N. lactamica 1.71 0.65 0.05
B:4:P1.15 0.76 0.66 0.18
B:15:P1.16 0.79 0.59 0.21
B:4:- 0.60 0.55 0.46
C:4:- 0.89 0.59 0.003
NG:4:- 0.97 0.65 0.22
* units for mean total serum IgG are expressed in mg/ml
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Table 6.10: Mean of IgG levels (on log scale) in sera with bactericidal










Total * B:4:P1.15 0.50 0.47 0.16
N. lactamica 0.60 0.45 0.23
B:4:P1.15 0.74 0.54 0.57
B:15:P1.16 0.79 0.53 0.01
B:4:- 0.78 0.55 0.03
C:4:- 0.72 0.53 0.07
NG:4:- 0.74 0.73 0.88
n=6 V©rHIIG
Total B:15:P1.16 0.49 0.47 0.33
N. lactamica 0.93 0.90 0.76
B:4:P1.15 0.77 0.53 0.57
B:15:P1.16 0.63 0.59 0.61
B:4:- 0.64 0.56 0.55
C:4:- 0.65 0.60 0.18
NG:4:- 0.58 0.79 0.08
n=8 n=14
Total B:4:- 0.49 0.47 0.22
N. lactamica 0.51 0.48 0.63
B:4:P1.15 0.69 0.53 0.57
B:15:P1.16 0.69 0.55 0.17
B:4:- 0.62 0.61 0.50
C:4:- 0.63 0.56 0.22
NG:4:- 0.59 0.82 0.81
n=6 n=16
Total C:4:- 0.49 0.47 0.61
N. lactamica 0.57 0.45 0.24
B:4:P1.15 0.68 0.53 0.43
B:15:P1.16 0.61 0.59 0.89
B:4:- 0.60 0.62 0.89
C:4:- 0.57 0.59 0.89
NG:4:- 0.62 0.80 0.08
* units for mean total serum IgA are expressed in mg/ml
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Table 6.11: Comparison ofmean (on log scale) of IgG levels to N. lactamica
between secretors and non-secretors of sera with bactericidal activity
test strain secretors non-secretors P
IgG levels pg/ml
IIfl n=20
B:4:P1.15 14.5 6.0 0.28
n=58 n=17
B:15:P1.16 16.9 9.3 0.08
n=58 n=17
B:4:- 17.2 5.1 0.38
n=58 n=17
C:4:- 17.1 5.7 0.78
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Table 6.12: The level of antibodies to B:4:P1.15 detected by whole cell












1 IgA 8.3 70* 57 22 47 63
IgM 9.7 94 83 31 74 86
IgG 23.0 88 51 38 38 56
2 IgA 15.6 90 60 47 47 62
IgM 11.5 85 67 32 50 62
IgG 25.0 78 50 46 53 64
3 IgA 7.3 85 43 15 35 46
IgM 8.0 90 87 65 74 80
IgG 17.0 97 73 47 56 74
4 IgA 12.7 71 51 37 42 45
IgM 8.03 92 46 32 41 53
IgG 30.0 98 76 25 46 76
5 IgA 15.8 84 30 11 15 54
IgM 7.2 95 65 34 33 44
IgG 32.0 95 76 38 28 73
6 IgA 8.40 85 64 35 30 61
IgM 5.50 81 68 28 47 55
IgG 11.0 96 48 12 43 57
7 IgA 2.97 85 33 12 13 38
IgM 1.70 79 60 19 39 53
IgG 7.00 90 59 35 59 58
8 IgA 6.88 57 35 17 26 37
IgM 4.40 68 33 14 19 43
IgG 18.3 94 75 19 40 63
9 IgA 9.38 76 47 27 34 37
IgM 4.40 79 52 18 36 40
IgG 20.3 82 59 11 37 55
* the percentage of reduction.
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Table 6.13: The level of antibodies to B:4:P1.15 detected by whole cell












1 IgA 8.3 70* 57 72
IgM 9.7 94 83 94
IgG 23.0 88 51 88
2 IgA 15.6 90 60 90
IgM 11.5 85 67 89
IgG 25.0 78 50 79
3 IgA 7.3 85 43 86
IgM 8.0 90 87 90
IgG 17.0 97 73 98
4 IgA 12.7 71 51 85
IgM 8.03 92 46 93
IgG 30.0 98 76 98
5 IgA 15.8 84 30 84
IgM 7.2 95 65 95
IgG 32.0 95 76 96
6 IgA 8.40 85 64 87
IgM 5.50 81 68 84
IgG 11.0 96 48 96
7 IgA 2.97 85 33 85
IgM 1.70 79 60 81
IgG 7.00 90 59 92
8 IgA 6.88 57 35 61
IgM 4.40 68 33 70
IgG 18.3 94 75 96
9 IgA 9.38 76 47 77
IgM 4.40 79 52 79
IgG 20.3 82 59 83
* the percentage of reduction.
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Given the heterogenecity of the antibody response, a pronounced antibody reduction
was observed when the sera were absorbed twice, first with N. lactamica followed by
B:4:P1.15. A reduction of IgG antibodies ranging from 79% to 98% was observed
after the sera were absorbed in this manner (Table 6.13).
6.4 Discussion
The results obtained provided data to answer the questions posed in the introduction.
(1) Most sera in this study had higher bactericidal titres against the usually non¬
pathogenic strains NG:4:- (88.9%) and A. lactamica (82.4%) compared to the capsulate
strains. (2) Bactericidal activity was higher for both carriers and secretors but the
differences were not significant. (3) Compared with sera in which there was no
bactericidal activity, in bactericidal sera there was no marked difference in levels of total
or specific IgA and IgM. IgG levels were significantly higher in sera bactericidal for
all four strains tested compared with sera in which there was no bactericidal activity.
(4) Carriers had significantly higher levels of IgG to N. lactamica in sera with
bactericidal activity for each of the four capsulate strains compared with sera in which
there was no bactericidal activity. While there were higher levels of IgG to N.
lactamica in sera of non-carriers with bactericidal activity, this was significantly
associated only with killing of B:4:P1.15 and B:4:-. Secretors' sera with bactericidal
activity had significantly higher levels of IgG to N. lactamica compared with sera that
were not bactericidal. There was no significant association of IgG levels and
bactericidal activity to N. lactamica among non-secretors. (5) Antibodies to the
outbreak strain B:4:P1.15 could be adsorbed by all Neisseria isolates tested.
Many previous studies of the serum bactericidal reaction with meningococci have
focused on the specificity and chemical composition of the target antigens
(Goldschneider et al., 1969b; Kasper et al., 1973b). Others have focused on the
classes of immunoglobulin involved in bactericidal killing by using antibodies from
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human sera obtained after infection with meningococci (Griffiss et al., 1975) or sera
collected after vaccination (Skevakis et al., 1984). In this study, levels of isotypes to
the outbreak strain and other Neisseria species in sera obtained from a school
population in which an outbreak of meningococcal disease occurred were measured.
It has been suggested that carriage of commensal enteric bacteria with cross-reactive
antigens might induce IgA antibodies that compete with IgG and IgM (Griffiss et al.,
1975). The results presented here suggest that the effect of circulating IgA antibodies
is not important. There was no statistical difference in levels of IgA between the sera
with bactericidal activity compared with sera in which no killing was observed. The
level of IgA might not be sufficient to block IgG and IgM in the sera tested for
bactericidal activity. This is in agreement with Griffiss and colleagues (1975) who
found that strain specific IgA isolated from convalescent-phase sera was capable of
blocking the complement-mediated bacteriolytic activity of IgM and IgG separated from
the same sera; however, the blocking effect of IgA was not demonstrable when using
whole sera.
The results of the present study showed that the IgM levels of bactericidal and non-
bactericidal sera were comparable. This might be due to the fact that there were about
15 days between the first screening of the school and treatment with rifampicin and the
the second screening when sera were collected. The levels of IgM might have
decreased, or there was no significant difference in the level of IgM between the
groups.
Previous workers have studied the IgG subclasses and found that the profile of IgG
subclass in the immune response varies according to the antigenic stimulus and might
reflect the mechanism and efficacy by which the meningococci are killed (Natvig and
Kunkel, 1973; Burton et al., 1986). Protein antigens mainly stimulate the production
of IgGl and IgG3 antibodies (Hammarstrom and Smith, 1986). Sjursen and
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colleagues (1990) found that the antibody levels in vaccinees and patients' sera were
comparable. Both had high levels of IgG with IgGl and IgG3 being demonstrated in
both groups. They also found that the level of the total IgG and IgGl remained high
for over three years which suggested that this might be stimulated by repeated exposure
to meningococci or cross reactive antigens on other species.
The higher levels of the IgG to N. lactamica in the sera with bactericidal activity to all
the capsular strains used, regardless of serogroups and serotypes suggests that these
antibodies might be directed to common antigens. This agrees with the suggestion that
noncapsular surface antigens shared between different meningococci play a role in the
induction and maintenance of natural meningococcal antibody in the population
(Goldschneider et al., 1969a). Sera from healthy individuals usually contain IgG
antibodies against outer membrane antigens from pathogenic Neisseria species
(Harthug et al., 1986; Hicks et al., 1987).
Commensal Neisseria species N. lactamica and N. cinerea are closely related to the
pathogenic strains on the basis of a variety of criteria (Aho et al., 1987). N.
meningitidis and N. lactamica share outer membrane proteins. These strains
synthesize the H.8 lipoprotein antigen (Aho et al., 1987; 1984; Kawula et al., 1987).
Antibodies against the H.8 protein are found in patients after disseminated
meningococcal and gonococcal disease (Black et al., 1985). Martin and colleagues
(1986) described a 70 kilodalton protein that is present in both pathogenic and most
non-pathogenic species, including N. lactamica. The importance of each of the various
common Neisseria antigens as a target for protective antibodies still remains to be
clarified.
N. lactamica is one of the first Neisseria species to colonize the infant's pharynx. By
four years of age 59% of children have carried N. lactamica at least once (Gold et al.,
1978a). They observed that 66% of the children (3 months to 8 years of age) who
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became colonized with N. lactamica developed significant levels of serum antibodies
which can bind meningococcal test strains of serogroups A, B and/or C; and 40%
developed bactericidal antibody against these strains.
In contrast to the serogroupable strains examined, most of the sera were bactericidal for
N. lactamica and NG:4:-. This suggests that these two strains are more sensitive to the
bactericidal activity of acquired antibodies than serogroupable isolate. Rosenqvist and
colleagues (1988) found that IgG antibody levels were significantly higher for carriers
than for non-carriers before and after vaccination.
The proposal for a role of the carrier state in developing and maintaining natural
immunity to meningococcal disease has been supported by other workers
(Goldschneider et al., 1969a; Reller et al., 1973). In this study of a non-vaccinated
population, the patterns of reactivity of antibodies in sera from carriers and non-carriers
to the four capsulate isolates are different. Generally among non-carriers, there was no
significant association between bactericidal activity and the presence of IgG antibodies
to these strains. In contrast, among carriers, sera bactericidal for the capsulate isolates
tested had high levels of the IgG to N. lactamica.
Nongroupable strains ofN. meningitidis are usually isolated from the throat and rarely
cause disease (Meningococcal Disease Surveillance Group, 1976b). These isolates
probably have either uncharacterized polysaccharide capsule or easily lack detectable
amount of capsular polysaccharide. The majority of individuals (99.1%) showed
bactericidal activity to NG:4:- compared with little bactericidal activity against
encapsulated strains sharing the same serotype antigen (Table 6.1). One possible
explanation is that the heavily encapsulated strains might impede the functional activity
of antibodies to the underlying proteins or lipopolysaccharide. These observations
need to be considered in assessment of serotype antigens for their use as vaccines for
serogroupable meningococci.
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Compared to non-secretors, secretors had higher IgG levels to N. lactamica in sera
showing bactericidal activity for all four isolates tested. The differences were not
significant, which is in agreement with the results obtained in chapter four when the
whole population were tested for levels of total and specific IgG.
By means of the absorption experiments, antigenic similarities have been demonstrated
among different strains ofNeisseria. Antibody levels were measured by ELISA to the
outbreak strain and N. lactamica before and after absorption with homologous and
heterologous isolates. Immunoglobulin levels in the serum were reduced by various
degrees after absorption with different strains of Neisseria in the nine sera tested.
Absorption of each serum sample with N. lactamica followed by another absorption
with the outbreak strain reduced the level of IgG antibodies to the outbreak strain by 73
- 93%. Reduction of IgA and IgM antibodies was also evident. Identification of the
bacterial determinants to which these antibodies are directed might be useful in
assessment of vaccine candidates.
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General discussion
The results have been discussed in detail at the end of each chapter. This chapter
summarizes the findings and conclusions with reference to the original objectives set
out in the general introduction, explores the limitations of the experimental methods
used and the prospects for future research.
7.1 Introduction
Non-secretors of blood group antigens are over-represented among patients with
bacterial meningitis. The study presented here tested whether there might be
differences between secretors and non-secretors in terms of their mucosal or systemic
immune response. To test the hypothesis, serum and salivary immunoglobulin levels
were measured and the functions of the immunoglobulin were studied by assessment of
bactericidal activity and the effect of salivary antibodies on bacterial binding to epithelial
cells.
7.2 The association between the immunoglobulin levels and
secretor status.
The first part of the study was designed to assess the reported lower levels of serum
and salivary antibodies reported for non-secretors. An ELISA was developed to
assess the level of total and specific antibodies in serum and saliva. Although there are
several methods suitable for the measurement of total immunoglobulins, ELISA was
chosen for this study because it was a more sensitive technique compared with SRID,
the other method usually used for this purpose. In addition, specific antibodies can be
determined and a large number of samples can be analyzed quickly. The ELISA
technique developed in this study can be applied to quantitative examination of immune
responses to other antigens for which there are no standard sera available.
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Non-secretors had significantly less total IgM in their saliva compared with secretors.
These differences were also observed for salivary IgM to N. lactamica and to five
isolates ofmeningococci expressing different combinations of serogroup, serotyp and
subtype antigens. As there was no correlation between salivary and serum levels of
IgM, the results suggest that salivary IgM is loccally produced and has not leaked from
the serum.
Previous studies on the association between secretor status ans immunoglobulin levels
failed to analyse several of the factors that might influence the results. In this study 39
variables were analysed including: secretor status; carriage of meningococci; smoking
habits; total serum and salivary IgA, IgG and IgM. In addition, specific salivary IgA
and IgM, and serum IgA, IgG and IgM to six different isolates of Neisseria were
assessed. The advantage of multivariant analysis is that it takes into account factors
that might be dependent variables which could obscure the results of univariant
analysis. Most other studies failed to look at all the factors outlined above.
The lower level of IgM in non-secretors might contribute to susceptibility to
colonization, particularly among infants under the age of 12 months in whom salivary
IgM is the major class of antibodies on the mucosal surfaces. In early childhood IgM,
might compensate for the relative immaturity of the secretory IgA response. Neonatal
B lymphocytes have been shown to be functionally defective in their capacity to
generate plasma cells, and this immaturity is reflected particularly in the IgA response
(Miyawaki et al., 1981). Healthy neonates are able to produce slgA antibodies
(Lodinova-Zadinkova et al., 1991), but the levels remain at the lower end of the adult
normal range until the age of 12 months (Mellander et al., 1984). These studies need
to be repeated with material from infants who have been screened for carriage of
commensal Neisseria and meningococci.
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7.3 Inhibition of meningococcal attachment to epithelial cells
Despite the importance of the initial colonization of mucosal surfaces by pathogenic
micro-organisms, very little is known about the molecules interacting in the process of
attachment. A major problem in studying the pathogenesis of meningococci is the
specificity of the disease for humans. This limits the use of animal models. To
overcome this problem, the attachment of meningococci to epithelial cells was studied
in vitro to test inhibitory activity of whole saliva and purified slgA and slgM. A flow
cytometry technique was developed to assess the attachment of meningococci to
epithelial cells under the conditions examined.
Whole saliva was used first to study its inhibitory activity. Treatment of bacteria with
saliva inhibited the attachment ofmeningococci. When the saliva was absorbed with a
cocktail ofmeningococci or absorbed then filtered, the inhibitory activity of these saliva
preparations was considerably less than that of untreated saliva; however, the inhibitory
activity was not due solely to antibodies to the bacteria. Compared with specimens
from non-secretors, secretors had significantly higher levels of inhibitory activity in
either the fresh saliva from individual donors or pooled saliva. The difference between
the two groups raised the possibility that slgM and/or other factors such as secreted
blood group antigens played a role in inhibition of bacterial binding. There is evidence
that the Lewisa antigen usually found in greater quantities on cells and in body fluids of
non-secretors is one of the receptors for attachment for some strains of Staphylococcus
aureus (Blackwell et al., 1992b; Saadi et al., 1993) and Candida albicans (May et al.,
1989; Tosh and Douglas, 1991; Aly, 1992). The role of this antigen in colonization by
meningococci needs to be examined, especially as it is expressed in significant
quantities in most infants (Issit, 1986) and by a significant number of secretors
(Blackwell et al, 1992b; Saadi et al., 1993). Outer membrane proteins from both S.
aureus and N. meningitidis have been obtained by affinity purification with synsorb
Lea (Saadi et al., submitted for publication; Raza et al., unpublished results); and >
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75% ofmeningococcal strains were agglutinated by anti-idiotypic antibodies produced
by immunization of mice with monoclonal anti-Lea (Essery et al., submitted for
publication).
Affinity purified preparations of IgA and IgM antibodies were tested for their ability to
inhibit attachment of meningococci. The results, though statistically significant, did
not indicate a high level of inhibition. The results do not conclusively indicate a role
for purified slgA or slgM in the inhibition of attachment of meningococci. This might
be due to low amounts of purified slgA specific for bacterial adhesins, the process of
purification affected the sensitivity of IgA, or IgA functions better in cooperation with
other factors in the saliva. A panel of saliva from which either IgG or IgM had been
absorbed demonstrated higher levels of inhibition compared with purified antibodies,
suggesting that purified antibodies played a minor part in the inhibitory activity
observed.
The integrity of mucosal defences in many IgA-deficient individuals demonstrates the
effectiveness of innate factors or slgM. During the maturation of the infant's own
immune system, the mucosal surfaces are protected by non-immune factors (Tenovuo
et al., 1986) and immune factors such IgA in breast milk. In addition, slgM might
play an important role in protection since its concentration is high during this period. It
is probably naive to consider any single defence factor in isolation because successful
mucosal protection is clearly due to a number of interactions between innate and
specific immune defences.
The conflicting results of the role of slgA in inhibition of attachment of bacteria might
be explained in many ways, including differences in populations under study, sample
collections, assay methods used and antibodies which might bind to a variable degree to
cross-reactive antigens on oral bacteria.
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Buccal epithelial cells used in this study are not the normal site of attachment of
meningococci, but the cells are easily available and have been used in many studies
(Craven et al., 1980; Salit and Morton, 1981; Stephens, 1989). The binding assay
might differ with different samples of buccal epithelial cells due to the presence of
molecules of food debris, normal flora, inherited differences between individuals, the
degree of maturity or viability of the cells. Pharyngeal cells can also be obtained
relatively easily; but, their use in vitro bacterial attachment assays is limited by similar
factors. The use of cell lines such as HeLa provide a homogeneous population free of
contaminantes; however, cell surface characteristics might be different from those
expressed by cells in vivo .
The importance of pili in meningococcal adhesion cannot be ignored. Pili are the most
important surface components mediating initial attachment of meningococci to human
mucosal epithelial cells (Stephens andWhitney, 1985). Genital secretions obtained after
gonococcal infection and after administration of a vaccine containing components to pili
have IgG and IgA antibodies which decreased adherence of homologous gonococcal
strains (Tramont et al., 1980; McChesney et al., 1982). Stephens and McGee (1981)
demonstrated that non-pilate meningococci bound at low levels with equal ability to
different cells. In contrast, the presence of pili, in addition to enhancing attachment,
also allowed meningococci to bind with differing affinities to epithelial cells from
different sites.
One major criticism of binding assays with flow cytometry is that the influence of pili
cannot be studied because of the washing step needed to remove unbound fluorescein
from the bacterial preparation. The other adhesive mediators used by the bacteria could
still be investigated by the assay. Extensive immunologic diversity of pili has been
reported (Olafson et al., 1985; Heckels, 1989). The diversity is present even among
pili isolated from the same strain and is a major problem in the design of vaccines that
contain pili as essential constituents. It is yet to be shown that vaccines containing pili
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can produce significant amounts of protective antibody at mucosal surfaces for
prolonged periods of time.
7.4 Bactericidal activity of sera from secretors and non-secretors
Sera from the school children were screened for bactericidal antibodies against isolates
ofNeisseria. Most of the individuals had high titres of antibodies to N. lactamica and
N. meningitidis NG:4:- but not to capsulate isolates. Since antigens of N. lactamica
are cross-reactive with other neisseria and they do not express capsules, the results
were expected to be similar to those for the NG:4:- strain.
Compared with non-carriers, carriers had high levels of IgG to N. lactamica and it was
associated with bacteriacidal activity to the encapsulated isolates examined. Carriage
might boost production of antibody to common epitopes and induce strain or species
specific antibody production. Capsular polysaccharides do not appear to contribute
significantly to cross-reactive antibodies as sera bactericidal for the serogroup B isolates
tested were usually bactericidal for serogroup C.
One of the major factors responsible for differences in studies of bactericidal assays
might be the sources of complement. The majority used sera obtained from rabbits,
and McCutchan and colleagues (1978) observed that gonococcal strains resistant to
normal human serum are killed by normal rabbit serum. It is, therefore, essential to
use human serum to get reliable results for humans.
There are wide variations in the ways the results of bactericidal activity are reported,
generally as percentages of death or survival of bacteria. Many investigators consider
significant killing of bacteria has occurred if there is a 50% reduction in viable bacteria
compared with the control (Skevakis et al., 1984; Rosenqvist et al., 1988). The
present study used 80% reduction of viable bacteria as significant killing which reduces
the probability that the results were due to experimental error.
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The increased susceptibility of non-secretors to meningococcal disease compared with
secretors might be partly explained by results of this this study. First, non-secretors
had significantly lower level of total IgM and IgM to N. lactamica and five isolates of
N. meningitidis in saliva. These differences might be important in infants in whom
IgM is the major class of antibodies on the mucosal surfaces. Second, the
susceptibility could be due to lower levels of inhibition of binding to epithelial cells
with saliva obtained from non-secretors. This might be explained either by the lower
levels of slgM in non-secretors or by differences in innate defences (inhibitory
glycoconjugates, lactoferrin, lysozyme and lactoperoxidase) of non-secretors compared
with secretors. The latter possibility needs to be investigated as absorption of anti-
meningococcal antibodies did not completely remove the inhibitory activity. Third,
secretors' sera had higher levels of IgG antibodies to N. lactamica, a factor that has
been associated with bactericidal activity to encapsulated isolates. The differences,
however, were not statistically significant. Further studies need to examine IgG
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SUMMARY
Non-secretors of ABO blood group antigens are over-represented among
patients with meningococcal diseases. Lower levels of secretory IgA reported for
non-secretors have been suggested to compromise mucosal defences. Total serum
and salivary IgO, IgA and IgM and levels of these isotypes specific for Neisseria
lactamica and five isolates of meningococci were determined by ELISA for 357
pupils and staff of a secondary school in which an outbreak ofmeningitis occurred.
There were no differences in total or specific levels of serum IgG, IgA or IgM or
salivary IgG or IgA of secretors compared with non-secretors. Non-secretors had
significantly lower levels of salivary IgM (P — 0-022) A similar pattern was
observed for levels of IgM specific for N. lactamica and five meningococcal isolates.
The significance of these results is discussed with reference to the role of secretory
IgM in protection of mucosal surfaces in infants.
INTRODUCTION
The ability of the host to resist infection or colonization by microorganisms is
partly dependent on the presence of a fully functional mucosal immune system.
Although IgA is the most abundant immunoglobulin in exocrine secretions such
as tears, saliva and milk, IgG and IgM are also found in these fluids [1, 2]. IgM can
also function as a true secretory immunoglobulin [3], reaching the mucosal surface
by the identical secretory-component mediated transcellular pathway that
transports IgA. The full protective potential of secretory IgA is not present in the
infant at birth [4, 5]. Adult levels of secretory IgA are not reached until after 1
year of age [6. 7]. It has been suggested that in infants the presence of IgM
compensates partially for the low levels of IgA [7]. IgM to poliovirus and
Escherichia coli has been found in infants [7. 8].
Protective immunity to disease due to Neisseria meningitidis is associated with
the presence of an intact complement system and opsonizing or bactericidal
antibodies specific for the invading strain [9-11]. These antibodies can be formed
through nasopharyngeal carriage ofmeningococci [12], The majority of individuals
This work was presented at the 120th meeting of the Society for General Microbiology,
Nottingham, UK. 27-29 August 1991.
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who develop invasive disease lack protective antibody to the pathogen [9, 10]. The
age range in which meningococcal infection is most prevalent (6 months to 4-5
years) reflects the natural development of antibodies to these pathogens.
Non-secretors of ABO blood group antigens are over-represented among
patients with disease due to N. meningitidis [13, 14] and among carriers of this
bacterium [15]. The lower immunoglobulin levels found in non-secretors compared
with secretors have been used to explain the increased susceptibility of non-
secretors to rheumatic fever and rheumatic heart disease [16, 17]. In later studies,
non-secretors were reported to have lower levels of both serum [18] and salivary
[ 19] IgA. It was suggested that specific immune responses at the mucosal surfaces
of non-secretors might be compromised compared with that of secretors. The aims
of the present study were to determine:
(1) if there is a difference in the amount of total serum and salivary IgA, IgG
and IgM between secretors and non-secretors;
(2) if there is a difference in the levels of isotypes specific for N. lactamica and
N. meningitidis in serum or saliva of secretors and non-secretors;
(3) if there is a correlation between levels of specific anti-meningococcal
antibodies in secretions and in serum:
(4) if carriage of meningococci affects the levels of antibody to these bacteria
found in secretors and non-secretors.
MATERIALS AND METHODS
Subjects
Sera and whole saliva specimens (357) were obtained from staff and pupils (most
within the 12-18 years age group) of a school in which there was an outbreak of
meningococcal disease due to a serogroup B, serotype 4, subtype PI. 15
sulphonamidc resistant strain (B:4:P1.15). Information regarding carriage of
meningococci, secretor status. ABO and Lewis blood group antigens were reported
in a previous study [15]. Informed consent to participate in the survey was
obtained from parents or guardians of the children.
Isolates of neisseria
An isolate ofAT. lactamica and five different isolates ofA7, meningitidis expressing
different serogroup, serotype and subtype antigens were obtained from the freeze-
dried strains in the collection of the Infection and Immunity Laboratory, Medical
Microbiology Department, University of Edinburgh. The outbreak strain and a
B: 15:PI. 16 sulphonamide resistant isolate were obtained from Dr R. J. Fallon,
Meningococcus Reference Laboratory (Scotland), Ruchill Hospital, Glasgow
(Table 1). The bacteria were grown on Modified New York City (MNYC) agar [20]
for 24 h in a humidified atmosphere with 10% C02.
Determination of total immunoglobulin isotype levels
The total amount of IgM and IgA were assayed by a capture ELISA method.
IgG from serum and saliva was coated directly onto ELISA plates. For the
measurement of total IgM and IgA, the wells of polystyrene microtitre plates were
coated overnight at 4 °C with either 100 /d of mouse monoclonal anti-human IgM
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Table 1. Bacterial isolates
Strain Source Serogroup Serotype Subtype
meningitidis
All Patient B 15 PI.16
A43 Patient B 4 PI.15
A-tl Carrier B 4 —
A26 Carrier C 4 —
A48 Carrier NG* 4 —
lactamica
L01 Carrier XG — —
* Non-groupable.
Clone Xo. MB-11. lot 69F-4807 (1/500) (Sigma. Poole. Dorset. UK) or mouse
monoclonal anti-serum IgA Clone Xo. GA-112. lot 99F-4803 (1/500) (Sigma)
diluted in coating buffer (15 niM XaC03, 35 mM XaH2C03, 3 mjvi XaX3; pH 9-6).
The coated plates were washed three times with phosphate buffered saline (PBS)
(046 M-XaCl, 8 m>i-XaP2HP04. 1 m.\i-KH2P04, 3mM-KCl; pH 7-2) containing
0 01 % bovine serum albumin (BSA) and Tween 20 (0-05% v/v) (PBS-Tween) and
blocked with BSA (1 %) in PBS (blocking buffer) for 30 min. After washing, 50 y\
of serum (1/2000) or saliva (1/10) diluted in blocking buffer were added and
incubated for 2 h at room temperature. Plates for detecting IgM were washed and
50/d of sheep /<-chain-specific anti-human IgM (1/80) (Scottish Antibody
Production Unit. Lanarkshire. Scotland) (SAPU) were added. After washing,
50/d of horseradish peroxidase conjugated (HRP) donkey anti-sheep/goat IgG
(1/20) were added to the plates for 1 h. For IgA plates. 50/d HRP rabbit anti-
human /t-chain-specific IgA (1/500) (Dako. High Wycombe, Bucks, UK) were
added to the plates and incubated for 2 h.
Finally, the plates were washed and 50 /d of phosphate citrate buffer (04 m-
XaHP04. 04 m citric acid) containing the substrate O-phenylene-diamine
(04 mg/ml. pH 5-0) activated by 0-02% H20, (30% v/v). The colour was allowed
to develop in the dark and the reaction was stopped after 20-30 min by adding
50/dof H2S04 (12-5%).
To determine total IgG. 100 /d of serum (1/50000) or saliva (1/2) diluted in
coating buffer were added to the microtitre plates and the plates incubated
overnight under the conditions used, none of the reagents was at a limiting
concentration. After washing, 50 y\ of HRP sheep anti-human IgG (1/20) (SAPU)
diluted in blocking buffer were added for 2 h. The plates were then treated as for
IgA and IgM.
Optical density (OD) at 490 nm was determined by an ELISA plate reader
(Dynatech) and corrected by subtracting the OD of the corresponding blank.
Samples were tested in duplicate and the readings averaged. ELISA readings were
converted to mg/ml by extrapolation from the curve that was constructed
from readings obtained with standard human serum: IgG = 1140 mg/dl;
IgA = 250 mg/dl; IgM =114 mg/dl (Behring lot no. 041024). A series of twofold
dilutions of standard human serum (Behring, London, LTK) containing known
concentrations of immunoglobulin (mg/ml) were tested with the specimens from
the children.
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Whole cell enzyme linked immunosorbent assay
Sera and saliva were examined for anti-meningococcal antibodies by a whole
bacterium ELISA. N. meningitidis and N. lactamica were cultured overnight on
MNYC agar at 37 °C. Large batches ofmicrotitre plates were coated with bacteria
to minimize variations due to different antigen preparations and coating
procedures. Plates were coated overnight at 4 °C with 100 pi of one of the six
bacterial isolates (6-6 x 107 bacteria/ml). The plates were washed and blocked with
PBS containing BSA (1%). The buffer was removed and plates washed with
washing buffer. Undiluted serum or saliva (50 p\) was added to the wells and
incubated at room temperature for 2 h. The assay was continued in the same way
as ELISA for total antibodies. The assay for total and specific antibodies were
determined at the same time under the same conditions.
Statistical methods
The statistical analysis of the data was performed with the package SPSS/PC +.
The results were summarized by geometric means, since the logarithmic values
were more normally distributed than the raw data. The significance levels for
differences between groups were examined with the Mann-Whitney U test and a
P value of < 0-05 was regarded as significant. The association between levels of
antibodies in serum and in saliva was assessed by Spearman rank correlation.
RESULTS
Total IgA. IgG and IgM antibodies of secretors and non-secretors
The specificity of the ELISA for detection of IgM, IgG and IgA was assayed
with purified IgM, IgG and IgA (data not shown). There was no cross reaction
between IgA, IgG and IgM. There was no marked difference in total
immunoglobulin levels between sera from secretors and non-secretors. Non-
secretors had higher levels of serum IgM antibody compared with secretors, but
the difference was not statistically significant. There was no difference in the levels
of IgA or IgG in the saliva from secretors compared with non-secretors; but, there
was significantly more total IgM in the saliva of secretors (P = 0-0274) (Table 2).
There was no difference in serum or salivary immunoglobulin levels of smokers
(37) compared with non-smokers (320).
Specific immune responses to Neisseria species
There was no marked difference in antibody levels to the isolates in sera of
secretors compared with non-secretors, except for IgM to the non-groupable
serotype 4 isolate (Table 2).
There were significant differences in the mean specific salivary IgM immuno¬
globulin levels of secretors and non-secretors. Non-secretors had significantly
lower levels IgM for N. lactamica and each of the meningococcal isolates tested
(Table 2). Statistical comparison of IgA and IgG antibody levels in saliva was also
performed, but there was no difference between secretors and non-secretors. For
both secretors and non-secretors, the highest levels of IgM were observed for the
NG:4 isolate.
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Table 2. Geometric mean levels of total and specific IgM of secretors and
non-secretors
Xon-secretors Secretors P
Serum (n = 107) (« = 171
Total IgM* 1-27 1-08 005
Specific
A. lactamica 9-7 7-7 012
B: 15: P1.16 10-5 8-5 015
C:4 6-0 5-3 0-25
B:4 22-4 14-7 011
XG:4 26-8 22-2 003
B :4 : PI. 15 5-2 4-8 0-48
Saliva (n = 129) (n = 208)
Total IgM 630 87-0 0027
Specific
A. lactamica 1-8 2o 0-0000
B: 15: PI.16 21 31 0-0000
C:4 2-9 3-6 0-040
B:4 2-2 3-5 0-0000
XG: 4 4-7 5-9 0017
B : 4: P1.15 1-9 2-9 0-0008
* Unit for mean total serum IgM levels are expressed in mg/ml; unit for mean total and
specific salivary IgM levels and specific serum IgM levels expressed in jug/m\.









IgA C:4 18-0 (67) 13-0 (209) 0-03
IgA B: 4: Pi .15 9-5 (66) 8-4 (207) 0-02
IgM C:4 12-4 (68) 4-1 (210) 0-0000
IgM B: 4: P1.15 8-3 (66) 6-5 (207) 0-0025
IgG* C:4 5-3 (68) 4-2 (205) 001
IgG B: 4: PI .15 7-2 (64) 6-1 (207) 00033
Saliva
IgA XG: 4 9-7 (89) 6-6 (243) 001
IgM XG:4 6-5 (89) 5-1 (243) 003
* Unit for mean total serum IgG are expressed in mg/ml.
The correlation between serum and salivary antibodies
Analysis by Spearman correlation test found no correlation between the levels
of IgG. IgA and IgM antibodies in serum and saliva (P > 0-05). This suggests that
the increased levels of secretory IgM found among secretors are due to locally
produced immunoglobulins.
Carriage of meningococci and immunoglobulin levels
Compared with non-carriers, carriers of meningococci had significantly higher
levels of salivary IgA and IgM to a NG:4 strain and serum antibodies to the
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outbreak strain and to a C:4:- isolate (Table 3); however, analysis with respect
to both secretor status and carriage revealed that immunoglobulin levels still
differed according to secretor status when carriage was taken into account.
There was no difference in salivary immunoglobulins to the outbreak strain; but
there were significantly higher levels of IgA and IgM to the NG:4 isolate.
DISCUSSION
An association between non-secretion and meningococcal disease has been
reported in studies of patients in Scotland, Iceland and Nigeria [13. 14], In this
study we tested the hypothesis that there might be differences in the humoral
immune responses of secretors and non-secretors that could contribute to the
apparent increased susceptibility of non-secretors to meningococcal disease. Both
serum and salivary immunoglobulin levels were examined.
Conflicting results have been reported for the differences in immunoglobulin
levels between secretors and non-secretors; however, most of these studies
measured total amounts of immunoglobulin in serum and saliva [18, 19, 21],
Lower levels of both serum [19] and salivary IgA [18] wrere reported for non-
secretors. suggesting that specific immune responses at the mucosal surfaces of
non-secretors might be reduced compared with secretors. Blackwell and her
colleagues [21] did not confirm the earlier observation with single radial
immunodiffusion; higher levels of IgA were associated with the presence of
meningococci in the individuals from whom the saliva was obtained. There was no
difference in the mean levels of total IgA in the saliva of secretors compared with
non-secretors from whom no Neisseria spp. were isolated.
There was no difference between secretors and non-secretors in total or specific
levels of salivary IgA or IgG: however, non-secretors had significantly less total
IgM in their saliva compared with secretors. These differences were also observed
for salivary IgM to N. lactamica and to five isolates of meningococci expressing
different combinations of serogroup, serotype and subtype antigens. There was no
correlation between levels of serum IgM and secretory IgM in saliva, suggesting
that salivary IgM is locally produced and has not leaked from the serum. Although
serum and saliva of carriers had significantly higher levels of antibodies to some
of the neisseria isolates, the effect of secretor status on IgM remained after
adjustment for the effect of carriage.
A major biological role of high molecular weight, polyvalent IgA and IgM
secretory antibodies might be to provide a first line of defence against particulate
and polyvalent antigens such as bacteria. Individuals with IgM deficiency appear
at risk of disseminated meningococcal disease [22. 23]. It has been demonstrated
that locally produced IgM in IgA-deficient patients exhibits anti-virus activity
[24].
The lower levels of secretory IgM in non-secretors might contribute to
susceptibility to colonization, particularly among infants under the age of 12
months in whom secretory IgM is the major class of antibody on mucosal surfaces.
The presence of secretory IgM in early infancy has been suggested to compensate
for the absence of secretory IgA [7], IgM had been detected in saliva of infants who
were as young as one month of age [25]. If secretory IgM provides a crucial host
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defence during this period of life the lower levels of secretory IgM found for non-
secretors might contribute to their apparent susceptibility to meningococcal
disease. This hypothesis is under investigation at present.
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